# EDGAR Filing Document

**Accession Number:** 0001046257
**File Stem:** 0001046257-26-000151
**Filing Date:** 2026-4
**Character Count:** 374576
**Document Hash:** b9dedd8c9cfa8c4729621d049edced80
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001046257-26-000151.hdr.sgml**: 20260408

**ACCESSION NUMBER**: 0001046257-26-000151

**CONFORMED SUBMISSION TYPE**: DEF 14A

**PUBLIC DOCUMENT COUNT**: 62

**CONFORMED PERIOD OF REPORT**: 20260408

**FILED AS OF DATE**: 20260408

**DATE AS OF CHANGE**: 20260408

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ingredion Inc
- **CENTRAL INDEX KEY:** 0001046257
- **STANDARD INDUSTRIAL CLASSIFICATION:** GRAIN MILL PRODUCTS [2040]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 223514823
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEF 14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-13397
- **FILM NUMBER:** 26846417

**BUSINESS ADDRESS:**
- **STREET 1:** 5 WESTBROOK CORPORATE CENTER
- **CITY:** WESTCHESTER
- **STATE:** IL
- **ZIP:** 60154
- **BUSINESS PHONE:** 7085512600

**MAIL ADDRESS:**
- **STREET 1:** INGREDION INCORPORATED
- **STREET 2:** 5 WESTBROOK CORPORATE CENTER
- **CITY:** WESTCHESTER
- **STATE:** IL
- **ZIP:** 60154

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CORN PRODUCTS INTERNATIONAL INC
- **DATE OF NAME CHANGE:** 19970917

?xml version='1.0' encoding='ASCII'? ingr-20260402

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the**

**Securities Exchange Act of 1934**

**(Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;)**

Filed by the Registrant ☒

Filed by a party other than the Registrant ☐

Check the appropriate box:

☐Preliminary Proxy Statement

☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☒Definitive Proxy Statement

☐Definitive Additional Materials

☐Soliciting Material under §240.14a-12

**Ingredion Incorporated**

**(Name of Registrant as Specified In Its Charter)**

**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)**

Payment of Filing Fee (Check all boxes that apply):

☒No fee required

☐Fee paid previously with preliminary materials

☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

---

| | |
|:---|:---|
| May 20, 2026 | Virtual Annual Meeting Site: |
| 8:00 a.m., Central Daylight Time | *www.virtualshareholdermeeting.com/INGR2026* |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

![Ingredionlogo.jpg](ingr-20260402_g1.jpg)

Notice of 2026

Annual Meeting

and Proxy Statement

---

| | |
|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

---

| | | |
|:---|:---|:---|
|  |  | Letter from our Chairman, <br>President, and CEO<br>|
| ![Zallie_Jim.jpg](ingr-20260402_g2.jpg)<br>![Ingredion_Logo_Web_rgbHEX.jpg](ingr-20260402_g3.jpg)<br>**5 Westbrook Corporate Center**<br>**Westchester, Illinois 60154** | April 8, 2026 |  |
| ![Zallie_Jim.jpg](ingr-20260402_g2.jpg)<br>![Ingredion_Logo_Web_rgbHEX.jpg](ingr-20260402_g3.jpg)<br>**5 Westbrook Corporate Center**<br>**Westchester, Illinois 60154** | **Dear Fellow Stockholders:** | **Dear Fellow Stockholders:** |
| ![Zallie_Jim.jpg](ingr-20260402_g2.jpg)<br>![Ingredion_Logo_Web_rgbHEX.jpg](ingr-20260402_g3.jpg)<br>**5 Westbrook Corporate Center**<br>**Westchester, Illinois 60154** |  |  |
| ![Zallie_Jim.jpg](ingr-20260402_g2.jpg)<br>![Ingredion_Logo_Web_rgbHEX.jpg](ingr-20260402_g3.jpg)<br>**5 Westbrook Corporate Center**<br>**Westchester, Illinois 60154** | It is my pleasure to invite you to Ingredion Incorporated's 2026 Annual Meeting of <br>Stockholders on Wednesday, May 20, 2026, at 8:00 a.m., Central Daylight Time. The annual <br>meeting will be conducted exclusively via the Internet and can be accessed by visiting <br>*www.virtualshareholdermeeting.com/INGR2026*, where you will be able to listen to the <br>virtual annual meeting live, submit questions, and vote online. | It is my pleasure to invite you to Ingredion Incorporated's 2026 Annual Meeting of <br>Stockholders on Wednesday, May 20, 2026, at 8:00 a.m., Central Daylight Time. The annual <br>meeting will be conducted exclusively via the Internet and can be accessed by visiting <br>*www.virtualshareholdermeeting.com/INGR2026*, where you will be able to listen to the <br>virtual annual meeting live, submit questions, and vote online. |
| ![Zallie_Jim.jpg](ingr-20260402_g2.jpg)<br>![Ingredion_Logo_Web_rgbHEX.jpg](ingr-20260402_g3.jpg)<br>**5 Westbrook Corporate Center**<br>**Westchester, Illinois 60154** |  |  |
| ![Zallie_Jim.jpg](ingr-20260402_g2.jpg)<br>![Ingredion_Logo_Web_rgbHEX.jpg](ingr-20260402_g3.jpg)<br>**5 Westbrook Corporate Center**<br>**Westchester, Illinois 60154** | In February 2026, our board of directors elected me to serve as Chairman of the Board in <br>addition to my roles as Ingredion's President and Chief Executive Officer. I am honored by <br>the board's confidence and grateful for the opportunity to serve as Chairman. Ingredion has <br>a strong foundation, a talented global team, and a clear strategy focused on becoming the <br>go-to provider of Texture & Healthful Solutions that make healthy taste better. I look <br>forward to continuing to work closely with the board as we execute our growth agenda and <br>advance our purpose of bringing the potential of people, nature, and technology together to <br>make life better. I look forward to working closely with Victoria J. Reich, who was elected to <br>serve as the Company's new, independent Lead Director at the same time I was elected as <br>Chairman of the Board. | In February 2026, our board of directors elected me to serve as Chairman of the Board in <br>addition to my roles as Ingredion's President and Chief Executive Officer. I am honored by <br>the board's confidence and grateful for the opportunity to serve as Chairman. Ingredion has <br>a strong foundation, a talented global team, and a clear strategy focused on becoming the <br>go-to provider of Texture & Healthful Solutions that make healthy taste better. I look <br>forward to continuing to work closely with the board as we execute our growth agenda and <br>advance our purpose of bringing the potential of people, nature, and technology together to <br>make life better. I look forward to working closely with Victoria J. Reich, who was elected to <br>serve as the Company's new, independent Lead Director at the same time I was elected as <br>Chairman of the Board. |
| ![Zallie_Jim.jpg](ingr-20260402_g2.jpg)<br>![Ingredion_Logo_Web_rgbHEX.jpg](ingr-20260402_g3.jpg)<br>**5 Westbrook Corporate Center**<br>**Westchester, Illinois 60154** |  |  |
| ![Zallie_Jim.jpg](ingr-20260402_g2.jpg)<br>![Ingredion_Logo_Web_rgbHEX.jpg](ingr-20260402_g3.jpg)<br>**5 Westbrook Corporate Center**<br>**Westchester, Illinois 60154** | Your vote is important, whether or not you plan to attend the annual meeting, and we <br>encourage you to vote promptly. You may submit your proxy or voting instructions via the <br>Internet or via a toll-free telephone number. Alternatively, if you received a paper copy of <br>the proxy card by mail, you may sign, date, and mail the proxy card in the envelope <br>provided. Instructions regarding all three methods of submitting your proxy or voting <br>instructions are contained in the accompanying proxy statement and the proxy card. If you <br>hold your shares through a bank, broker, or other holder of record, you should submit your <br>voting instructions in accordance with your voting instruction form or notice provided by the <br>holder of record. | Your vote is important, whether or not you plan to attend the annual meeting, and we <br>encourage you to vote promptly. You may submit your proxy or voting instructions via the <br>Internet or via a toll-free telephone number. Alternatively, if you received a paper copy of <br>the proxy card by mail, you may sign, date, and mail the proxy card in the envelope <br>provided. Instructions regarding all three methods of submitting your proxy or voting <br>instructions are contained in the accompanying proxy statement and the proxy card. If you <br>hold your shares through a bank, broker, or other holder of record, you should submit your <br>voting instructions in accordance with your voting instruction form or notice provided by the <br>holder of record. |
| ![Zallie_Jim.jpg](ingr-20260402_g2.jpg)<br>![Ingredion_Logo_Web_rgbHEX.jpg](ingr-20260402_g3.jpg)<br>**5 Westbrook Corporate Center**<br>**Westchester, Illinois 60154** |  |  |
| ![Zallie_Jim.jpg](ingr-20260402_g2.jpg)<br>![Ingredion_Logo_Web_rgbHEX.jpg](ingr-20260402_g3.jpg)<br>**5 Westbrook Corporate Center**<br>**Westchester, Illinois 60154** | I look forward to sharing more about Ingredion with you at our annual meeting. In addition <br>to the business to be transacted as described in the accompanying Notice of Annual Meeting <br>of Stockholders, I will discuss Ingredion's recent business performance and we will conduct a <br>question-and-answer period, as further described in the proxy statement. | I look forward to sharing more about Ingredion with you at our annual meeting. In addition <br>to the business to be transacted as described in the accompanying Notice of Annual Meeting <br>of Stockholders, I will discuss Ingredion's recent business performance and we will conduct a <br>question-and-answer period, as further described in the proxy statement. |
| ![Zallie_Jim.jpg](ingr-20260402_g2.jpg)<br>![Ingredion_Logo_Web_rgbHEX.jpg](ingr-20260402_g3.jpg)<br>**5 Westbrook Corporate Center**<br>**Westchester, Illinois 60154** |  |  |
| ![Zallie_Jim.jpg](ingr-20260402_g2.jpg)<br>![Ingredion_Logo_Web_rgbHEX.jpg](ingr-20260402_g3.jpg)<br>**5 Westbrook Corporate Center**<br>**Westchester, Illinois 60154** | On behalf of our board, I thank you for your participation, investment, and continued <br>interest in Ingredion. | On behalf of our board, I thank you for your participation, investment, and continued <br>interest in Ingredion. |
| ![Zallie_Jim.jpg](ingr-20260402_g2.jpg)<br>![Ingredion_Logo_Web_rgbHEX.jpg](ingr-20260402_g3.jpg)<br>**5 Westbrook Corporate Center**<br>**Westchester, Illinois 60154** |  |  |
| ![Zallie_Jim.jpg](ingr-20260402_g2.jpg)<br>![Ingredion_Logo_Web_rgbHEX.jpg](ingr-20260402_g3.jpg)<br>**5 Westbrook Corporate Center**<br>**Westchester, Illinois 60154** | Sincerely, |  |
| ![Zallie_Jim.jpg](ingr-20260402_g2.jpg)<br>![Ingredion_Logo_Web_rgbHEX.jpg](ingr-20260402_g3.jpg)<br>**5 Westbrook Corporate Center**<br>**Westchester, Illinois 60154** |  |  |
| ![Zallie_Jim.jpg](ingr-20260402_g2.jpg)<br>![Ingredion_Logo_Web_rgbHEX.jpg](ingr-20260402_g3.jpg)<br>**5 Westbrook Corporate Center**<br>**Westchester, Illinois 60154** | James P. Zallie<br>Chairman of the Board, President, and <br>Chief Executive Officer<br>|  |

---

---

| | |
|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

**Ingredion Incorporated**<br>**5 Westbrook Corporate Center**<br>**Westchester, IL 60154**<br>

**NOTICE OF ANNUAL MEETING**

We are pleased to invite you to attend the 2026 Annual Meeting of Stockholders of Ingredion Incorporated (the "Company") to

be held on Wednesday, May 20, 2026, at 8:00 a.m., Central Daylight Time, and conducted exclusively via the Internet. The

meeting may be accessed by visiting *www.virtualshareholdermeeting.com/INGR2026*, where you will be able to listen to the

virtual annual meeting live, submit questions, and vote online.

The annual meeting will be held for the following purposes:

• to elect to the Company's Board of Directors the 11 nominees who are named in the accompanying proxy statement,

each to serve for a term of one year,

• to approve, by advisory vote, the compensation of the Company's named executive officers, as described in the

accompanying proxy statement,

• to ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal

year ending December 31, 2026, and

• to transact other business, if any, that is properly brought before the meeting or any adjournment or postponement

thereof.

Only stockholders who owned Ingredion common stock as of the close of business on March 23, 2026, which is the record date

for the annual meeting, will be entitled to participate in the meeting and at any adjournment or postponement thereof.

This proxy statement, our annual report to stockholders, and the proxy are first being made available to stockholders on or

about April 8, 2026.

**Your vote is important. Please ensure that your vote will be counted by submitting your proxy or voting instructions via the** 

**Internet or by using the toll-free telephone number, as described in the accompanying materials. Alternatively, if you** 

**received a copy of the proxy card by mail, you may sign, date, and mail the proxy card in the envelope provided. If you hold** 

**your shares through a bank, broker, or other holder of record, you should submit your voting instructions in accordance with** 

**your voting instruction form or notice provided by the holder of record.**

By order of the Board of Directors,

Tanya Jaeger de Foras

Senior Vice President, Chief Legal Officer,

Corporate Secretary, and Chief Compliance Officer

April 8, 2026

**IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING**<br>**TO BE HELD ON WEDNESDAY, MAY 20, 2026**<br>**The Notice of Annual Meeting of Stockholders, Proxy Statement, and** <br>**2025 Annual Report to Stockholders are available at *www.proxyvote.com*.**<br>

---

| | |
|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

**ATTENDING THE 2026 ANNUAL MEETING VIA** 

**THE INTERNET**

The annual meeting of Ingredion Incorporated ("Ingredion") will be conducted exclusively via the Internet without an option to

attend in person. You will be able to access the meeting at *www.virtualshareholdermeeting.com/INGR2026* using a 16-digit

control number.

• If you received a notice of availability of proxy materials in the mail, your 16-digit control number was included as part of

your notice.

• If your Ingredion shares are registered in your name and you received an e-mail with instructions containing a link to the

website where those materials are available and a link to the proxy voting website, your 16-digit control number was

included as part of your e-mail notification.

• If your Ingredion shares are registered in your name and you received proxy materials by mail, your 16-digit control

number was included as part of your proxy card.

• If your Ingredion shares are held by a bank, broker, or other holder of record, your 16-digit control number was included

as part of the voting instruction form provided by your bank, broker, or other holder of record. If you did not receive a

voting instruction form with this control number, please contact your holder of record.

We encourage you to access the virtual annual meeting before the start time of 8:00 a.m., Central Daylight Time, on

Wednesday, May 20, 2026. Please allow ample time for online check-in, which will begin at 7:45 a.m., Central Daylight Time, on

May 20, 2026. If you encounter any difficulties accessing the virtual annual meeting during the check-in or meeting time, please

call the technical support number that will be posted on the virtual annual meeting login page.

If you do not have a 16-digit control number, you may still attend the virtual annual meeting as a guest in listen-only mode. To

attend as a guest, please visit *www.virtualshareholdermeeting.com/INGR2026* and enter the information requested on the

screen to register as a guest. Please note that you will not have the ability to vote or ask questions during the annual meeting if

you attend as a guest.

You may submit a question in advance of the annual meeting at *www.proxyvote.com* after logging in with the 16-digit control

number provided on your proxy card, voting instruction form, or notice of availability of proxy materials. In addition, you may

ask a question during the annual meeting if you have logged in to the annual meeting website with your 16-digit control

number. There is a limit of two questions per stockholder. Each question should be succinct and cover only a single topic.

Shortly after the annual meeting, we will post the questions submitted in accordance with the meeting rules of conduct and

procedures and the associated answers on our Investor Relations website, *https://ir.ingredionincorporated.com/events-and-*

*presentations*. Similar questions on the same topic may be answered as a group.

For additional information about the annual meeting, see "Questions and Answers About This Proxy Statement and Our 2026

Annual Meeting."

---

| | |
|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

**VOTING ROADMAP**

---

| | | |
|:---|:---|:---|
| **Proposal** | **1Election of Directors** | **Our Board recommends a vote FOR** <br>**each director nominee**<br>|
|  | The Board of Directors and the Corporate Governance and <br>Nominating Committee believe that the 11 director nominees <br>possess the necessary qualifications and experience to <br>effectively oversee our management and business and <br>promote the long-term interests of our stockholders.<br>| See page <u>[1](#ie7e472361805446c8b302de30ed47fbf_25)</u> for further information |
| **Proposal** | **2Advisory Vote on Compensation of Our Named** <br>**Executive Officers** | **Our Board recommends a vote FOR** <br>**this proposal**<br>|
|  | The Company seeks a non-binding advisory vote to approve <br>the compensation of our named executive officers as <br>described in the Compensation Discussion and Analysis section <br>of this proxy statement beginning on page <u>[26](#ie7e472361805446c8b302de30ed47fbf_49)</u> and the <br>compensation tables and related narrative disclosures <br>beginning on page <u>[47](#ie7e472361805446c8b302de30ed47fbf_55)</u>.<br>| See page <u>[67](#ie7e472361805446c8b302de30ed47fbf_88)</u> for further information |
| **Proposal** | **3Ratification of Appointment of KPMG LLP as Our** <br>**Independent Registered Public Accounting Firm** | **Our Board recommends a vote FOR** <br>**this proposal**<br>|
|  | The Board of Directors and the Audit Committee believe that <br>the retention of KPMG LLP to serve as the Company's <br>independent registered public accounting firm for the fiscal <br>year ending December 31, 2026 is in the best interests of the <br>Company and its stockholders. As a matter of good corporate <br>governance, stockholders are being asked to ratify the Audit <br>Committee's appointment of KPMG LLP.<br>| See page <u>[71](#ie7e472361805446c8b302de30ed47fbf_100)</u> for further information |

---

**<u>QUESTIONS AND ANSWERS</u>: Please see "Questions and Answers About This Proxy Statement and Our 2026 Annual** 

**Meeting" beginning on page <u>[73](#ie7e472361805446c8b302de30ed47fbf_103)</u> for important information about the proxy materials, voting, the 2026 Annual Meeting of** 

**Stockholders, and the deadlines to submit stockholder proposals and director nominees for the 2027 Annual Meeting of** 

**Stockholders.**

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **i** |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

**Table of Contents**

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| **<u>[PROPOSAL 1. ELECTION OF DIRECTORS](#ie7e472361805446c8b302de30ed47fbf_25)</u>** | <u>[1](#ie7e472361805446c8b302de30ed47fbf_25)</u> |
| <u>[Directors Nominated for Election at the](#ie7e472361805446c8b302de30ed47fbf_28)</u><br><u>[Annual Meeting](#ie7e472361805446c8b302de30ed47fbf_28)</u><br>| <u>[1](#ie7e472361805446c8b302de30ed47fbf_28)</u> |
| <u>[The Board and Committees](#ie7e472361805446c8b302de30ed47fbf_31)</u> | <u>[9](#ie7e472361805446c8b302de30ed47fbf_31)</u> |
| <u>[Compensation of Non-employee Directors](#ie7e472361805446c8b302de30ed47fbf_34)</u> | <u>[20](#ie7e472361805446c8b302de30ed47fbf_34)</u> |
| **<u>[OWNERSHIP OF OUR STOCK](#ie7e472361805446c8b302de30ed47fbf_37)</u>** | <u>[23](#ie7e472361805446c8b302de30ed47fbf_37)</u> |
| <u>[Security Ownership of Certain Beneficial](#ie7e472361805446c8b302de30ed47fbf_40)</u><br><u>[Owners and Management](#ie7e472361805446c8b302de30ed47fbf_40)</u><br>| <u>[23](#ie7e472361805446c8b302de30ed47fbf_40)</u> |
| <u>[Delinquent Section 16(a) Reports](#ie7e472361805446c8b302de30ed47fbf_43)</u> | <u>[25](#ie7e472361805446c8b302de30ed47fbf_43)</u> |
| **<u>[EXECUTIVE COMPENSATION](#ie7e472361805446c8b302de30ed47fbf_46)</u>** | <u>[26](#ie7e472361805446c8b302de30ed47fbf_46)</u> |
| <u>[Compensation Discussion and Analysis](#ie7e472361805446c8b302de30ed47fbf_49)</u> | <u>[26](#ie7e472361805446c8b302de30ed47fbf_49)</u> |
| <u>[2025 Summary Compensation Table](#ie7e472361805446c8b302de30ed47fbf_55)</u> | <u>[47](#ie7e472361805446c8b302de30ed47fbf_55)</u> |
| <u>[2025 Grants of Plan-Based Awards](#ie7e472361805446c8b302de30ed47fbf_58)</u> | <u>[49](#ie7e472361805446c8b302de30ed47fbf_58)</u> |
| <u>[2025 Outstanding Equity Awards at Fiscal](#ie7e472361805446c8b302de30ed47fbf_61)</u><br><u>[Year-End](#ie7e472361805446c8b302de30ed47fbf_61)</u><br>| <u>[50](#ie7e472361805446c8b302de30ed47fbf_61)</u> |
| <u>[2025 Option Exercises and Stock Vested](#ie7e472361805446c8b302de30ed47fbf_64)</u> | <u>[51](#ie7e472361805446c8b302de30ed47fbf_64)</u> |
| <u>[2025 Pension Benefits](#ie7e472361805446c8b302de30ed47fbf_67)</u> | <u>[52](#ie7e472361805446c8b302de30ed47fbf_67)</u> |
| <u>[2025 Nonqualified Deferred](#ie7e472361805446c8b302de30ed47fbf_70)</u><br><u>[Compensation](#ie7e472361805446c8b302de30ed47fbf_70)</u><br>| <u>[53](#ie7e472361805446c8b302de30ed47fbf_70)</u> |
| <u>[Potential Payments Upon Termination or](#ie7e472361805446c8b302de30ed47fbf_73)</u><br><u>[Change in Control](#ie7e472361805446c8b302de30ed47fbf_73)</u><br>| <u>[54](#ie7e472361805446c8b302de30ed47fbf_73)</u> |
| <u>[Pay Ratio Disclosure](#ie7e472361805446c8b302de30ed47fbf_76)</u> | <u>[61](#ie7e472361805446c8b302de30ed47fbf_76)</u> |
| <u>[Pay Versus Performance Disclosure](#ie7e472361805446c8b302de30ed47fbf_79)</u> | <u>[62](#ie7e472361805446c8b302de30ed47fbf_79)</u> |

---

---

| | |
|:---|:---|
| **<u>[COMPENSATION COMMITTEE REPORT](#ie7e472361805446c8b302de30ed47fbf_82)</u>** | <u>[66](#ie7e472361805446c8b302de30ed47fbf_82)</u> |
| **<u>[COMPENSATION COMMITTEE INTERLOCKS](#ie7e472361805446c8b302de30ed47fbf_85)</u>**<br>**<u>[AND INSIDER PARTICIPATION](#ie7e472361805446c8b302de30ed47fbf_85)</u>** | <u>[66](#ie7e472361805446c8b302de30ed47fbf_85)</u> |
| **<u>[PROPOSAL 2. ADVISORY VOTE ON](#ie7e472361805446c8b302de30ed47fbf_88)</u>**<br>**<u>[COMPENSATION OF OUR NAMED](#ie7e472361805446c8b302de30ed47fbf_88)</u>**<br>**<u>[EXECUTIVE OFFICERS](#ie7e472361805446c8b302de30ed47fbf_88)</u>** | <u>[67](#ie7e472361805446c8b302de30ed47fbf_88)</u> |
| **<u>[REVIEW AND APPROVAL OF TRANSACTIONS](#ie7e472361805446c8b302de30ed47fbf_91)</u>**<br>**<u>[WITH RELATED PERSONS](#ie7e472361805446c8b302de30ed47fbf_91)</u>** | <u>[68](#ie7e472361805446c8b302de30ed47fbf_91)</u> |
| **<u>[EQUITY COMPENSATION PLAN INFORMATION](#ie7e472361805446c8b302de30ed47fbf_94)</u>**<br>**<u>[AS OF DECEMBER 31, 2](#ie7e472361805446c8b302de30ed47fbf_94)</u><u>025</u>** | <u>[70](#ie7e472361805446c8b302de30ed47fbf_94)</u> |
| **<u>[AUDIT COMMITTEE REPORT](#ie7e472361805446c8b302de30ed47fbf_97)</u>** | <u>[70](#ie7e472361805446c8b302de30ed47fbf_97)</u> |
| **<u>[PROPOSAL 3. RATIFICATION OF APPOINTMENT](#ie7e472361805446c8b302de30ed47fbf_100)</u>**<br>**<u>[OF KPMG AS OUR INDEPENDENT](#ie7e472361805446c8b302de30ed47fbf_100)</u>**<br>**<u>[REGISTERED PUBLIC ACCOUNTING FIRM](#ie7e472361805446c8b302de30ed47fbf_100)</u>** | <u>[71](#ie7e472361805446c8b302de30ed47fbf_100)</u> |
| **<u>[QUESTIONS AND ANSWERS ABOUT THIS](#ie7e472361805446c8b302de30ed47fbf_103)</u>**<br>**<u>[PROXY STATEMENT AND OUR 2026 ANNUAL](#ie7e472361805446c8b302de30ed47fbf_103)</u>**<br>**<u>[MEETING](#ie7e472361805446c8b302de30ed47fbf_103)</u>** | <u>[73](#ie7e472361805446c8b302de30ed47fbf_103)</u> |
| **<u>[OTHER MATTERS](#ie7e472361805446c8b302de30ed47fbf_106)</u>** | <u>[82](#ie7e472361805446c8b302de30ed47fbf_106)</u> |
| **<u>[OTHER INFORMATION](#ie7e472361805446c8b302de30ed47fbf_109)</u>** | <u>[82](#ie7e472361805446c8b302de30ed47fbf_109)</u> |
| **<u>[APPENDIX A—RECONCILIATION OF NON-GAAP](#ie7e472361805446c8b302de30ed47fbf_112)</u>**<br>**<u>[FINANCIAL MEASURE](#ie7e472361805446c8b302de30ed47fbf_112)</u>** | <u>[A-1](#ie7e472361805446c8b302de30ed47fbf_112)</u> |

---

---

| | |
|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT<sub>1</sub> |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

---

| | |
|:---|:---|
| **PROXY STATEMENT** | **Ingredion Incorporated**<br>**5 Westbrook Corporate Center**<br>**Westchester, IL 60154** |
| **PROXY STATEMENT** | **Ingredion Incorporated**<br>**5 Westbrook Corporate Center**<br>**Westchester, IL 60154** |
| **PROXY STATEMENT** | **Ingredion Incorporated**<br>**5 Westbrook Corporate Center**<br>**Westchester, IL 60154** |

---

In this proxy statement we refer to Ingredion Incorporated individually and collectively with its consolidated subsidiaries as

"Ingredion," the "Company," "we," or "us."

**Proposal 1. Election of Directors**

In this Proposal 1, the Board of Directors is asking stockholders to elect to the Board of Directors the 11 director nominees who

are named in this proxy statement, each to serve for a term of one year.

**The Board of Directors unanimously recommends that you vote FOR the nominees** <br>**for election as directors.**<br>

**Directors Nominated for Election at the Annual** 

**Meeting**

The Company is engaged in ongoing efforts to refresh the board to ensure that it includes a mix of directors who will meet both

the current and long-term needs of the board, the Company, and our stockholders. As part of these efforts, the board has

proposed for election at this annual meeting one nominee who has joined the board since the 2025 annual meeting of

stockholders. Ms. Siobhán Talbot joined the board on April 1, 2026.

Mr. Gregory Kenny retired from the board on March 23, 2026. The board has conveyed its gratitude to Mr. Kenny for his

distinguished service as a director and many contributions to the Company.

The terms of all 11 of our incumbent directors, including Ms. Talbot, will expire at the 2026 annual meeting. All of our current

board members serving as of the date of this proxy statement have been nominated for re-election as directors. If elected, each

nominee will hold office for a one-year term expiring at our 2027 annual meeting. Each director who is elected by our

stockholders will serve until his or her successor has been elected and qualified or until his or her earlier death, resignation, or

removal.

All of the nominees for election, who are listed below, have consented to being named in this proxy statement and to serve if

elected. If, for any reason, any nominee ceases to be a candidate for election at the annual meeting, the proxies will be voted

for a substitute nominee designated by the board unless the board chooses to reduce the number of authorized directors or to

leave the vacancy unfilled.

The information in the table below and in the following director biographies is presented as of April 1, 2026.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | **Director** <br>**Since** | **Committee Membership** | **Committee Membership** |
| **Name and Primary Occupation** | **Age** | **Director** <br>**Since** | AC | PCCC<br> CGNC |
| **David B. Fischer** \| Independent Director |  |  |  |  |
| Former Chief Executive Officer of Greif, Inc. | 63 | 2013 |  | ✔ |
| **Rhonda L. Jordan** \| Independent Director |  |  |  |  |
| Former President, Global Health & Wellness, and Sustainability of <br>Kraft Foods Inc.<br>| 68 | 2013 |  | ![ASE.jpg](ingr-20260402_g4.jpg) |
| **Charles V. Magro** \| Independent Director |  |  |  |  |
| Chief Executive Officer of Corteva, Inc. | 56 | 2022 |  | ✔ |
| **Victoria J. Reich** \| Independent Director, Lead Director |  |  |  |  |
| Former Senior Vice President and Chief Financial Officer of Essendant <br>Inc.<br>| 68 | 2013 | ✔ |  |

---

---

| | | |
|:---|:---|:---|
| **2** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  | **Director** <br>**Since** | **Committee Membership** | **Committee Membership** | **Committee Membership** |
| **Name and Primary Occupation** | **Age** | **Director** <br>**Since** | AC | PCCC | CGNC |
| **Catherine A. Suever** \| Independent Director |  |  |  |  |  |
| Former Executive Vice President – Finance and Administration and <br>Chief Financial Officer of Parker-Hannifin Corporation<br>| 67 | 2021 | ![face.jpg](ingr-20260402_g5.jpg) |  |  |
| **Siobhán Talbot** \| Independent Director |  |  |  |  |  |
| Former Group Managing Director and Chief Executive Officer of <br>Glanbia plc<br>| 62 | 2026 |  |  |  |
| **Stephan B. Tanda** \| Independent Director |  |  |  |  |  |
| President and Chief Executive Officer of AptarGroup, Inc. | 60 | 2019 |  |  | ![face.jpg](ingr-20260402_g5.jpg) |
| **Jorge A. Uribe** \| Independent Director |  |  |  |  |  |
| Former Global Productivity and Organization Transformation Officer <br>of The Procter & Gamble Company<br>| 69 | 2015 |  |  | ✔ |
| **Patricia Verduin** \| Independent Director |  |  |  |  |  |
| Former Chief Technology Officer, Global Technology of Colgate-<br>Palmolive Company<br>| 66 | 2023 |  |  | ✔ |
| **Dwayne A. Wilson** \| Independent Director |  |  |  |  |  |
| Former Senior Vice President of Fluor Corporation | 67 | 2010 | ✔ |  |  |
| **James P. Zallie** |  |  |  |  |  |
| Chairman of the Board, President and Chief Executive Officer of the <br>Company<br>| 64 | 2017 |  |  |  |

---

**AC –** Audit Committee • **PCCC –** People, Culture, and Compensation Committee • **CGNC –** Corporate Governance and

Nominating Committee

&nbsp;&nbsp;&nbsp;&nbsp;Chair&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ✔ Member

![Image_31.jpg](ingr-20260402_g6.jpg)

---

| | |
|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT<sub>3</sub> |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

**DIRECTOR NOMINEE BIOGRAPHIES**

---

| | | | |
|:---|:---|:---|:---|
| David B. Fischer<br>Independent Director | David B. Fischer<br>Independent Director | Rhonda L. Jordan<br>Independent Director | Rhonda L. Jordan<br>Independent Director |
| ![fischer-sos-proxy.jpg](ingr-20260402_g7.jpg) | Former Chief Executive Officer <br>of Greif, Inc.<br>**Age:** 63<br>**Director since:** May 2013<br>**Committees:** People, Culture, <br>and Compensation <br>**Other Current Public** <br>**Company Boards:** Balchem <br>Corporation<br>| ![jordan-sos-proxy.jpg](ingr-20260402_g8.jpg) | Former President, Global Health & <br>Wellness, and Sustainability of Kraft <br>Foods Inc<br>**Age:** 68<br>**Director since:** November 2013<br>**Committees:** People, Culture, and <br>Compensation, Chair<br>**Other Current Public Company** <br>**Boards:** ESAB Corporation<br>|
| Mr. Fischer served as Chief Executive Officer and a director of <br>Greif, Inc. from November 2011 to October 2015, and as <br>President of Greif, Inc. from October 2007 to October 2015. <br>Greif, Inc. is a manufacturer and provider of industrial <br>packaging and services for a wide range of industries. Mr. <br>Fischer serves as a director of Balchem Corporation, a <br>publicly traded manufacturer of performance ingredients and <br>products for the food, nutritional, feed, pharmaceutical and <br>medical sterilization industries, and DoMedia Inc., a privately <br>held technology company that operates a market for out-of-<br>home advertising sales. | Mr. Fischer served as Chief Executive Officer and a director of <br>Greif, Inc. from November 2011 to October 2015, and as <br>President of Greif, Inc. from October 2007 to October 2015. <br>Greif, Inc. is a manufacturer and provider of industrial <br>packaging and services for a wide range of industries. Mr. <br>Fischer serves as a director of Balchem Corporation, a <br>publicly traded manufacturer of performance ingredients and <br>products for the food, nutritional, feed, pharmaceutical and <br>medical sterilization industries, and DoMedia Inc., a privately <br>held technology company that operates a market for out-of-<br>home advertising sales. | Ms. Jordan served from September 2009 to March 2012 as <br>President, Global Health & Wellness, and Sustainability of <br>Kraft Foods Inc., one of the largest consumer packaged food <br>and beverage companies in North America and one of the <br>largest worldwide among publicly traded consumer packaged <br>food and beverage companies. Prior to that service, she held <br>positions as President of Kraft's Cheese and Dairy business <br>unit and its Grocery business unit. Ms. Jordan serves as a <br>director of ESAB Corporation, an NYSE-listed global <br>manufacturing and engineering company that provides <br>fabrication technology products and services. Ms. Jordan is <br>also lead director of Bush Brothers & Company, a privately <br>held branded vegetable processor, and a director of I and <br>Love and You, a privately held branded manufacturer of <br>grain-free food and healthy chews and treats for pets. | Ms. Jordan served from September 2009 to March 2012 as <br>President, Global Health & Wellness, and Sustainability of <br>Kraft Foods Inc., one of the largest consumer packaged food <br>and beverage companies in North America and one of the <br>largest worldwide among publicly traded consumer packaged <br>food and beverage companies. Prior to that service, she held <br>positions as President of Kraft's Cheese and Dairy business <br>unit and its Grocery business unit. Ms. Jordan serves as a <br>director of ESAB Corporation, an NYSE-listed global <br>manufacturing and engineering company that provides <br>fabrication technology products and services. Ms. Jordan is <br>also lead director of Bush Brothers & Company, a privately <br>held branded vegetable processor, and a director of I and <br>Love and You, a privately held branded manufacturer of <br>grain-free food and healthy chews and treats for pets. |
|  |  | Ms. Jordan served from September 2009 to March 2012 as <br>President, Global Health & Wellness, and Sustainability of <br>Kraft Foods Inc., one of the largest consumer packaged food <br>and beverage companies in North America and one of the <br>largest worldwide among publicly traded consumer packaged <br>food and beverage companies. Prior to that service, she held <br>positions as President of Kraft's Cheese and Dairy business <br>unit and its Grocery business unit. Ms. Jordan serves as a <br>director of ESAB Corporation, an NYSE-listed global <br>manufacturing and engineering company that provides <br>fabrication technology products and services. Ms. Jordan is <br>also lead director of Bush Brothers & Company, a privately <br>held branded vegetable processor, and a director of I and <br>Love and You, a privately held branded manufacturer of <br>grain-free food and healthy chews and treats for pets. | Ms. Jordan served from September 2009 to March 2012 as <br>President, Global Health & Wellness, and Sustainability of <br>Kraft Foods Inc., one of the largest consumer packaged food <br>and beverage companies in North America and one of the <br>largest worldwide among publicly traded consumer packaged <br>food and beverage companies. Prior to that service, she held <br>positions as President of Kraft's Cheese and Dairy business <br>unit and its Grocery business unit. Ms. Jordan serves as a <br>director of ESAB Corporation, an NYSE-listed global <br>manufacturing and engineering company that provides <br>fabrication technology products and services. Ms. Jordan is <br>also lead director of Bush Brothers & Company, a privately <br>held branded vegetable processor, and a director of I and <br>Love and You, a privately held branded manufacturer of <br>grain-free food and healthy chews and treats for pets. |
| Mr. Fischer is also chairman of the board and co-founder of <br>10x Engineered Materials LLC, a privately held materials <br>science-based company that manufactures high-tech <br>industrial abrasives. He also is the chairman of the board of <br>Flexible Products and Services, a wholly-owned subsidiary of <br>National Scientific Company Limited. Mr. Fischer also serves <br>as a board member of Partners for Care, a U.S.-based not-<br>for- profit organization focused on water, health, and <br>nutrition in developing countries. | Mr. Fischer is also chairman of the board and co-founder of <br>10x Engineered Materials LLC, a privately held materials <br>science-based company that manufactures high-tech <br>industrial abrasives. He also is the chairman of the board of <br>Flexible Products and Services, a wholly-owned subsidiary of <br>National Scientific Company Limited. Mr. Fischer also serves <br>as a board member of Partners for Care, a U.S.-based not-<br>for- profit organization focused on water, health, and <br>nutrition in developing countries. | Ms. Jordan served from September 2009 to March 2012 as <br>President, Global Health & Wellness, and Sustainability of <br>Kraft Foods Inc., one of the largest consumer packaged food <br>and beverage companies in North America and one of the <br>largest worldwide among publicly traded consumer packaged <br>food and beverage companies. Prior to that service, she held <br>positions as President of Kraft's Cheese and Dairy business <br>unit and its Grocery business unit. Ms. Jordan serves as a <br>director of ESAB Corporation, an NYSE-listed global <br>manufacturing and engineering company that provides <br>fabrication technology products and services. Ms. Jordan is <br>also lead director of Bush Brothers & Company, a privately <br>held branded vegetable processor, and a director of I and <br>Love and You, a privately held branded manufacturer of <br>grain-free food and healthy chews and treats for pets. | Ms. Jordan served from September 2009 to March 2012 as <br>President, Global Health & Wellness, and Sustainability of <br>Kraft Foods Inc., one of the largest consumer packaged food <br>and beverage companies in North America and one of the <br>largest worldwide among publicly traded consumer packaged <br>food and beverage companies. Prior to that service, she held <br>positions as President of Kraft's Cheese and Dairy business <br>unit and its Grocery business unit. Ms. Jordan serves as a <br>director of ESAB Corporation, an NYSE-listed global <br>manufacturing and engineering company that provides <br>fabrication technology products and services. Ms. Jordan is <br>also lead director of Bush Brothers & Company, a privately <br>held branded vegetable processor, and a director of I and <br>Love and You, a privately held branded manufacturer of <br>grain-free food and healthy chews and treats for pets. |
| **Qualifications**<br>*The qualifications and experiences the board considered in* <br>*determining that Mr. Fischer should serve as a director of* <br>*the Company include his service as the Chief Executive* <br>*Officer of a public company, his operating and* <br>*manufacturing, sales and marketing and general* <br>*management experience, including responsibility for* <br>*international operations while based in the U.S. and in* <br>*Switzerland, his service on the board of a public company* <br>*in addition to Ingredion, including his service as a member* <br>*of its compensation committee, and his current and prior* <br>*service on the boards of privately held companies and not-*<br>*for-profit organizations.* | **Qualifications**<br>*The qualifications and experiences the board considered in* <br>*determining that Mr. Fischer should serve as a director of* <br>*the Company include his service as the Chief Executive* <br>*Officer of a public company, his operating and* <br>*manufacturing, sales and marketing and general* <br>*management experience, including responsibility for* <br>*international operations while based in the U.S. and in* <br>*Switzerland, his service on the board of a public company* <br>*in addition to Ingredion, including his service as a member* <br>*of its compensation committee, and his current and prior* <br>*service on the boards of privately held companies and not-*<br>*for-profit organizations.* | **Qualifications**<br>*The qualifications and experiences the board* <br>*considered in determining that Ms. Jordan should serve* <br>*as a director of the Company include her 25 years of* <br>*operating, general management and marketing* <br>*experience within a large, publicly held, global* <br>*corporation, her service as a director, chair of the* <br>*compensation committee and a member of the* <br>*nominating and corporate governance committee of* <br>*another public company, and her current and prior* <br>*service on the boards of privately held companies. In* <br>*addition, our board has determined that Ms. Jordan* <br>*qualifies as an audit committee financial expert as* <br>*defined in Item 407(d)(5) of Regulation S-K of the* <br>*Securities and Exchange Commission.* | **Qualifications**<br>*The qualifications and experiences the board* <br>*considered in determining that Ms. Jordan should serve* <br>*as a director of the Company include her 25 years of* <br>*operating, general management and marketing* <br>*experience within a large, publicly held, global* <br>*corporation, her service as a director, chair of the* <br>*compensation committee and a member of the* <br>*nominating and corporate governance committee of* <br>*another public company, and her current and prior* <br>*service on the boards of privately held companies. In* <br>*addition, our board has determined that Ms. Jordan* <br>*qualifies as an audit committee financial expert as* <br>*defined in Item 407(d)(5) of Regulation S-K of the* <br>*Securities and Exchange Commission.* |

---

---

| | | |
|:---|:---|:---|
| **4** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

---

| | | | |
|:---|:---|:---|:---|
| Charles V. Magro<br>Independent Director | Charles V. Magro<br>Independent Director | Victoria J. Reich<br>Independent Director, Lead Director | Victoria J. Reich<br>Independent Director, Lead Director |
| ![magro-sos-proxy.jpg](ingr-20260402_g9.jpg) | Chief Executive Officer of Corteva, <br>Inc.<br>**Age:** 56<br>**Director since:** May 2022<br>**Committees:** People, Culture, and <br>Compensation<br>**Other Current Public Company** <br>**Boards:** Corteva, Inc.<br>| ![reich-sos-proxy.jpg](ingr-20260402_g10.jpg) | Former Senior Vice President and <br>Chief Financial Officer of Essendant <br>Inc.<br>**Age:** 68<br>**Director since:** November 2013<br>**Committees:** Audit <br>**Other Current Public Company** <br>**Boards:** Ecolab, Inc., H&R Block, Inc.<br>|
| Mr. Magro currently serves as the Chief Executive Officer <br>and a director of Corteva, Inc., an NYSE-listed global <br>agriculture company that provides farmers around the world <br>with a balanced and diverse mix of seed, crop protection and <br>digital solutions focused on maximizing productivity to <br>enhance yield and profitability. He has served in this position <br>since November 2021. Prior to assuming his current role, Mr. <br>Magro served as a self-employed consultant from April 2021 <br>to November 2021. From January 2018 to April 2021, he <br>served as the President and Chief Executive Officer of <br>Nutrien Ltd., a Canadian-based supplier of fertilizer and <br>other crop inputs, services, and solutions that had <br>approximately $20 billion in revenue. Mr. Magro previously <br>served as a director of the Canada Pension Plan Investment <br>Board, a Canadian state-owned pension plan sponsor that <br>oversees and invests the funds contributed to and held by <br>the Canada Pension Plan, and Canpotex Ltd., one of the <br>world's largest marketers and exporters of potash. | Mr. Magro currently serves as the Chief Executive Officer <br>and a director of Corteva, Inc., an NYSE-listed global <br>agriculture company that provides farmers around the world <br>with a balanced and diverse mix of seed, crop protection and <br>digital solutions focused on maximizing productivity to <br>enhance yield and profitability. He has served in this position <br>since November 2021. Prior to assuming his current role, Mr. <br>Magro served as a self-employed consultant from April 2021 <br>to November 2021. From January 2018 to April 2021, he <br>served as the President and Chief Executive Officer of <br>Nutrien Ltd., a Canadian-based supplier of fertilizer and <br>other crop inputs, services, and solutions that had <br>approximately $20 billion in revenue. Mr. Magro previously <br>served as a director of the Canada Pension Plan Investment <br>Board, a Canadian state-owned pension plan sponsor that <br>oversees and invests the funds contributed to and held by <br>the Canada Pension Plan, and Canpotex Ltd., one of the <br>world's largest marketers and exporters of potash. | Ms. Reich served as Senior Vice President and Chief Financial <br>Officer of Essendant Inc., formerly United Stationers Inc., a <br>wholesale distributor of business products, from June 2007 to <br>July 2011. Ms. Reich is a director of NYSE-listed H&R Block, <br>Inc., a provider of tax preparation and related services, and a <br>director of NYSE-listed Ecolab Inc., a provider of water and <br>hygiene services and technologies for the food, hospitality, <br>industrial and energy markets. She serves as the chair of the <br>audit committee of H&R Block and is a member of the audit <br>committee of Ecolab. Ms. Reich also serves as a director of <br>Logan Health Whitefish Hospital, a not-for-profit <br>organization. | Ms. Reich served as Senior Vice President and Chief Financial <br>Officer of Essendant Inc., formerly United Stationers Inc., a <br>wholesale distributor of business products, from June 2007 to <br>July 2011. Ms. Reich is a director of NYSE-listed H&R Block, <br>Inc., a provider of tax preparation and related services, and a <br>director of NYSE-listed Ecolab Inc., a provider of water and <br>hygiene services and technologies for the food, hospitality, <br>industrial and energy markets. She serves as the chair of the <br>audit committee of H&R Block and is a member of the audit <br>committee of Ecolab. Ms. Reich also serves as a director of <br>Logan Health Whitefish Hospital, a not-for-profit <br>organization. |
| **Qualifications**<br>*The qualifications and experiences the board considered* <br>*in determining that Mr. Magro should serve as a director* <br>*of the Company include his current and prior service as* <br>*Chief Executive Officer of public companies, his* <br>*accounting and financial, operating and manufacturing,* <br>*sales and marketing and general management* <br>*experience, including extensive experience with mergers* <br>*and acquisitions and responsibility for international* <br>*operations while living and working outside the U.S., his* <br>*service on the boards of public companies in addition to* <br>*Ingredion, and his prior service on the boards of privately* <br>*held companies. In addition, our board has determined* <br>*that Mr. Magro qualifies as an audit committee financial* <br>*expert as defined in Item 407(d)(5) of Regulation S-K.* | **Qualifications**<br>*The qualifications and experiences the board considered* <br>*in determining that Mr. Magro should serve as a director* <br>*of the Company include his current and prior service as* <br>*Chief Executive Officer of public companies, his* <br>*accounting and financial, operating and manufacturing,* <br>*sales and marketing and general management* <br>*experience, including extensive experience with mergers* <br>*and acquisitions and responsibility for international* <br>*operations while living and working outside the U.S., his* <br>*service on the boards of public companies in addition to* <br>*Ingredion, and his prior service on the boards of privately* <br>*held companies. In addition, our board has determined* <br>*that Mr. Magro qualifies as an audit committee financial* <br>*expert as defined in Item 407(d)(5) of Regulation S-K.* | **Qualifications**<br>*The qualifications and experiences the board considered in* <br>*determining that Ms. Reich should serve as a director of* <br>*the Company include her more than 30 years of service in* <br>*corporate financial and accounting roles, her service as the* <br>*Chief Financial Officer of public companies and as a* <br>*controller, her operating and general management* <br>*experience, including responsibility for international* <br>*operations while living and working outside the U.S., her* <br>*service as a member of the finance committee of a public* <br>*company, as chair of the audit committee of two other* <br>*public companies and as a member of the governance* <br>*committee of another public company. In addition, our* <br>*board has determined that Ms. Reich qualifies as an audit* <br>*committee financial expert as defined in Item 407(d)(5) of* <br>*Regulation S-K.* | **Qualifications**<br>*The qualifications and experiences the board considered in* <br>*determining that Ms. Reich should serve as a director of* <br>*the Company include her more than 30 years of service in* <br>*corporate financial and accounting roles, her service as the* <br>*Chief Financial Officer of public companies and as a* <br>*controller, her operating and general management* <br>*experience, including responsibility for international* <br>*operations while living and working outside the U.S., her* <br>*service as a member of the finance committee of a public* <br>*company, as chair of the audit committee of two other* <br>*public companies and as a member of the governance* <br>*committee of another public company. In addition, our* <br>*board has determined that Ms. Reich qualifies as an audit* <br>*committee financial expert as defined in Item 407(d)(5) of* <br>*Regulation S-K.* |

---

---

| | |
|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT<sub>5</sub> |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

---

| | | | |
|:---|:---|:---|:---|
| Catherine A. Suever<br>Independent Director | Catherine A. Suever<br>Independent Director | Siobhán Talbot<br>Independent Director | Siobhán Talbot<br>Independent Director |
| ![suever-sos-proxy.jpg](ingr-20260402_g11.jpg) | Former Executive Vice President – <br>Finance and Administration and <br>Chief Financial Officer of Parker-<br>Hannifin Corporation<br>**Age:** 67<br>**Director since:** August 2021<br>**Committees:** Audit, Chair<br>**Other Current Public Company** <br>**Boards:** Hexcel Corporation<br>| ![Talbot-sos-proxy.jpg](ingr-20260402_g12.jpg) | Former Group Managing Director <br>and Chief Executive Officer of <br>Glanbia plc<br>**Age:** 62<br>**Director since:** April 2026<br>**Other Current Public Company** <br>**Boards:** CRH plc<br>|
| Ms. Suever served as Executive Vice President – Finance and <br>Administration and Chief Financial Officer of Parker-Hannifin <br>Corporation, an NYSE-listed global leader in motion and <br>control technologies, from April 2017 until her retirement in <br>December 2020. Prior to that service, Ms. Suever held roles <br>of increasing responsibility with Parker-Hannifin within the <br>finance department in addition to serving as the Business <br>Unit Manager for two of the company's business units.<br>Ms. Suever serves as a director and member of the audit <br>committee of Hexcel Corporation, an NYSE-listed global <br>leader in advanced composites technology that sells its <br>products in commercial, military, and recreational markets <br>for use in commercial and military aircraft, space launch <br>vehicles and satellites, wind turbine blades, sports <br>equipment, and automotive products. In addition, she is a <br>member of the American Institute of Certified Public <br>Accountants (AICPA). | Ms. Suever served as Executive Vice President – Finance and <br>Administration and Chief Financial Officer of Parker-Hannifin <br>Corporation, an NYSE-listed global leader in motion and <br>control technologies, from April 2017 until her retirement in <br>December 2020. Prior to that service, Ms. Suever held roles <br>of increasing responsibility with Parker-Hannifin within the <br>finance department in addition to serving as the Business <br>Unit Manager for two of the company's business units.<br>Ms. Suever serves as a director and member of the audit <br>committee of Hexcel Corporation, an NYSE-listed global <br>leader in advanced composites technology that sells its <br>products in commercial, military, and recreational markets <br>for use in commercial and military aircraft, space launch <br>vehicles and satellites, wind turbine blades, sports <br>equipment, and automotive products. In addition, she is a <br>member of the American Institute of Certified Public <br>Accountants (AICPA). | Ms. Talbot served as Group Managing Director and Chief <br>Executive Officer of Glanbia plc, a Euronext Dublin and <br>London-listed multinational nutrition company, from <br>November 2013 to December 2023. She served in roles of <br>increasing responsibility with that company over the course <br>of 31 years of service. She currently serves as a director of <br>CRH plc, a NYSE-listed multinational building materials and <br>solutions provider, and is a member of its audit committee. | Ms. Talbot served as Group Managing Director and Chief <br>Executive Officer of Glanbia plc, a Euronext Dublin and <br>London-listed multinational nutrition company, from <br>November 2013 to December 2023. She served in roles of <br>increasing responsibility with that company over the course <br>of 31 years of service. She currently serves as a director of <br>CRH plc, a NYSE-listed multinational building materials and <br>solutions provider, and is a member of its audit committee. |
| **Qualifications**<br>*The qualifications and experiences the board considered in* <br>*determining that Ms. Suever should serve as a director of* <br>*the Company include her extensive background in finance* <br>*and accounting, including her service as the Chief Financial* <br>*Officer of a public company, her significant experience in* <br>*compliance, risk management, systems solutions, and* <br>*investor relations, and her service as a member of the* <br>*audit committee of another public company. In addition,* <br>*our board has determined that Ms. Suever qualifies as an* <br>*audit committee financial expert as defined in* <br>*Item 407(d)(5) of Regulation S-K.* | **Qualifications**<br>*The qualifications and experiences the board considered in* <br>*determining that Ms. Suever should serve as a director of* <br>*the Company include her extensive background in finance* <br>*and accounting, including her service as the Chief Financial* <br>*Officer of a public company, her significant experience in* <br>*compliance, risk management, systems solutions, and* <br>*investor relations, and her service as a member of the* <br>*audit committee of another public company. In addition,* <br>*our board has determined that Ms. Suever qualifies as an* <br>*audit committee financial expert as defined in* <br>*Item 407(d)(5) of Regulation S-K.* | **Qualifications**<br>*The qualifications and experiences the board considered in* <br>*determining that Ms. Talbot should serve as a director of* <br>*the Company include her prior service as a Chief Executive* <br>*Officer of a public company, her extensive strategic,* <br>*accounting, financial, commercial, operating and* <br>*manufacturing experience, her responsibility for* <br>*international operations while living and working outside* <br>*of the U.S., and her service on the board and the audit* <br>*committee of another public company. In addition, our* <br>*board has determined that Ms. Talbot qualifies as an audit* <br>*committee financial expert as defined in Item 407(d)(5) of* <br>*Regulation S-K.* | **Qualifications**<br>*The qualifications and experiences the board considered in* <br>*determining that Ms. Talbot should serve as a director of* <br>*the Company include her prior service as a Chief Executive* <br>*Officer of a public company, her extensive strategic,* <br>*accounting, financial, commercial, operating and* <br>*manufacturing experience, her responsibility for* <br>*international operations while living and working outside* <br>*of the U.S., and her service on the board and the audit* <br>*committee of another public company. In addition, our* <br>*board has determined that Ms. Talbot qualifies as an audit* <br>*committee financial expert as defined in Item 407(d)(5) of* <br>*Regulation S-K.* |

---

---

| | | |
|:---|:---|:---|
| **6** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

---

| | | | |
|:---|:---|:---|:---|
| Stephan B. Tanda<br>Independent Director | Stephan B. Tanda<br>Independent Director | Jorge A. Uribe<br>Independent Director | Jorge A. Uribe<br>Independent Director |
| ![tanda-sos-proxy.jpg](ingr-20260402_g13.jpg) | President and Chief Executive Officer <br>of AptarGroup, Inc.<br>**Age:** 60<br>**Director since:** August 2019<br>**Committees:** Corporate Governance <br>and Nominating, Chair<br>**Other Current Public Company** <br>**Boards:** AptarGroup, Inc.<br>| ![uribe-sos-proxy.jpg](ingr-20260402_g14.jpg) | Former Global Productivity and <br>Organization Transformation <br>Officer of The Procter & <br>Gamble Company<br>**Age:** 69<br>**Director since:** July 2015<br>**Committees:** Corporate Governance <br>and Nominating<br>**Other Current Public Company** <br>**Boards:** General Mills, Inc.<br>|
| Mr. Tanda has served as President and Chief Executive Officer <br>and as a director of AptarGroup, Inc., an NYSE-listed global <br>leader in consumer dispensing, active packaging, and drug <br>delivery solutions, since February 2017. He has announced <br>his intention to retire as Chief Executive Officer of <br>AptarGroup, Inc. on September 1, 2026 and as a director of <br>AptarGroup, Inc. by the end of 2026. Mr. Tanda's business <br>career spans over 34 years and includes living in seven <br>countries while working in leadership roles for various public <br>companies. Mr. Tanda is a member of the Executive <br>Education Board of The Wharton School of the University of <br>Pennsylvania. He previously served as a director of Patheon <br>NV, formerly an NYSE-listed company that provided <br>pharmaceutical development and manufacturing services, <br>and Semperit AG Holding, a Vienna Stock Exchange-listed <br>manufacturer of industrial rubber and plastic products. | Mr. Tanda has served as President and Chief Executive Officer <br>and as a director of AptarGroup, Inc., an NYSE-listed global <br>leader in consumer dispensing, active packaging, and drug <br>delivery solutions, since February 2017. He has announced <br>his intention to retire as Chief Executive Officer of <br>AptarGroup, Inc. on September 1, 2026 and as a director of <br>AptarGroup, Inc. by the end of 2026. Mr. Tanda's business <br>career spans over 34 years and includes living in seven <br>countries while working in leadership roles for various public <br>companies. Mr. Tanda is a member of the Executive <br>Education Board of The Wharton School of the University of <br>Pennsylvania. He previously served as a director of Patheon <br>NV, formerly an NYSE-listed company that provided <br>pharmaceutical development and manufacturing services, <br>and Semperit AG Holding, a Vienna Stock Exchange-listed <br>manufacturer of industrial rubber and plastic products. | Mr. Uribe served as the Global Productivity and Organization <br>Transformation Officer of The Procter & Gamble Company, <br>the world's largest maker of consumer packaged goods, from <br>December 2012 to July 2015. Prior to that service, Mr. Uribe <br>spent more than 33 years with Procter & Gamble, where his <br>various roles included responsibility over operations in Latin <br>America, Switzerland, Central America and the Caribbean, <br>Cyprus, Malaysia, the United Arab Emirates and the Gulf <br>countries, Saudi Arabia, and Colombia. Mr. Uribe is a director <br>of General Mills, Inc., an NYSE-listed leading global food <br>company. | Mr. Uribe served as the Global Productivity and Organization <br>Transformation Officer of The Procter & Gamble Company, <br>the world's largest maker of consumer packaged goods, from <br>December 2012 to July 2015. Prior to that service, Mr. Uribe <br>spent more than 33 years with Procter & Gamble, where his <br>various roles included responsibility over operations in Latin <br>America, Switzerland, Central America and the Caribbean, <br>Cyprus, Malaysia, the United Arab Emirates and the Gulf <br>countries, Saudi Arabia, and Colombia. Mr. Uribe is a director <br>of General Mills, Inc., an NYSE-listed leading global food <br>company. |
| **Qualifications**<br>*The qualifications and experiences the board considered in* <br>*determining that Mr. Tanda should serve as a director of the* <br>*Company include his current service as the President and* <br>*Chief Executive Officer of a public company, his operating,* <br>*manufacturing, and general management experience,* <br>*including while living and working outside the U.S., and his* <br>*service on the boards of other public companies. In addition,* <br>*our board has determined that Mr. Tanda qualifies as an* <br>*audit committee financial expert as defined in Item 407(d)(5)* <br>*of Regulation S-K.* | **Qualifications**<br>*The qualifications and experiences the board considered in* <br>*determining that Mr. Tanda should serve as a director of the* <br>*Company include his current service as the President and* <br>*Chief Executive Officer of a public company, his operating,* <br>*manufacturing, and general management experience,* <br>*including while living and working outside the U.S., and his* <br>*service on the boards of other public companies. In addition,* <br>*our board has determined that Mr. Tanda qualifies as an* <br>*audit committee financial expert as defined in Item 407(d)(5)* <br>*of Regulation S-K.* | **Qualifications**<br>*The qualifications and experiences the board considered in* <br>*determining that Mr. Uribe should serve as a director of* <br>*the Company include his more than 30 years of operating* <br>*and general management experience and sales and* <br>*marketing experience, including multi-regional and multi-*<br>*country responsibility for international operations while* <br>*living and working outside the U.S. within a larger, publicly* <br>*held, global corporation, and his service on the board of a* <br>*public company in addition to Ingredion, including the* <br>*compensation committee of another public company, and* <br>*his prior service on the boards of other private and public* <br>*companies and a not-for-profit organization.* | **Qualifications**<br>*The qualifications and experiences the board considered in* <br>*determining that Mr. Uribe should serve as a director of* <br>*the Company include his more than 30 years of operating* <br>*and general management experience and sales and* <br>*marketing experience, including multi-regional and multi-*<br>*country responsibility for international operations while* <br>*living and working outside the U.S. within a larger, publicly* <br>*held, global corporation, and his service on the board of a* <br>*public company in addition to Ingredion, including the* <br>*compensation committee of another public company, and* <br>*his prior service on the boards of other private and public* <br>*companies and a not-for-profit organization.* |

---

---

| | |
|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT<sub>7</sub> |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

---

| | | | |
|:---|:---|:---|:---|
| Patricia Verduin<br>Independent Director | Patricia Verduin<br>Independent Director | Dwayne A. Wilson<br>Independent Director | Dwayne A. Wilson<br>Independent Director |
| ![verduin-sos-proxy.jpg](ingr-20260402_g15.jpg) | Former Chief Technology Officer, <br>Global Technology for Colgate-<br>Palmolive Company<br>**Age:** 66<br>**Director since:** May 2023<br>**Committees:** Corporate Governance <br>and Nominating<br>**Other Current Public Company** <br>**Boards:** Avient Corporation, FMC <br>Corporation<br>| ![willis-sos-proxy.jpg](ingr-20260402_g16.jpg) | Former Senior Vice President of <br>Fluor Corporation<br>**Age:** 67<br>**Director since:** May 2010<br>**Committees:** Audit<br>**Other Current Public Company** <br>**Boards:** Crown Holdings, Inc., DT <br>Midstream, Inc., Sterling <br>Construction Company, Inc.<br>|
| Dr. Verduin served as Chief Technology Officer, Global <br>Technology, for Colgate-Palmolive Company, an NYSE-listed <br>multinational consumer products company that specializes in <br>the production, distribution, and provision of household, <br>health care, personal care, and veterinary products, from <br>February 2009 to January 2023. Dr. Verduin serves as a <br>director of Avient Corporation, an NYSE-listed global <br>manufacturer of specialized polymer materials; FMC <br>Corporation, an NYSE-listed global agricultural science <br>company specializing in crop protection; and Reckitt <br>Benckiser Group PLC, a FTSE-listed global consumer products <br>company. Dr. Verduin was a director of the Monsanto <br>Company, an NYSE-listed agrochemical and agricultural <br>biotechnology corporation, prior to its acquisition by Bayer <br>AG. | Dr. Verduin served as Chief Technology Officer, Global <br>Technology, for Colgate-Palmolive Company, an NYSE-listed <br>multinational consumer products company that specializes in <br>the production, distribution, and provision of household, <br>health care, personal care, and veterinary products, from <br>February 2009 to January 2023. Dr. Verduin serves as a <br>director of Avient Corporation, an NYSE-listed global <br>manufacturer of specialized polymer materials; FMC <br>Corporation, an NYSE-listed global agricultural science <br>company specializing in crop protection; and Reckitt <br>Benckiser Group PLC, a FTSE-listed global consumer products <br>company. Dr. Verduin was a director of the Monsanto <br>Company, an NYSE-listed agrochemical and agricultural <br>biotechnology corporation, prior to its acquisition by Bayer <br>AG. | Mr. Wilson served as Senior Vice President of Fluor <br>Corporation, reporting to the Chairman and CEO on key <br>initiatives of strategic importance, from June 2014 to <br>June 2016. Fluor is one of the world's largest publicly <br>owned engineering, procurement, construction, <br>maintenance, and project management companies.<br>Mr. Wilson previously served as President and Chief <br>Executive Officer of Savannah River Nuclear Solutions, LLC, <br>the managing and operating contractor of the U.S. <br>Department of Energy's Savannah River Site including the <br>Savannah River National Laboratory, from October 2011 to <br>June 2014. Mr. Wilson is a director and member of the audit <br>committee of NYSE-listed Crown Holdings, Inc., a leading <br>global supplier of rigid packaging products to consumer <br>marketing companies; a director of NYSE-listed DT <br>Midstream, Inc., an owner, operator and developer of <br>natural gas midstream interstate and intrastate pipelines, <br>storage, and gathering systems, and compression, treatment <br>and surface facilities; and a director and member of the audit <br>committee of publicly traded Sterling Construction Company, <br>Inc., a leading infrastructure services provider of e-<br>infrastructure solutions, building solutions, and <br>transportation solutions. Mr. Wilson is a National Association <br>of Corporate Directors Fellow. | Mr. Wilson served as Senior Vice President of Fluor <br>Corporation, reporting to the Chairman and CEO on key <br>initiatives of strategic importance, from June 2014 to <br>June 2016. Fluor is one of the world's largest publicly <br>owned engineering, procurement, construction, <br>maintenance, and project management companies.<br>Mr. Wilson previously served as President and Chief <br>Executive Officer of Savannah River Nuclear Solutions, LLC, <br>the managing and operating contractor of the U.S. <br>Department of Energy's Savannah River Site including the <br>Savannah River National Laboratory, from October 2011 to <br>June 2014. Mr. Wilson is a director and member of the audit <br>committee of NYSE-listed Crown Holdings, Inc., a leading <br>global supplier of rigid packaging products to consumer <br>marketing companies; a director of NYSE-listed DT <br>Midstream, Inc., an owner, operator and developer of <br>natural gas midstream interstate and intrastate pipelines, <br>storage, and gathering systems, and compression, treatment <br>and surface facilities; and a director and member of the audit <br>committee of publicly traded Sterling Construction Company, <br>Inc., a leading infrastructure services provider of e-<br>infrastructure solutions, building solutions, and <br>transportation solutions. Mr. Wilson is a National Association <br>of Corporate Directors Fellow. |
| **Qualifications**<br>*The qualifications and experiences the board considered in* <br>*determining that Dr. Verduin should serve as a director of* <br>*the Company include her four decades of leadership in the* <br>*consumer- packaged goods industry and significant* <br>*contributions in innovation, operations, scientific policy, and* <br>*communications, including her service as Chief Technology* <br>*Officer, Global Technology, of a public company, her* <br>*extensive experience with leading new product launches* <br>*(encompassing both regulatory and product quality aspects),* <br>*her leadership of a public company's sustainability* <br>*programs, and her service as a director of other public* <br>*companies.* | **Qualifications**<br>*The qualifications and experiences the board considered in* <br>*determining that Dr. Verduin should serve as a director of* <br>*the Company include her four decades of leadership in the* <br>*consumer- packaged goods industry and significant* <br>*contributions in innovation, operations, scientific policy, and* <br>*communications, including her service as Chief Technology* <br>*Officer, Global Technology, of a public company, her* <br>*extensive experience with leading new product launches* <br>*(encompassing both regulatory and product quality aspects),* <br>*her leadership of a public company's sustainability* <br>*programs, and her service as a director of other public* <br>*companies.* | **Qualifications**<br>*The qualifications and experiences the board considered* <br>*in determining that Mr. Wilson should serve as a director* <br>*of the Company include his more than 35 years of project* <br>*management, operating and manufacturing, sales and* <br>*marketing and general management experience,* <br>*including responsibility for international operations while* <br>*based in the U.S., within a large publicly held corporation,* <br>*his service as President and Chief Executive Officer of the* <br>*managing and operating contractor of a significant U.S.* <br>*Department of Energy site, including a National* <br>*Laboratory, and his current and past service on the* <br>*boards of multiple public companies in addition to* <br>*Ingredion and on the board of a not-for-profit* <br>*organization.* | **Qualifications**<br>*The qualifications and experiences the board considered* <br>*in determining that Mr. Wilson should serve as a director* <br>*of the Company include his more than 35 years of project* <br>*management, operating and manufacturing, sales and* <br>*marketing and general management experience,* <br>*including responsibility for international operations while* <br>*based in the U.S., within a large publicly held corporation,* <br>*his service as President and Chief Executive Officer of the* <br>*managing and operating contractor of a significant U.S.* <br>*Department of Energy site, including a National* <br>*Laboratory, and his current and past service on the* <br>*boards of multiple public companies in addition to* <br>*Ingredion and on the board of a not-for-profit* <br>*organization.* |

---

---

| | | |
|:---|:---|:---|
| **8** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

---

| | |
|:---|:---|
| James P. Zallie<br>Director<br>|  |
| ![zallie-sos-proxy.jpg](ingr-20260402_g17.jpg) | Chairman of the Board, President <br>and Chief Executive Officer of the <br>Company<br>**Age:** 64<br>**Director since:** September 2017<br>**Other Current Public Company** <br>**Boards:** Sylvamo Corporation<br>|
| Mr. Zallie has been President and Chief Executive Officer of <br>the Company since January 1, 2018 and Chairman since <br>February 9, 2026. Before assuming his current position, he <br>served at Ingredion as Executive Vice President, Global <br>Specialties and President, Americas from January 2016 to <br>December 2017. Mr. Zallie previously served at Ingredion as <br>Executive Vice President, Global Specialties and President, <br>North America and EMEA from January 2014 to December <br>2015; as Executive Vice President, Global Specialties and <br>President, EMEA and Asia-Pacific from February 2012 to <br>January 2014; and as Executive Vice President and President, <br>Global Ingredient Solutions from October 2010 to January <br>2012. Mr. Zallie served as President and Chief Executive <br>Officer of the National Starch LLC business from January 2007 <br>to September 2010. National Starch was acquired by <br>Ingredion in October 2010.<br>Mr. Zallie serves as a director and member of the audit <br>committee of Sylvamo Corporation, an NYSE-listed global <br>producer of uncoated papers, and as a director of <br>Northwestern Medicine North Region, a not-for-profit <br>organization. Mr. Zallie served as a director of Innophos <br>Holdings, Inc., a formerly publicly traded international <br>producer of food and beverage ingredients, from September <br>2014 to April 2018. | Mr. Zallie has been President and Chief Executive Officer of <br>the Company since January 1, 2018 and Chairman since <br>February 9, 2026. Before assuming his current position, he <br>served at Ingredion as Executive Vice President, Global <br>Specialties and President, Americas from January 2016 to <br>December 2017. Mr. Zallie previously served at Ingredion as <br>Executive Vice President, Global Specialties and President, <br>North America and EMEA from January 2014 to December <br>2015; as Executive Vice President, Global Specialties and <br>President, EMEA and Asia-Pacific from February 2012 to <br>January 2014; and as Executive Vice President and President, <br>Global Ingredient Solutions from October 2010 to January <br>2012. Mr. Zallie served as President and Chief Executive <br>Officer of the National Starch LLC business from January 2007 <br>to September 2010. National Starch was acquired by <br>Ingredion in October 2010.<br>Mr. Zallie serves as a director and member of the audit <br>committee of Sylvamo Corporation, an NYSE-listed global <br>producer of uncoated papers, and as a director of <br>Northwestern Medicine North Region, a not-for-profit <br>organization. Mr. Zallie served as a director of Innophos <br>Holdings, Inc., a formerly publicly traded international <br>producer of food and beverage ingredients, from September <br>2014 to April 2018. |
| **Qualifications**<br>*The qualifications and experiences the board considered in* <br>*determining that Mr. Zallie should serve as a director of the* <br>*Company include his current service as the Chairman of the* <br>*Board, President and Chief Executive Officer of Ingredion, his* <br>*prior service as the President of a large business unit of a* <br>*public company, his operating and manufacturing, sales and* <br>*marketing and general management experience, including* <br>*while living and working outside the U.S., and his current* <br>*service on the board of a public company in addition to* <br>*Ingredion, his prior service on the board of another public* <br>*company, and his current service on the board of a not-for-*<br>*profit organization.* | **Qualifications**<br>*The qualifications and experiences the board considered in* <br>*determining that Mr. Zallie should serve as a director of the* <br>*Company include his current service as the Chairman of the* <br>*Board, President and Chief Executive Officer of Ingredion, his* <br>*prior service as the President of a large business unit of a* <br>*public company, his operating and manufacturing, sales and* <br>*marketing and general management experience, including* <br>*while living and working outside the U.S., and his current* <br>*service on the board of a public company in addition to* <br>*Ingredion, his prior service on the board of another public* <br>*company, and his current service on the board of a not-for-*<br>*profit organization.* |

---

---

| | |
|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT<sub>9</sub> |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

**The Board and Committees**

The business and affairs of the Company are conducted under the direction of its Board of Directors.

Under our certificate of incorporation, the Board of Directors may have not fewer than seven or more than 17 members. The

Board of Directors is currently composed of 11 directors, ten of whom are non-employee directors.

The experience, qualifications, attributes, and skills the board considered in determining that the nominees standing for

election should serve as directors are discussed above in their biographies. See the discussion under "Corporate Governance

and Nominating Committee" for a description of the board's criteria for selecting director nominees.

**INDEPENDENCE**

The Board of Directors has determined that the following ten directors each satisfy the definition of independence under the

Company's Corporate Governance Principles, which incorporate the director independence standards established by the rules

of the New York Stock Exchange ("NYSE"): Mr. Fischer, Ms. Jordan, Mr. Magro, Ms. Reich, Ms. Suever, Ms. Talbot, Mr. Tanda,

Mr. Uribe, Ms. Verduin, and Mr. Wilson. In addition, the Board of Directors has determined that the members of the People,

Culture, and Compensation Committee ("PCC Committee") and the Audit Committee satisfy the additional independence

requirements established by Securities and Exchange Commission ("SEC") and NYSE rules for membership on those committees.

Under the rules of the NYSE, a director is considered to be independent if the Board of Directors has affirmatively determined

that the director has no material relationship with the Company or any of its subsidiaries (either directly or as a partner,

stockholder or officer of an organization that has a relationship with the Company or any of its subsidiaries). In addition, the

NYSE rules stipulate that certain relationships preclude a director from being considered to be independent.

**MEETINGS**

The board held six meetings in 2025. Each director attended at least 75 percent of the meetings of the board and the

committees of the board on which he or she served during 2025 during the period of such service.

We encourage, but do not require, our directors to attend the annual meeting of stockholders. All 11 directors then serving on

the board attended our 2025 annual meeting of stockholders.

Non-employee directors meet regularly in executive sessions without the presence of management. Executive sessions are held

in conjunction with each regularly scheduled meeting of the board. "Non-employee" directors are board members who are not

Company officers or employees and may include directors who are not "independent" by reason of the existence of a material

relationship with the Company. All of the Company's ten current non-employee directors qualify as independent directors. The

independent Lead Director presides over executive sessions of our non-employee directors.

**TERM OF SERVICE**

The board does not impose term limits on service, as it believes term limits could unnecessarily interfere with the continuity,

diversity, developed experience and knowledge, and the long-term outlook the board must possess. The Corporate Governance

and Nominating Committee ("CGN Committee") will consider the length of a director's prior service in making a

recommendation to the board as to whether a director should be nominated for re-election. In making its recommendation, the

CGN Committee will consider such factors as effectiveness and productivity of the director, the need for retaining an

experienced director, and other factors identified during the board self-evaluation process.

Board policy requires non-employee directors to retire no later than the annual meeting following their 75th birthday.

Employee directors, including the Chief Executive Officer ("CEO"), are required to retire from the board upon their retirement

or other cessation of service as an employee, unless the board determines otherwise. In general, board policy requires

executive officers to retire at age 65. In November 2025, the board waived the applicability of this policy with respect to James

P. Zallie, our current Chairman of the Board, CEO, and President.

---

| | | |
|:---|:---|:---|
| **10** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

**CORPORATE GOVERNANCE DOCUMENTS**

The Company's Corporate Governance Principles; Code of Ethics for Chief Executive Officer, Chief Financial Officer, and Other

Executives Involved in Financial Reporting; and Code of Conduct are available in the "Corporate Governance" section of our

investor relations website at *https://ir.ingredionincorporated.com/corporate-governance/highlights*.

The Company's Corporate Governance Principles were adopted by our Board of Directors. The Corporate Governance Principles

are designed to promote effective functioning of the board's activities, to ensure that we conduct our business in accordance

with the highest legal and ethical standards, and to enhance shareholder value. We seek under our Corporate Governance

Principles to ensure that strong, independent directors continue to effectively oversee our management and provide vigorous

oversight of how we address key issues relating to strategy, risk, and integrity.

Among the topics addressed in our Corporate Governance Guidelines are:

---

| | |
|:---|:---|
| •Number and structure of committees | •Board membership criteria and selection |
| •Assignment and rotation of committee members | •Continuing education for directors |
| •Frequency, length, and agendas for meetings | •Term limits for directors |
| •Director responsibilities | •Evaluation of the CEO and succession planning |
| •Board oversight of risk management processes | •Board interaction with investors, the press, customers, and <br>others<br>|
| •Access to management | •Membership on other boards |
| •Size of the board | •Engagement of independent advisors |
| •Board independence |  |

---

**BOARD OVERSIGHT OF RISK MANAGEMENT PROCESSES**

The Board of Directors regularly devotes time during its meetings to review and discuss the significant risks facing the Company

and the steps that the Company takes to monitor, manage, and mitigate such exposures. The board's oversight of risk

management includes consideration of strategic, competitive, economic, geopolitical, and political risks, among others.

Significant risks include those identified in the Company's disclosures in its Annual Report on Form 10-K and its other SEC filings

and forward-looking statements disclosures. The management of these risks are prioritized by Company management and

discussed with the board and the appropriate committees of the board in the exercise by the board and those committees of

their respective oversight roles. The board conducts a comprehensive annual review of the Company's risk management

processes with input from management and all relevant board committees. The CEO and the Chief Financial Officer ("CFO")

report to the board quarterly on risk management matters.

The Audit Committee is the board committee with primary responsibility for oversight of the Company's risk management

profile and compliance with financial, legal, and regulatory requirements. Under its charter, the Audit Committee has the

responsibility to review policies with respect to risk assessment and risk management, to discuss the Company's major risk

exposures and the steps management has taken to monitor such exposures, and to review, on an annual basis, a report

prepared by the Chief Legal Officer on litigation in which the Company is a party or otherwise affected. In the exercise of that

responsibility, the Audit Committee discusses with management the major financial, legal, and regulatory compliance risk

exposures facing the Company and the appropriate responses to such risks. The Audit Committee considers financial risk

management policies and exposures relating to commodity prices, including corn and energy prices, foreign exchange rates,

interest rates, and financial derivatives, and reviews insurable risk management policies. The Audit Committee also reviews the

Company's capital structure, access to capital markets, liquidity, credit availability, and related matters.

The Audit Committee also exercises oversight with respect to the status of corporate security, the security for the Company's

electronic data processing and information systems ("information security"), and the general security of the Company's people

and assets. The board receives information security updates at its regularly scheduled meetings that address cybersecurity

metrics, highlights, and risks. At least two times each year, the Company's Chief Digital and Information Officer reports to the

Audit Committee on information security controls, risks, guidelines, and developments. The Chief Digital and Information

Officer oversees the Global Information Security Team and works in partnership with our Internal Audit function to review

information security and technology-related internal controls and controls processes. Our Company-wide information security

---

| | |
|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT<sub>11</sub> |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

training program includes security awareness training, regular phishing simulations, and other targeted communications and

trainings throughout the year.

In addition to the Audit Committee, the other committees of the board consider risk in connection with their oversight of the

matters within the scope of their respective charters.

The PCC Committee oversees labor and other human capital management matters as well as executive and director

compensation programs. In addition, the PCC Committee considers whether the Company's compensation plans, policies, and

practices encourage excessive or inappropriate risk-taking that could have a material adverse effect on the Company's business

and performance. Furthermore, the PCC Committee considers the Company's compensation and benefit programs in the

context of competitive risks faced by the Company. In its 2025 risk review, the PCC Committee determined that the Company's

pay programs did not contain any features that would encourage excessive risk-taking.

The CGN Committee addresses potential risks that could result from inadequate independence or other matters relating to

board composition and effectiveness, potential conflicts of interest, environmental compliance matters, and the operation and

effectiveness of the Company's compliance programs related to business ethics and product safety and quality.

Each committee provides regular reports on its activities to the Board of Directors with respect to its oversight and review of

risk assessment and risk management matters.

As part of overall governance and risk management, the board and its three committees are actively engaged in oversight of

responsible business and sustainability-related matters, including environmental, social, and governance-related topics.

Exercise of such oversight includes reviewing the Company's strategy and providing guidance with respect to these matters and

overseeing performance against the Company's goals. A summary of the board governance with respect to sustainability-

related matters is as follows:

---

| | | | |
|:---|:---|:---|:---|
| <u>Board of Directors</u> | <u>Board of Directors</u> | <u>Board of Directors</u> |  |
| •Active oversight over the Company's strategy, risk management, and overall performance<br>•Strategic oversight includes integration of responsible business and sustainability-related matters in the <br>Company's overall strategy<br>•Review of relevant Company reports prior to external publication | •Active oversight over the Company's strategy, risk management, and overall performance<br>•Strategic oversight includes integration of responsible business and sustainability-related matters in the <br>Company's overall strategy<br>•Review of relevant Company reports prior to external publication | •Active oversight over the Company's strategy, risk management, and overall performance<br>•Strategic oversight includes integration of responsible business and sustainability-related matters in the <br>Company's overall strategy<br>•Review of relevant Company reports prior to external publication | ![theboardandcommittes1a.jpg](ingr-20260402_g18.jpg) |
|  |  |  | ![theboardandcommittes1a.jpg](ingr-20260402_g18.jpg) |
| <u>Audit Committee</u> | <u>CGN Committee</u> | <u>PCC Committee</u> | ![theboardandcommittes1a.jpg](ingr-20260402_g18.jpg) |
| •Governance over financial <br>reporting process and controls<br>•Oversight over enterprise risk <br>management, including <br>cybersecurity<br>•Governance over the <br>sustainability-related reporting <br>process and controls, as <br>required by applicable laws and <br>regulations<br>| •Corporate governance and <br>stockholders' rights<br>•Ensuring the board has the right <br>mix of skills and experience to <br>be effective, including the <br>evaluation of the board and its <br>committees<br>•Oversight over:<br>◦Environmental impact and <br>sustainability, including <br>emissions, water usage, and <br>climate-related risk<br>◦People and food safety/<br>quality<br>◦Corporate compliance <br>program<br>| •Oversight over human capital <br>management strategies linked <br>to recruitment, talent <br>development, retention, <br>inclusion & belonging, and <br>overall Company culture<br>•Aligning executive <br>compensation to the Company <br>strategy and best interests of <br>stockholders<br>•Monitoring management <br>initiatives related to the <br>Company's ongoing <br>commitment to pay equity<br>| ![theboardandcommittes1a.jpg](ingr-20260402_g18.jpg) |
|  |  |  | ![theboardandcommittes1a.jpg](ingr-20260402_g18.jpg) |
| <u>Company Management</u> | <u>Company Management</u> | <u>Company Management</u> | ![theboardandcommittes1a.jpg](ingr-20260402_g18.jpg) |
| •Development and execution of Company strategy and capital investment plan<br>•Day-to-day responsibility for Company performance<br>•Oversight and decision-making via Sustainability Executive Advisory Committee (seven executive leadership team <br>members and the Vice President, Corporate Sustainability) and other relevant executive forums | •Development and execution of Company strategy and capital investment plan<br>•Day-to-day responsibility for Company performance<br>•Oversight and decision-making via Sustainability Executive Advisory Committee (seven executive leadership team <br>members and the Vice President, Corporate Sustainability) and other relevant executive forums | •Development and execution of Company strategy and capital investment plan<br>•Day-to-day responsibility for Company performance<br>•Oversight and decision-making via Sustainability Executive Advisory Committee (seven executive leadership team <br>members and the Vice President, Corporate Sustainability) and other relevant executive forums | ![theboardandcommittes1a.jpg](ingr-20260402_g18.jpg) |

---

![](ingr-20260402_g19.gif)

![](ingr-20260402_g20.gif)

![](ingr-20260402_g20.gif)

![](ingr-20260402_g20.gif)

![](ingr-20260402_g21.gif)

![](ingr-20260402_g22.gif)

![](ingr-20260402_g22.gif)

![](ingr-20260402_g20.gif)

![](ingr-20260402_g20.gif)

![](ingr-20260402_g20.gif)

![](ingr-20260402_g23.gif)

---

| | | |
|:---|:---|:---|
| **12** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

**BOARD LEADERSHIP**

The board periodically evaluates the leadership structure that best meets the Company's and stockholders' needs based on the

individuals then serving and the Company's particular circumstances. Board policy and the Company's bylaws afford the board

flexibility to separate or combine the positions of Chairman of the Board and CEO as the board, from time to time, may

determine to be the most suitable structure for governance and effective board functioning.

Since February 9, 2026, both the Chairman of the Board and Chief Executive Officer positions have been held by Mr. Zallie. Our

Corporate Governance Principles provide that if the Chairman and CEO positions are combined, the board's independent

directors will elect an independent director to serve as Lead Director for a term of one year. On February 9, 2026, the

independent directors elected Ms. Reich to serve as the Lead Director.

The board has determined that its current structure, with combined Chairman and Chief Executive Officer roles and a Lead

Director, together with the exercise of key oversight responsibilities by our independent directors, is in the best interests of the

Company and its stockholders. The board believes that combining the Chairman and CEO positions is currently the most

effective leadership structure for the Company given Mr. Zallie's in-depth knowledge of the Company's businesses and industry,

his ability to formulate and implement strategic initiatives, and his extensive contact with and knowledge of the Company's

customers and other business partners. As Chief Executive Officer, Mr. Zallie is deeply involved in the Company's day-to-day

operations and is therefore able to effectively elevate the most critical business issues for consideration by the board's

independent directors and is best positioned to oversee the execution of strategy across each of the Company's businesses to

maximize long-term shareholder value. The Lead Director is given broad authority, as described below, to lead oversight of

management by our independent directors.

In accordance with the Company's Corporate Governance Principles, the Lead Director is charged with overseeing the board's

governance processes, including board self-evaluations, CEO succession planning, and other governance-related matters. The

Lead Director's other responsibilities include the following:

• presiding at meetings of the board in the absence of the Chairman and at executive sessions of the board conducted

without the presence of management,

• serving as a liaison between the independent directors and the Chairman,

• providing direct feedback to the Chairman on matters discussed in executive sessions of the board and serving as an

informal communication link between the directors and management,

• working with the Chairman and the Chair of the CGN Committee regarding matters to be included in board agendas and

the information associated with those agendas,

• approving the agendas, meeting schedules, and information provided to the board,

• working with the Chairman to ensure that the board conducts its business in an independent manner and is alert to its

obligations to the Company's stockholders,

• working with the Chairman to ensure that board meetings are conducted in such a manner as to allow adequate time

and opportunity for appropriate discussion of matters brought before the board,

• as appropriate, exercising authority to call meetings of the board and meetings of the independent directors, and

• being available as deemed appropriate by the board for consultation and direct communication with stockholders.

The Lead Director may assume such other responsibilities as the independent directors may designate from time to time.

The Lead Director is subject to appointment or reappointment on an annual basis.

**COMMITTEES OF THE BOARD**

The board currently has three standing committees, consisting of the Audit Committee, the PCC Committee, and the CGN

Committee. Each of these committees operates pursuant to a written charter adopted by the board. These charters are

available in the "Corporate Governance" section of our investor relations website at *https://ir.ingredionincorporated.com/*

*corporate-governance/highlights*.

---

| | |
|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT<sub>13</sub> |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

**AUDIT COMMITTEE**

---

| | | |
|:---|:---|:---|
| **Membership** | **Membership** |  |
| **Number of meetings held during 2025: 10** | **Number of meetings held during 2025: 10** | Report: page <u>[70](#ie7e472361805446c8b302de30ed47fbf_97)</u> |
| ![suever-sos-proxy.jpg](ingr-20260402_g11.jpg) | ![reich-sos-proxy.jpg](ingr-20260402_g10.jpg) | ![willis-sos-proxy.jpg](ingr-20260402_g16.jpg) |
| C. A. Suever <br>(Chair, since February 10, 2026)<br>| V. J. Reich | D. A. Wilson |

---

Our Audit Committee is composed entirely of independent directors, as "independent director" is defined under the rules of the

NYSE, including the additional independence requirements under SEC rules applicable to Audit Committee membership. Each of

the members of the Audit Committee is "financially literate," as required by the rules of the NYSE. The board has determined

that Ms. Suever, the Chair of the Audit Committee, and Ms. Reich, who also serves as a committee member as of the date of

this proxy statement, each qualify as an "audit committee financial expert" as defined in Item 407(d)(5) of Regulation S-K. In

addition, as described in the director qualifications matrix below, four other board members who do not serve on the Audit

Committee (Ms. Jordan, Mr. Magro, Ms. Talbot, and Mr. Tanda) have been determined by the board to be audit committee

financial experts. Ms. Suever succeeded Ms. Reich, who served as Chair of the Audit Committee during 2025, as committee

Chair.

The primary responsibilities of the Audit Committee, among others, are to:

• assist the board in fulfilling its oversight responsibilities related to the integrity of the financial reporting process, the

effectiveness of the systems of financial control, and the Company's compliance with legal and regulatory requirements,

• act as a separately designated standing audit committee established in accordance with the Securities Exchange Act of

1934, as amended (the "Exchange Act"), and NYSE rules,

• select the Company's independent auditors, who are accountable to and meet privately with this committee on a

regular basis, and exercise direct responsibility for the retention, evaluation, termination, compensation, and oversight

of the independent auditors,

• review the scope of the audit to be conducted by the independent auditors and the results of their audit,

• oversee the Company's financial reporting activities and adherence to accounting standards and principles,

• oversee the Company's enterprise risk management program,

• review policies and procedures with respect to risk assessment and risk management, including risk with respect to

cybersecurity, commodity prices and hedging strategies, foreign exchange rates, interest rates, and foreign exchange

derivatives,

• discuss with management the Company's risks relating to the Company's financial statements and financial reporting

processes, and the guidelines, policies, and processes for monitoring and mitigating such risks,

• approve audit and non-audit services provided to the Company by the independent auditors,

• review the organization, scope, and independence of the Company's internal audit function and the Company's

disclosure controls and internal control over financial reporting, and

• conduct ongoing reviews of potential related-party transactions, including the review and approval of transactions with

"related persons," as defined under SEC rules.

---

| | | |
|:---|:---|:---|
| **14** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

**PEOPLE, CULTURE, AND COMPENSATION COMMITTEE**

---

| | | |
|:---|:---|:---|
| **Membership** | **Membership** | **Membership** |
| **Number of meetings held during 2025: 5** | **Number of meetings held during 2025: 5** | Report: page <u>[66](#ie7e472361805446c8b302de30ed47fbf_82)</u> |
| ![jordan-sos-proxy.jpg](ingr-20260402_g8.jpg) | ![fischer-sos-proxy.jpg](ingr-20260402_g7.jpg) | ![magro-sos-proxy.jpg](ingr-20260402_g9.jpg) |
| R. L. Jordan <br>(Chair, since May 2017) <br>| D. B. Fischer | C. V. Magro |

---

In addition to its responsibilities with respect to executive and director compensation, the PCC Committee oversees overall

human capital management at Ingredion and the Company's commitment to continually advancing a culture that eliminates

barriers to participation and creates a high degree of engagement across the Company's global workforce.

Our PCC Committee is composed entirely of independent directors, as "independent director" is defined under the rules of the

NYSE, including the additional independence requirements applicable to PCC Committee membership.

The primary responsibilities of the PCC Committee, among others, are to:

• review CEO compensation and make a recommendation to the board regarding the annual compensation for the CEO

(including base salary, annual incentive plan target, and long-term incentive grant),

• meet with the CEO annually to review the performance of the Company's other executive officers,

• together with the CEO, determine the total compensation for the Company's other executive officers,

• govern our executive compensation programs and ensure that compensation programs are implemented according to

our compensation philosophy, as established by the PCC Committee, and that compensation actions are designed to

attract, motivate, and retain our executive officers while aligning with our business strategy, our expected financial

results, interests of our stockholders, and market practice,

• annually review the design of the Company's executive compensation plans,

• recommend to the board the compensation arrangements for non-employee directors, including deferred

compensation plans,

• review and discuss with management the Compensation Discussion and Analysis to be included in our annual proxy

statement or Annual Report on Form 10-K filed with the SEC,

• prepare the PCC Committee Report, as required by the rules of the SEC,

• review the results of the annual advisory vote on named executive officer compensation, determine what, if any, actions

or policy recommendations are warranted based on the advisory vote and other feedback from stockholders, and make

recommendations on how frequently we should provide our stockholders with such an advisory vote,

• review, oversee, and administer compliance with the Ingredion Policy on Recoupment of Incentive Compensation,

including recovery or "clawback" of excess incentive-based compensation (including stock options) paid to the CEO or

any other covered officer,

• provide oversight of the Company's workforce and human capital management processes, including strategies for

attraction and retention, career development and progression, workplace environment and culture, and organizational

engagement and effectiveness, and

• review, assess and provide updates to the board regarding the Company's strategic people and culture initiatives that

function to identify and develop talent.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **15** |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

At least annually, the PCC Committee reviews the engagement, objectivity, and independence of the advice provided by its

independent executive compensation consultant. The PCC Committee has selected and directly retained the services of

Meridian Compensation Partners, LLC ("Meridian") as its independent executive compensation consultant to advise on specified

compensation matters. Meridian does not provide any other services to the Company and works with Company management

only on matters as directed by the PCC Committee. The PCC Committee assessed the independence of Meridian pursuant to

SEC and NYSE rules and concluded that no conflict of interest existed that would preclude Meridian from serving as an

independent consultant to the committee.

Meridian attends PCC Committee meetings and communicates with the PCC Committee outside of meetings. The PCC

Committee has instructed the independent consultant to:

• act independently of management and at the direction of the PCC Committee,

• understand that the PCC Committee will determine the firm's ongoing engagement,

• keep the PCC Committee informed of trends and regulatory developments relevant to executive and director

compensation, and

• provide detailed compensation data based on information from comparable businesses of a similar size to Ingredion to

allow the PCC Committee to review compensation arrangements for non-employee directors and formulate

recommendations for executive officer compensation.

Our CEO generally attends meetings of the PCC Committee by invitation of the committee, except for meetings or portions of

meetings in which CEO compensation is being discussed and considered.

**CORPORATE GOVERNANCE AND NOMINATING COMMITTEE**

---

| | | | |
|:---|:---|:---|:---|
| **Membership** | **Membership** | **Membership** | **Membership** |
| **Number of meetings held during 2025: 4** | **Number of meetings held during 2025: 4** |  |  |
| ![tanda-sos-proxy.jpg](ingr-20260402_g13.jpg) | ![kenney-sos-proxy.jpg](ingr-20260402_g24.jpg) | ![uribe-sos-proxy.jpg](ingr-20260402_g14.jpg) | ![verduin-sos-proxy.jpg](ingr-20260402_g15.jpg) |
| S. B. Tanda (Chair, since <br>February 10, 2026)<br>| G. B. Kenny<br>(retired March 23, 2026)<br>| J. A. Uribe | P. Verduin |

---

Our CGN Committee is composed entirely of independent directors, as "independent director" is defined under the rules of the

NYSE. Mr. Tanda succeeded Mr. Kenny, who served as Chair of the CGN Committee during 2025, as committee Chair.

The primary responsibilities of the CGN Committee, among others, are to:

• identify, recruit, and recommend candidates to be nominated for election as directors at the Company's annual

meeting, consistent with criteria approved by the board,

• develop and periodically review corporate governance principles and related policies for approval by the board,

• take a leadership role in shaping the Company's corporate governance,

• oversee stockholder engagement with respect to corporate governance-related matters,

• assess the size and composition of the board and committees, including developing and reviewing director qualifications

for approval by the board,

• recommend assignments of directors to committees to ensure that committee membership complies with applicable

laws and stock exchange corporate governance standards,

---

| | | |
|:---|:---|:---|
| **16** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

• conduct a preliminary review of director independence and financial literacy and expertise of Audit Committee

members and oversee director orientation and continuing education,

• review proposed changes to the Company's certificate of incorporation, bylaws, and board committee charters, and

assess and make recommendations regarding stockholder protections, as appropriate,

• conduct ongoing reviews of potential conflicts of interest and review and approve any executive officers standing for

election to boards of directors of not-for-profit organizations,

• review stockholder proposals in conjunction with the Chairman of the Board and recommend board responses,

• oversee the self-evaluation of the board and its committees and management,

• review requests for indemnification under the Company's bylaws,

• review internal and external information to evaluate the operation and effectiveness of the Company's compliance

programs related to product safety and quality, including self-audits and internal compliance assessments, results of

product, environmental, and other tests, lawsuits, customer complaints, and product recalls,

• oversee procedures for the receipt, retention, and treatment of complaints received by the Company regarding product

safety or quality,

• oversee the Company's sustainability and social responsibility programs, and

• oversee the Company's business conduct and anti-corruption compliance programs and meet with the Company's

corporate compliance officer in executive session as often as the committee deems appropriate.

The Company's work on environmental stewardship and sustainability, which is subject to the CGN Committee's oversight,

continued to progress in 2025.

• Our 15th consecutive annual sustainability report, covering 2025, is expected to be released in May 2026 and will be

available at *https://www.ingredion.com/na/en-us/company/meet-ingredion/sustainability.html*.

• Our 2030 emissions reduction targets have been approved by the Science Based Targets initiative ("SBTi") and are

consistent with levels required to meet the goals set by the Paris Agreement. The targets, covering greenhouse gas

emissions from the Company's operations (Scopes 1 and 2), are consistent with reductions required to keep warming to

well below 2°C. Additionally, the Company's target for the emissions from its value chain (Scope 3) meets the SBTi's

criteria for ambitious value chain goals.

• More than 96% of our corn, tapioca, potato, stevia, and pulses were sustainably sourced using Sustainable Agriculture

Initiative ("SAI") Platform protocols, up from approximately 85% in the prior year.

• We are a founding member of SAI Platform's regenerative agriculture program, which is working to establish a standard

for the food and beverage industry. With the support of farmers, our customers, and certain non-governmental

organizations, on a year-over-year basis, we continue to increase the number of acres on which regenerative agriculture

practices are being used.

• We recognize the human right of all people to clean water and sanitation, and we have enacted and continue to

evaluate initiatives that attempt to minimize our impact on climate, biodiversity, and water resources.

• As a company committed to reducing our environmental impact, based upon a self-audit, in 2025, 16 of our

manufacturing facilities met their goal of having more that 99.5% of their waste avoid landfills. These sites have found

innovative solutions for reducing the need for landfills that can be shared throughout our global network.

In addition, the Company's efforts to promote employee health and safety, which is also subject to the CGN Committee's

oversight, resulted in the following achievements in 2025:

• Our employees experienced zero reported injuries (i.e., were injury-free) in 56% of our global locations. In addition, 95%

of our non-manufacturing facilities were employee injury-free.

• Our employee Total Recordable Incidence Rate ("TRIR") was 0.28, as compared to the 2024 rate of 0.31, and our Lost-

Time Incidence Rate ("LTIR") was 0.15, as compared to the 2024 rate of 0.07. We continue to perform at low incidence

rates as compared to our peers and the industry average.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **17** |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

• We achieved key milestones at several manufacturing facilities, with the following number of years since a lost-time

case was reported:

✓&nbsp;&nbsp;&nbsp;&nbsp;5 Years – three manufacturing facilities globally

✓&nbsp;&nbsp;&nbsp;&nbsp;1 Year – six manufacturing facilities globally

• Some of our other manufacturing facilities also have not experienced a lost-time case for multiple years.

**DIRECTOR NOMINATION CRITERIA**

The Company retains a third-party search firm to help identify and facilitate the screening and interview process for potential

director candidates.

The CGN Committee applies formal criteria for selecting director nominees approved by the board. Candidates for director are

identified for the contributions they can make to the deliberations of the board and their ability to act in the best interests of all

of the Company's stockholders.

In addition to other considerations, all potential nominees are expected to have:

• the highest personal and professional ethics, integrity, and values,

• education, breadth of experience, insight, and knowledge to understand global business problems and evaluate possible

solutions,

• the ability to think strategically and make decisions with a forward-looking focus, with the ability to assimilate relevant

information on a broad range of complex topics,

• leadership skills,

• the ability to work effectively with others,

• respect for the views of others and an open-minded approach to problems,

• an awareness of the responsibilities of the Company to its employees, its customers, and regulatory authorities,

• a reasoned and balanced commitment to the Company's social responsibilities,

• an interest and availability of time to be engaged with the Company and its employees over a sustained period,

• stature and experience to represent the Company before the public, stockholders, and other individuals and groups that

affect the Company,

• an ability and willingness to represent the stockholders' financial interests,

• the willingness to objectively appraise management performance in the interest of the stockholders,

• an open mind on all policy issues and areas of activity affecting overall interests of the Company and its stockholders,

and

• no involvement in other activities or interests that create a conflict with the director's responsibility to the Company and

its stockholders.

The above attributes are expected to be maintained by each board member as a condition of the director's ongoing

membership on the board. The CGN Committee reviews the composition of the board and the tenure of its members at least

annually in evaluating the number and experience of directors required.

The CGN Committee has also established the following additional criteria as an aid in the selection of potential director

candidates. The weight given to any particular item may vary based on the CGN Committee's assessment of the needs of the

board, and not all criteria may be applicable to each candidate. Similarly, these criteria, in whole or in part, may be modified or

waived by the CGN Committee in connection with a particular candidate or as otherwise deemed appropriate by the

committee. Candidates should have all or a majority of the following important or desired attributes:

• active employment as a chief executive officer, president, chief financial officer, other senior officer, or general manager

(or a comparable position of responsibility) of a publicly traded company (or a significant privately held company) with

sales and complexity comparable with that of Ingredion,

• international business experience,

---

| | | |
|:---|:---|:---|
| **18** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

• financial responsibility during career, and financial literacy,

• general management experience,

• experience on boards of publicly traded or significant privately held companies,

• experience with corporate governance issues and, ideally, background in the legal aspects of governance applicable to

publicly traded companies,

• expertise that is useful to the Company and complementary to the background and experience of other board members,

so that an appropriate balance of skills and experience of the membership of the board can be achieved and maintained,

• contribution to board diversity in the broadest sense (taking into account characteristics that include gender, race,

ethnicity, geographic background, and personal experience), and

• an understanding of technologies pertinent to the Company's businesses, production, marketing, finance, regulation,

and public policy.

In addition to these minimum requirements and desired attributes, the CGN Committee also evaluates whether the candidates

meet the board's need for operational, management, financial, international, technological, or other expertise. The search firm

identifies and screens the candidates, performs reference checks, prepares a biography of each candidate for the CGN

Committee to review, and assists in organizing interviews. The CGN Committee members interview candidates that meet the

applicable criteria and selects those it will recommend to the board for nomination. The board considers the nominees and

selects those whom it believes would best suit the needs of the board.

The CGN Committee and the board consider the composition of the entire board and the entire range of diversity (including

gender, race, ethnicity, geographic background, and personal experience) in its determinations. We do not have a formal

diversity policy, but we have historically had a diverse board. Our director qualifications matrix below illustrates the diversity of

experiences, qualifications, and backgrounds of our board nominees. Our current directors and nominees for re-election include

five women directors, one male director of Hispanic ethnicity, one African-American male director, and two directors who live

outside the United States.

Verduin

Uribe

Fischer

Jordan

Reich

Suever

Tanda

Wilson

Zallie

Talbot

Magro

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Executive leadership: <br>CEO, CFO, or senior <br>executive at a <br>comparable company<br>| ●  | ●  | ●  | ●  | ●  | ●  | ●  | ●  | ●  | ●  | ●  |
| Financial literacy | ●  | ●  | ●  | ●  | ●  | ●  | ●  | ●  | ●  | ●  | ●  |
| International business <br>experience<br>| ●  | ●  | ●  | ●  | ●  | ●  | ●  | ●  | ●  | ●  | ●  |
| Corporate governance <br>experience<br>| ●  | ●  | ●  | ●  | ●  | ●  | ●  | ●  | ●  | ●  | ●  |
| Technology <br>experience pertinent <br>to the Company's <br>business<br>| ●  |  | ●  |  |  | ●  | ●  | ●  | ●  | ●  | ●  |
| Food industry <br>experience<br>|  | ●  |  |  |  | ●  | ●  | ●  | ●  |  | ●  |
| Qualified audit <br>committee financial <br>expert<br>|  | ●  | ●  | ●  | ●  | ●  | ●  |  |  |  |  |
| Gender, race, ethnic, <br>or geographic diversity<br>| | ●  | ●  | ●  | ●  | ●  | ●  | ●  | ●  | ●  | |

---

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **19** |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

**Additional Information Regarding Nominees**

---

| | | | | |
|:---|:---|:---|:---|:---|
| 10 of 11 | 64.5 yrs | 8.3 yrs | 5 | 2 |
| Independent | Average Age | Average Tenure | Women | Ethnic Minorities |

---

The CGN Committee will consider qualified candidates for director nominees recommended by our stockholders. Stockholders

may recommend qualified candidates for nomination by writing to the Corporate Governance and Nominating Committee, c/o

Corporate Secretary, Ingredion Incorporated, 5 Westbrook Corporate Center, Westchester, Illinois 60154. The CGN Committee

intends to evaluate candidates proposed by stockholders in the same manner and according to the same criteria as other

candidates.

For information about how stockholders may nominate directors for election, see "Questions and Answers About This Proxy

Statement and Our 2026 Annual Meeting – 'How can I submit a stockholder proposal for the 2027 annual meeting?".

**COMMUNICATION WITH THE BOARD**

Interested parties may communicate directly with any member or members of the Board of Directors, including the Chairman of

the Board, the independent directors, as a group, or any individual director, by writing in care of:

Corporate Secretary

Ingredion Incorporated

5 Westbrook Corporate Center

Westchester, Illinois 60154

The Company's Corporate Secretary will collect all such communications and organize them by subject matter. All such

communications will be promptly forwarded to the appropriate board committee chair according to the subject matter of the

communication, except for solicitations or other matters inappropriate for the intended recipient or otherwise unrelated to the

Company. Communications addressed directly to the Chairman of the Board, the independent directors as a group, or any

individual director will be forwarded in the same manner to the Chairman of the Board, the independent directors, or the

named individual director, as the case may be.

---

| | | |
|:---|:---|:---|
| **20** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

**Compensation of Non-employee Directors**

**DIRECTOR STOCK OWNERSHIP REQUIREMENTS**

To align our non-employee director and stockholder interests, we require our non-employee directors to hold meaningful

amounts of our common stock. Our requirements as of December 31, 2025 are as follows:

---

| | |
|:---|:---|
| Key Provision | Explanation of Key Provision |
| Ownership requirement | Amount equal to a minimum of five times the value of the annual board cash retainer <br>(i.e., currently $525,000)<br>|
| Time to meet <br>requirement<br>| Within five years of election to the board |
| Shares counted toward <br>ownership<br>| Common stock owned outright and vested and unvested restricted stock, restricted stock units, <br>and phantom stock units<br>|

---

As of December 31, 2025, all non-employee directors either exceeded their stock ownership requirements or were within the

five-year compliance window in which to meet the ownership requirement.

**REVIEW OF NON-EMPLOYEE DIRECTOR COMPENSATION**

The objective of the compensation program for our non-employee directors, each of whom the board has determined to be an

"independent director" under NYSE rules, is to:

• provide fair compensation commensurate with the work required to serve on the board and board committees of a

company with Ingredion's size, scope, and complexity,

• attract and retain high-quality talent for the board, and

• align directors' interests with the interests of stockholders.

To determine the appropriate non-employee director compensation level, the PCC Committee reviews non-employee director

compensation every other year using the same peer group of companies, referred to as the Compensation Peer Group, used in

determining executive officer compensation, as described beginning on page <u>[41](#idbd8228798374a95ab5d4e1f889f4e94_42821)</u>. At the committee's request, this benchmarking

review was most recently led by Meridian and performed during 2025 for the 2026 fiscal year's compensation. Considering this

assessment and other relevant factors, the PCC Committee recommends to the board, and the board approves, the

compensation for the non-employee directors. Generally, the PCC Committee seeks to position pay within a median range

relative to the market as determined by reference to the Compensation Peer Group. In addition, we generally pay a majority

portion of non-employee director compensation in equity, except that we paid Mr. Kenny, who in 2025 served as the non-

executive Chairman of the Board and Chair of the CGN Committee, retainers for these additional roles in cash. The PCC

Committee believes the combination of equity-weighted compensation and share ownership requirements further aligns the

interests of our non-employee directors with the interests of our stockholders.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **21** |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

**SUMMARY OF 2025 NON-EMPLOYEE DIRECTOR** 

**COMPENSATION ELEMENTS**

The following table sets forth the individual components of our 2025 non-employee director compensation.

---

| | |
|:---|:---|
| Annual Compensation Elements | Amount ($) |
| Annual Cash Retainer | 105000 |
| Annual Equity Retainer | 160000 |
| Additional Compensation (retainer fees) |  |
| Chairman of the Board | 160000 |
| Audit Committee Chair | 25000 |
| PCC Committee Chair | 20000 |
| Corporate Governance and Nominating Committee Chair | 15000 |

---

In 2025, all payments of cash and equity, as applicable, were paid in quarterly installments on the last business day of each

calendar quarter, with the exception of the fourth quarter, which was paid on the date of the December PCC Committee

meeting. The additional compensation retainer fees were paid 100% in cash. The equity portion of the annual retainer is issued

in shares of common stock calculated by dividing the dollar value of the applicable retainer quarterly installment by the trailing

20-day average closing price of our common stock as reported on the NYSE (with the closing price of our common stock as

reported on the NYSE on any day referred to in this proxy statement as that day's "Closing Price").

Directors are permitted to defer all or a portion of their cash retainer into restricted stock units ("RSUs") under our Stock

Incentive Plan and the Ingredion Incorporated Amended and Restated Director Deferred Compensation Plan (the "Director

Deferred Compensation Plan"), pursuant to which settlement is deferred until a date not less than six months after the

director's termination of board service. All directors are reimbursed for board and committee meeting expenses, but no

meeting attendance fees are paid.

James Zallie, our President and CEO, whose compensation is presented in the "2025 Summary Compensation Table" on

page <u>[47](#ie7e472361805446c8b302de30ed47fbf_55)</u>, did not receive any additional compensation for serving as a director.

We provide our independent directors with liability insurance coverage for their activities as directors.

Our certificate of incorporation and bylaws provide that all of our directors are entitled to indemnification and advancement of

expenses from us to the fullest extent permitted by Delaware law. We have entered into indemnification agreements with each

of our directors to afford them contractual assurances regarding the scope of their indemnification and to provide procedures

for the determination of a director's right to receive indemnification.

---

| | | |
|:---|:---|:---|
| **22** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Proposal 1. Election of Directors<br>

The following table summarizes the compensation earned by our non-employee directors for service during 2025.

**2025 NON-EMPLOYEE DIRECTOR COMPENSATION**

---

| | | | | |
|:---|:---|:---|:---|:---|
| Name | Fees Earned or<br>Paid in Cash<sup>(1)</sup><br>($)<br>| Stock Awards<sup>(2)</sup><br>($)<br>| All Other<br>Compensation<sup>(3)</sup><br>($)<br>| Total<br>($)<br>|
| David B. Fischer | 105000 | 159690 | 3551 | 268241 |
| Rhonda L. Jordan<sup>(4)</sup> | 125000 | 159690 | 8500 | 293190 |
| Gregory B. Kenny<sup>(5)</sup> | 280000 | 159690 |  | 439690 |
| Charles V. Magro<sup>(6)</sup> | 105000 | 159690 |  | 264690 |
| Victoria J. Reich<sup>(7)</sup> | 130000 | 159690 | 7500 | 297190 |
| Catherine A. Suever | 105000 | 159690 | 2000 | 266690 |
| Stephan B. Tanda | 105000 | 159690 |  | 264690 |
| Jorge A. Uribe | 105000 | 159690 |  | 264690 |
| Patricia Verduin | 105000 | 159690 | 8500 | 273190 |
| Dwayne A. Wilson | 105000 | 159690 |  | 264690 |

---

(1)Includes all retainer fees earned or deferred pursuant to the Director Deferred Compensation Plan.

(2)The equity retainer is granted in quarterly increments on the last business day of each calendar quarter, with the exception of the fourth

quarter, which is granted on the date of the December PCC Committee meeting, in an amount determined by dividing the equity retainer

value by the trailing 20-day average Closing Price of our common stock. Equity retainers are immediately vested and delivered as common

stock. If a director elects to defer the equity retainer, the director receives RSUs and receipt of shares is deferred until a date not less than

six months after the director no longer serves on the board. The grant date fair value of RSU grants in 2025 was calculated in accordance

with Accounting Standards Codification Topic 718 ("FASB ASC Topic 718") of the Financial Accounting Standards Board. See note 11

(Equity) to our consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2025, for

a statement of the assumptions made with respect to the valuation under FASB ASC Topic 718. As of December 31, 2025, each director

had the following aggregate number of RSUs accumulated in his or her deferral account for all years of service as a director, including

additional share units credited as a result of the reinvestment of dividend equivalents: Mr. Fischer, 17,073 units; Ms. Jordan, 26,349 units;

Mr. Kenny, 65,840 units; Mr. Magro, 9,035 units; Ms. Reich, 19,466 units; Ms. Suever, 2,486 units; Mr. Tanda, 0 units; Mr. Uribe, 12,826

units; Dr. Verduin, 0 units; and Mr. Wilson, 27,956 units.

(3)Amounts shown are matching contributions by the Company made under a charitable matching gift program in which non-employee

directors may participate. Matching contributions by the Company consisted of a $2 match for every $1 of the first $1,000 contributed and

a $1 match for every $1 of the next $6,500 contributed.

(4)Ms. Jordan serves as Chair of the PCC Committee.

(5)In 2025, Mr. Kenny served as Chair of the CGN Committee and as non-executive Chairman of the Board.

(6)Pursuant to the Director Deferred Compensation Plan, Mr. Magro deferred his cash retainer into RSUs.

(7)In 2025, Ms. Reich served as Chair of the Audit Committee.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **23** |

---

**<u>**Table of Contents**</u>**

Ownership of Our Stock<br>

**Ownership of Our Stock**

**Security Ownership of Certain Beneficial Owners** 

**and Management**

The calculation of beneficial ownership of the Company's issued and outstanding common stock presented in the following

tables is made in accordance with SEC rules. Under these rules, a person is deemed to be a "beneficial owner" of shares of

common stock if that person has or shares the power to vote or direct the voting of the shares or the power to dispose or direct

the disposition of the shares. Beneficial ownership as of any date includes any shares as to which a person has the right to

acquire voting or dispositive power as of that date or within 60 days thereafter through the exercise of any stock option or

other right or the vesting of any RSU, without regard to whether such right expires before the end of such 60-day period or

continues thereafter. If two or more persons share voting power or dispositive power with respect to specific shares, all such

persons may be deemed to be beneficial owners of such shares.

As of March 23, 2026, which is the record date for the 2026 annual meeting, 63,054,170 shares of the Company's common

stock were issued and outstanding.

The following table shows, as of the dates indicated, all persons known by the Company to be beneficial owners of more than

5% of the Company's issued and outstanding common stock based on the number of shares issued and outstanding as of

March 23, 2026. The amount and nature of beneficial ownership shown in the table is based solely on information contained in

the most recent Schedule 13G statement filed with the SEC by the reporting person.

---

| | | |
|:---|:---|:---|
| Name and Address of Beneficial Owner<sup>(1)</sup> | Amount and Nature of<br>Beneficial Ownership<br>| Percent of<br>Class<br>|
| BlackRock, Inc.<sup>(2)</sup><br>50 Hudson Yards<br>New York, NY 10001 | 6566730 | 10.4% |
| BlackRock, Inc.<sup>(2)</sup><br>50 Hudson Yards<br>New York, NY 10001 | 6566730 | 10.4% |
| BlackRock, Inc.<sup>(2)</sup><br>50 Hudson Yards<br>New York, NY 10001 | 6566730 | 10.4% |

---

(1)In a Schedule 13G/A statement filed with the SEC by The Vanguard Group ("Vanguard") on March 27, 2026, Vanguard reports that, as of

March 13, 2026, it did not beneficially own any shares of our common stock. In its most recent Schedule 13G/A statement filed by

Vanguard with the SEC prior to the filing on March 27, 2027, which prior statement Vanguard filed on February 13, 2024, Vanguard

reported that, as of December 29, 2023, it beneficially owned 7,773,126 shares. In its statement filed on March 27, 2026, Vanguard

reports that it went through an internal realignment as a result of which, in accordance with SEC rules regarding reporting of beneficial

ownership in publicly held companies, certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc. that formerly

had, or were deemed to have, beneficial ownership over securities with The Vanguard Group, Inc. will report such beneficial ownership

separately (on a disaggregated basis) from The Vanguard Group, Inc., and that The Vanguard Group, Inc. no longer has, or is deemed to

have, beneficial ownership over securities held by such subsidiaries or business divisions. Vanguard further reports that such subsidiaries

or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.

As of the most recent practicable date before the printing of this proxy statement, no subsidiaries or business divisions of subsidiaries of

The Vanguard Group, Inc. had filed a Schedule 13G statement reporting beneficial ownership of our common stock.

(2)The amount and nature of beneficial ownership shown is based solely on a Schedule 13G statement filed with the SEC on September 10,

2024, which is the most recent Schedule 13G statement filed by BlackRock, Inc. BlackRock, Inc. reports that, as of August 31, 2024, it had

sole voting power over 6,215,032 shares and sole dispositive power over 6,566,730 shares. BlackRock, Inc. also reports that it is the parent

holding company of the subsidiaries identified in the Schedule 13G that hold shares of the common stock reported in the Schedule 13G.

The following table shows, as of March 23, 2026, information based on filings with the SEC and our records regarding the

beneficial ownership of the Company's issued and outstanding common stock by:

• each director and director nominee,

• each executive officer named in the "2025 Summary Compensation Table" on page <u>[47](#ie7e472361805446c8b302de30ed47fbf_55)</u>, and

• all executive officers and directors as a group.

---

| | | |
|:---|:---|:---|
| **24** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Ownership of Our Stock<br>

The percentage of beneficial ownership as to any person as of March 23, 2026 is calculated by dividing the number of shares

beneficially owned by such person, which includes the number of shares as to which such person has the right to acquire voting

or dispositive power as of or within 60 days after March 23, 2026, by the sum of the number of shares outstanding as of

March 23, 2026, plus the number of shares as to which such person has the right to acquire voting or dispositive power as of or

within 60 days after March 23, 2026. Consequently, the denominator used for calculating such percentage may be different for

each beneficial owner.

---

| | | | |
|:---|:---|:---|:---|
|  | Amount and Nature of<br>Beneficial Ownership | Amount and Nature of<br>Beneficial Ownership |  |
| Beneficial Owner | Shares of<br>Common<br>Stock<sup>(1)</sup><br>(#)<br>| Shares Underlying<br>Phantom Stock<br>Units and Restricted<br>Stock Units<sup>(2)</sup><br>(#)<br>| Percent<br>of<br>Class<sup>(3)</sup><br>|
| David B. Fischer | 1935 | 17195 | \* |
| Rhonda L. Jordan |  | 26537 |  |
| Gregory B. Kenny |  | 66309 |  |
| Charles V. Magro |  | 9100 |  |
| Victoria J. Reich |  | 19605 |  |
| Catherine A. Suever | 4011 | 2504 | \* |
| Stephan B. Tanda | 10357 |  | \* |
| Jorge A. Uribe | 6145 | 12917 | \* |
| Patricia Verduin | 3443 |  | \* |
| Dwayne A. Wilson |  | 28155 |  |
| James Zallie | 541172 | 59999 | \* |
| James Gray | 160315 | 14374 | \* |
| Tanya Jaeger de Foras | 39714 | 7353 | \* |
| Robert Ritchie | 49985 | 16624 | \* |
| Eric Seip | 60586 | 19466 | \* |
| All directors and executive officers as a group (21 persons) | 1039203 | 332440 | 1.6% |

---

(1)Includes shares of common stock held individually, jointly with others, in the name of an immediate family member or under trust for the

benefit of the named individual and/or one or more children of the named individual. Unless otherwise noted, the beneficial owner has

sole voting and dispositive power. Fractional amounts have been rounded to the nearest whole share.

Includes shares of common stock that may be acquired through the exercise of stock options vested or subject to vesting as of or within

60 days after March 23, 2026 in the following amounts: Mr. Zallie, 465,801; Mr. Gray, 105,789; Ms. Jaeger de Foras, 27,002; Mr. Ritchie,

33,521; Mr. Seip, 36,292; and all directors and executive officers as a group, 778,623. Totals include 3,099 RSUs attributable to Rob

Ritchie's May 2, 2023 grant, which vests on May 2, 2026.

Includes 267 shares of common stock held in the Ingredion Incorporated Stock Fund of our Retirement Savings Plans by all directors and

executive officers as a group.

(2)Includes shares of common stock represented by deferred phantom stock units and deferred RSUs of the Company credited to the

deferred compensation plan accounts of the non-employee directors and certain executive officers. The directors and executive officers

have no voting or dispositive power over the common stock by virtue of their ownership of phantom stock units or RSUs. The phantom

stock units and RSUs held by directors and executive officers and included in this column are not vested or subject to vesting as of or

within 60 days after March 23, 2026. Fractional amounts have been rounded to the nearest whole share.

(3)An asterisk indicates less than one percent beneficial ownership. Does not include shares shown in the column headed "Shares Underlying

Phantom Stock Units and Restricted Stock Units."

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **25** |

---

**<u>**Table of Contents**</u>**

Ownership of Our Stock<br>

**Delinquent Section 16(a) Reports**

Section 16(a) of the Exchange Act requires our directors, executive officers, and holders of more than 10% of Ingredion's

common stock to file reports with the SEC regarding their ownership and changes in ownership of our equity securities. Based

upon our examination of the copies of reports on Forms 3, 4, and 5, and amendments thereto filed electronically with the SEC

and the written representations of our directors and executive officers, we believe that, during fiscal year 2025, except as

described in the following sentence, our directors and executive officers complied with all Section 16(a) filing requirements.

During fiscal year 2025, one Form 4 report was filed late with respect to one transaction by Tanya Jaeger de Foras, an executive

officer, in connection with a contribution to the 401(k) plan in the Ingredion Stock Fund; one Form 4 report was filed late with

respect to one transaction by Eric Seip, an executive officer, in connection with shares of phantom stock allocated to him under

our Non-Qualified Deferred Compensation Plan; and one Form 4 report was filed late with respect to one transaction by

Michael Leonard, an executive officer, in connection with shares of phantom stock allocated to him under our Non-Qualified

Deferred Compensation Plan.

---

| | | |
|:---|:---|:---|
| **26** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

## Executive Compensation
**Compensation Discussion and Analysis**

This Compensation Discussion and Analysis ("CD&A") explains the guiding principles and practices upon which our executive

compensation program is based, highlights the alignment of pay with our financial and strategic objectives that drive long-term

shareholder value, and describes the compensation paid to our named executive officers ("NEOs") for their service in fiscal year

2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| ![zallie-sos-proxy.jpg](ingr-20260402_g17.jpg) | ![gray-sos-proxy.jpg](ingr-20260402_g25.jpg) | ![jaeger-sos-proxy.jpg](ingr-20260402_g26.jpg) | ![ritchier-sos-proxy.jpg](ingr-20260402_g27.jpg) | ![seip-sos-proxy.jpg](ingr-20260402_g28.jpg) |
| **James Zallie** | **James Gray** | **Tanya Jaeger de Foras** | **Robert Ritchie** | **Eric Seip** |
| Chairman of the Board, <br>President and Chief <br>Executive Officer<br>| Executive Vice President <br>and Chief Financial Officer<br>| Senior Vice President, <br>Chief Legal Officer, <br>Corporate Secretary and <br>Chief Compliance Officer <br>| Executive Vice President, <br>Food & Industrial <br>Ingredients, US/Canada & <br>Latin America and Sugar <br>Reduction<br>| Senior Vice President, <br>Global Operations, and <br>Chief Supply Chain Officer<br>|

---

As previously reported, Mr. Gray retired from his position effective March 31, 2026.

---

| | |
|:---|:---|
| <u>[Executive Summary](#idbd8228798374a95ab5d4e1f889f4e94_42809)</u> | <u>[26](#idbd8228798374a95ab5d4e1f889f4e94_42809)</u> |
| <u>[2025 Business Performance](#idbd8228798374a95ab5d4e1f889f4e94_42817)</u> | <u>[27](#idbd8228798374a95ab5d4e1f889f4e94_42817)</u> |
| <u>[Core Compensation Practices](#idbd8228798374a95ab5d4e1f889f4e94_42818)</u> | <u>[27](#idbd8228798374a95ab5d4e1f889f4e94_42818)</u> |
| <u>[2025 Executive Pay Highlights](#idbd8228798374a95ab5d4e1f889f4e94_42813)</u> | <u>[28](#idbd8228798374a95ab5d4e1f889f4e94_42813)</u> |
| <u>[Consideration of the 2025 Say-on-Pay Advisory Vote](#i4eba37fe5aea4915908948b43ded5a8b_0-0-1-2-231704)</u> | <u>[29](#i4eba37fe5aea4915908948b43ded5a8b_0-0-1-2-231704)</u> |
| <u>[Our Executive Compensation Program](#idbd8228798374a95ab5d4e1f889f4e94_42807)</u> | <u>[29](#idbd8228798374a95ab5d4e1f889f4e94_42807)</u> |
| <u>[Elements of Compensation](#idbd8228798374a95ab5d4e1f889f4e94_42814)</u> | <u>[31](#idbd8228798374a95ab5d4e1f889f4e94_42814)</u> |
| <u>[Other Compensation Elements](#idbd8228798374a95ab5d4e1f889f4e94_42816)</u> | <u>[38](#idbd8228798374a95ab5d4e1f889f4e94_42816)</u> |
| <u>[How Compensation Decisions Are Made](#idbd8228798374a95ab5d4e1f889f4e94_42820)</u> | <u>[41](#idbd8228798374a95ab5d4e1f889f4e94_42820)</u> |
| <u>[Compensation Governance](#idbd8228798374a95ab5d4e1f889f4e94_42806)</u> | <u>[44](#idbd8228798374a95ab5d4e1f889f4e94_42806)</u> |

---

**EXECUTIVE SUMMARY**

We are a leading global ingredient solutions provider that transforms grains, fruits, vegetables, and other plant-based materials

into value-added ingredient solutions for the food, beverage, animal nutrition, brewing, and industrial markets. We co-create

with customers to fulfill our purpose to be recognized as the go-to provider for texture and healthful solutions that make

healthy taste better.

Our roadmap for growth is designed to deliver shareholder value by accelerating customer co-creation and enabling consumer-

preferred innovation by developing on-trend ingredient solutions that make life better. We are well-positioned to help

customers navigate and adapt to the accelerated pace of the food and beverage industry to create innovative products that win

in the marketplace.

Grounded in our values of Care First, Be Preferred, Everyone Belongs, Innovate Boldly and Owner's Mindset, we employ more

than 11,000 employees around the world. Our employees bring their skills, creativity, and passion together to deliver ingredient

solutions that enhance people's lives. We are innovators who combine the power of technology with the best of nature to

![](ingr-20260402_g29.gif)

<sup>1</sup>Adjusted diluted earnings per common share is not a financial measure calculated in accordance with U.S. generally accepted accounting

principles ("GAAP"). See Appendix A for a reconciliation of this non-GAAP financial measure to diluted earnings per common share, as

calculated in accordance with GAAP.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **27** |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

delight customers and consumers, all while holding ourselves to the highest standards in ethics, safety, quality, and

sustainability.

Amid a challenging economic backdrop, our business delivered increased profit in fiscal year 2025. Supported by strong cash

generation and a healthy balance sheet, we continue to demonstrate disciplined capital allocation to create long-term value for

shareholders.

**2025 BUSINESS PERFORMANCE**

Fiscal year 2025 was a record year for earnings despite a challenging market environment. Our teams demonstrated continued

resilience, agility, and excellent collaboration across functions and businesses to drive growth and expand and transform our

solutions and opportunity set with customers.

Net sales in 2025 were $7.2 billion, a decrease of 3% from the prior year driven by lower volume from each of the Food and

Industrial Ingredients ("F&II") segments and price mix, primarily from lower raw material costs, partially offset by Texture &

Healthful Solutions ("T&HS") volume increases.

We achieved gross profit margins of over 25%, up 120 basis points year over year, as a continued focus on cost competitiveness

through operational excellence more than offset the decrease in net sales. Continued network optimization, procurement

savings, and improved forecast accuracy and service levels were keys to the operational efforts.

Our diluted earnings per common share increased from $9.71 in 2024 to $11.18 in 2025. Adjusted diluted earnings per common

share increased from $10.65 in 2024 to $11.13 in 2025.<sup>1</sup>

Among other 2025 business highlights, we:

• delivered strong profit growth and cash from operations,

• continued to return value to stockholders, including the return of $435 million to stockholders, through the eleventh

consecutive annual increase in our dividend rate and the repurchase of 1.8 million outstanding shares of common stock,

and

• continued to generate strong net sales volume growth in Texture & Healthful Solutions, driven by Clean Label and

Solutions selling.

In addition to our strong business results, we continued to be recognized for our people-centric culture, ethics, integrity,

inclusion, and leadership development, resulting in the following accomplishments in 2025:

• recognized as one of the World's Most Admired Companies by *Fortune* magazine for the 15th year,

• named to *The Wall Street Journal*'s list of the 250 Best-Managed Companies for the second consecutive year,

• named as one of the World's Most Ethical Companies by Ethisphere for the eleventh time, and

• certified as a Top Employer in Singapore and Thailand for the fifth consecutive year and as a Top Employer in China,

Germany, Malaysia, and the United Kingdom for the third consecutive year, which was also the third year Ingredion was

certified as a Top Employer for the APAC region, with Ingredion India included in the certification for the first time.

**CORE COMPENSATION PRACTICES**

We are focused on creating an executive compensation program that successfully attracts, motivates, and retains executive

officers while also aligning the interests of the NEOs with the interests of our stockholders. We believe our executive pay

programs provide appropriate incentives to our executive officers to achieve our financial and strategic goals without

---

| | | |
|:---|:---|:---|
| **28** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

encouraging them to take excessive risks. To reinforce this alignment, we have adopted the following governance practices to

guide our compensation programs:

---

| | | | |
|:---|:---|:---|:---|
| **✓ What We Do** | **✓ What We Do** |  |  |
| ![tick.jpg](ingr-20260402_g30.jpg) | Maintain significant stock ownership requirements | ![tick.jpg](ingr-20260402_g30.jpg) | Provide a majority of compensation based on <br>objective, quantifiable, pre-established <br>performance goals<br>|
| ![tick.jpg](ingr-20260402_g30.jpg) | Offer limited perquisites | ![tick.jpg](ingr-20260402_g30.jpg) | Engage an independent compensation <br>consultant reporting directly to the PCC <br>Committee<br>|
| ![tick.jpg](ingr-20260402_g30.jpg) | Hold an annual Say-on-Pay vote and engage with <br>stockholders throughout the year to address any <br>pay-related questions, among other topics<br>| ![tick.jpg](ingr-20260402_g30.jpg) | Use a balance of short- and long-term incentive <br>awards and establish diverse performance <br>metrics for both programs<br>|
| ![tick.jpg](ingr-20260402_g30.jpg) | Manage a clawback policy applicable to our <br>executive officers<br>| ![tick.jpg](ingr-20260402_g30.jpg) | Benchmark executive compensation and our <br>performance against relevant comparators<br>|
| ![tick.jpg](ingr-20260402_g30.jpg) | Pay severance and vest equity only upon a "double <br>trigger" in the event of a change in control ("CIC")<br>| ![tick.jpg](ingr-20260402_g30.jpg) | Conduct an annual risk assessment of our <br>executive compensation program<br>|

---

---

| | | | |
|:---|:---|:---|:---|
| **X What We Don't Do** | **X What We Don't Do** |  |  |
| ![wrong.jpg](ingr-20260402_g31.jpg) | No automatic or guaranteed annual base salary <br>increases<br>| ![wrong.jpg](ingr-20260402_g31.jpg) | No payment of dividends or dividend <br>equivalents to NEOs on unearned performance <br>share awards<br>|
| ![wrong.jpg](ingr-20260402_g31.jpg) | No guaranteed annual or long-term incentive <br>awards<br>| ![wrong.jpg](ingr-20260402_g31.jpg) | No tax gross-ups for perquisites or in the event <br>of a CIC<br>|
| ![wrong.jpg](ingr-20260402_g31.jpg) | No employment agreements for any executive <br>officers<br>| ![wrong.jpg](ingr-20260402_g31.jpg) | No incentives to produce short-term results to <br>the detriment of long-term goals and results<br>|
| ![wrong.jpg](ingr-20260402_g31.jpg) | No repricing of underwater stock options |  |  |
| ![wrong.jpg](ingr-20260402_g31.jpg) | No authorization of hedging of Company stock by <br>independent directors and executive officers<br>|  |  |

---

**2025 EXECUTIVE PAY HIGHLIGHTS**

• In light of the business environment, Company performance, individual contributions, internal equity, and competitive

compensation positioning relative to peer market data, the PCC Committee (and, with respect to the CEO, the Board of

Directors) approved base salary increases for our NEOs that averaged 5.1%. The average increase excluding the increase

awarded to Robert Ritchie, who received a market-based adjustment to account for additional responsibilities in 2025,

was 3.7%.

• A substantial majority of 2025 total target compensation (consisting of base salary plus target short- and long-term

incentive compensation) for the NEOs was in the form of annual and long-term incentives, providing, as in prior years, a

strong incentive to drive Company results and increase shareholder value. Approximately 88% of the CEO's and 74% of

the other NEOs' target 2025 total direct compensation was performance-based.

• Annual Incentive Plan ("AIP") awards were based on targets ranging from 75% to 150% of 2025 base salary for the NEOs

and were determined based on achievement of financial goals and personal objectives. See "Annual Incentive Plan"

beginning on page <u>[31](#idbd8228798374a95ab5d4e1f889f4e94_42810)</u> for additional information.

• Actual payouts to the NEOs under the 2025 AIP varied from 106.4% to 114.3% of target. See "2025 AIP Payouts" on

page <u>[35](#idbd8228798374a95ab5d4e1f889f4e94_42819)</u> for details on the AIP payout for each NEO.

• Target grant date value of long-term incentive awards represented 46% to 71% of the 2025 total target compensation

for the NEOs. These awards were in the form of performance shares, nonqualified stock options, and restricted stock

units granted pursuant to our Stock Incentive Plan.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **29** |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

• Performance shares for the 2023 – 2025 performance period paid out at 183.4% of target as a result of the Company's

relative total shareholder return ("rTSR") and adjusted return on invested capital ("Adjusted ROIC") results. See "2023 –

2025 Performance Share Plan Results" on page <u>[37](#idbd8228798374a95ab5d4e1f889f4e94_42815)</u> for details on performance against these metrics.

---

| | |
|:---|:---|
| **CONSIDERATION OF THE 2025 SAY-ON-PAY ADVISORY VOTE** | **CONSIDERATION OF THE 2025 SAY-ON-PAY ADVISORY VOTE** |
| ![SOP 2025.jpg](ingr-20260402_g32.jpg) | When making decisions regarding our executive compensation program, including the <br>compensation of our NEOs, the PCC Committee considers the results from the say-on-pay <br>advisory vote. As shown in the graphic to the left, 94.4% of the votes cast at our 2025 annual <br>meeting approved the NEO compensation program, as described in our 2025 proxy statement. <br>We believe this result continues to demonstrate our stockholders' support of our executive <br>compensation program and the PCC Committee's decisions and policies. The PCC Committee will <br>continue to consider results from future stockholder advisory votes, which will continue to be <br>held annually unless stockholders select a different frequency for future votes on executive <br>compensation, when making decisions on the Company's executive compensation programs, <br>including NEO compensation.<br>|

---

**OUR EXECUTIVE COMPENSATION PROGRAM**

**Core Principles and Philosophy.** Our compensation philosophy is designed to align the interests of stockholders and executives

through compensation programs that incentivize and reward executives for performance that builds long-term shareholder

value. The objectives of our compensation programs are to:

• attract, retain, and motivate executives to drive business results,

• support business strategies that promote long-term shareholder value, and

• align pay and performance by making a significant portion of executive compensation dependent on achieving financial

and other critical strategic and individual goals.

Our executive compensation guiding principles must be flexible enough to tailor compensation programs to the needs of our

global workforce while, at the same time, also seeking to ensure that our compensation programs are equitable and

competitive. To achieve our objectives, we structure compensation programs that:

• **align with our business:** Incentive designs are aligned with the Company's strategy and support long-term shareholder

value creation while avoiding excessive risk-taking. We provide an appropriate balance of fixed and at-risk pay with both

short- and long-term performance horizons, using a variety of metrics tied to key drivers of sustainable value creation.

• **link pay and performance:** The percentage of at-risk performance-based pay increases with the level of responsibility

and pay outcomes are dependent on the achievement of financial and other strategic goals over both the short and long

term, with the objective of driving shareholder value.

• **remain competitive:** We structure our compensation programs competitively both in the amount and type of

compensation we offer in order to attract, retain, and motivate talent. We regularly benchmark pay and program design

to ensure we are competitive while also evaluating and considering internal pay equity. In general, we target base

salary, annual cash compensation, and long-term incentive compensation opportunities for the NEOs within a

reasonable range around median pay based on data for executives with similar responsibilities among a peer group of

companies, as well as across the broader market. Actual pay opportunities may vary from this market reference based

on factors such as experience, performance, retention impacts, and overall expertise in a role, among other factors.

• **drive an owner's mindset:** We think and act like owners and make decisions that we believe are in the best interests of

the Company. To facilitate the owner's mindset, we grant equity-based incentives as an effective method of facilitating

stock ownership and further aligning the interests of our executives with those of our stockholders. A significant portion

of total target compensation for our NEOs consists of equity-based incentives. Additionally, we have robust stock

ownership requirements to strengthen the link between the interests of NEOs and stockholders.

Our compensation programs are intended to balance these principles, and we believe our compensation programs and

corresponding pay opportunities allow us to achieve these principles in a practical and effective way. Our executive

compensation structure is straightforward and market-competitive with a strong emphasis on performance.

---

| | | |
|:---|:---|:---|
| **30** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

**Elements of our 2025 Annual Compensation Program**

The following table identifies and describes the primary elements of the 2025 executive compensation programs for our NEOs

and the corresponding objectives for each compensation component.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Pay Element | Pay Element | Pay Element | Pay Mix | Description | Objective |
|  |  |  |  | Fixed cash compensation based on size and scope <br>of role, responsibilities, experience, and individual <br>performance. | •Attract and retain talented <br>executives<br>•Drive performance through <br>individual contributions<br>•Provide a consistent and stable <br>source of compensation that <br>allows executives to focus on <br>long-term strategic initiatives <br>and operational excellence <br>without being distracted by <br>short-term fluctuations in <br>performance-based pay |
| FIXED |  | **Base**<br>**Salary** | ![CEO Base Pay Mix.jpg](ingr-20260402_g33.jpg) | Fixed cash compensation based on size and scope <br>of role, responsibilities, experience, and individual <br>performance. | •Attract and retain talented <br>executives<br>•Drive performance through <br>individual contributions<br>•Provide a consistent and stable <br>source of compensation that <br>allows executives to focus on <br>long-term strategic initiatives <br>and operational excellence <br>without being distracted by <br>short-term fluctuations in <br>performance-based pay |
| FIXED |  | **Base**<br>**Salary** |  | Fixed cash compensation based on size and scope <br>of role, responsibilities, experience, and individual <br>performance. | •Attract and retain talented <br>executives<br>•Drive performance through <br>individual contributions<br>•Provide a consistent and stable <br>source of compensation that <br>allows executives to focus on <br>long-term strategic initiatives <br>and operational excellence <br>without being distracted by <br>short-term fluctuations in <br>performance-based pay |
| FIXED |  | **Base**<br>**Salary** |  | Fixed cash compensation based on size and scope <br>of role, responsibilities, experience, and individual <br>performance. | •Attract and retain talented <br>executives<br>•Drive performance through <br>individual contributions<br>•Provide a consistent and stable <br>source of compensation that <br>allows executives to focus on <br>long-term strategic initiatives <br>and operational excellence <br>without being distracted by <br>short-term fluctuations in <br>performance-based pay |
|  | ANNUAL CASH <br>COMPENSATION | **Base**<br>**Salary** | ![NEO Base Pay Mix.jpg](ingr-20260402_g34.jpg) | Fixed cash compensation based on size and scope <br>of role, responsibilities, experience, and individual <br>performance. | •Attract and retain talented <br>executives<br>•Drive performance through <br>individual contributions<br>•Provide a consistent and stable <br>source of compensation that <br>allows executives to focus on <br>long-term strategic initiatives <br>and operational excellence <br>without being distracted by <br>short-term fluctuations in <br>performance-based pay |
|  | ANNUAL CASH <br>COMPENSATION |  |  |  |  |
|  | ANNUAL CASH <br>COMPENSATION |  |  |  |  |
|  | ANNUAL CASH <br>COMPENSATION | **Annual**<br>**Incentive** | ![CEO STI Mix.jpg](ingr-20260402_g35.jpg) | Annual cash incentive with a target award for each <br>NEO based on a percentage of base salary. Actual <br>awards may be higher or lower than target based <br>on Company, business and individual performance. <br>Awards range from 0% - 200% of target based on <br>performance. | •Motivate achievement of <br>annual financial, operational, <br>and individual goals<br>•Encourage individual <br>contributions that support our <br>strategic initiatives |
|  |  | **Annual**<br>**Incentive** |  | Annual cash incentive with a target award for each <br>NEO based on a percentage of base salary. Actual <br>awards may be higher or lower than target based <br>on Company, business and individual performance. <br>Awards range from 0% - 200% of target based on <br>performance. | •Motivate achievement of <br>annual financial, operational, <br>and individual goals<br>•Encourage individual <br>contributions that support our <br>strategic initiatives |
|  |  | **Annual**<br>**Incentive** | ![NEO Annual Incentive Mix.jpg](ingr-20260402_g36.jpg) | Annual cash incentive with a target award for each <br>NEO based on a percentage of base salary. Actual <br>awards may be higher or lower than target based <br>on Company, business and individual performance. <br>Awards range from 0% - 200% of target based on <br>performance. | •Motivate achievement of <br>annual financial, operational, <br>and individual goals<br>•Encourage individual <br>contributions that support our <br>strategic initiatives |
|  |  |  |  | Performance-based, overlapping three-year <br>performance cycles. Actual awards are determined <br>at the end of the performance cycle by evaluating <br>financial performance against predetermined <br>metrics and targets. Awards range from 0% - 200% <br>of target based on performance. Awards are <br>delivered in common stock. | •Drive long-term performance<br>•Align executive interests with <br>those of stockholders and <br>encourage an owner's mindset<br>•Actual payouts determined by <br>performance |
|  |  | **Performance**<br>**Share Units** <br>**(50%)** | ![CEO LTI Mix.jpg](ingr-20260402_g37.jpg) | Performance-based, overlapping three-year <br>performance cycles. Actual awards are determined <br>at the end of the performance cycle by evaluating <br>financial performance against predetermined <br>metrics and targets. Awards range from 0% - 200% <br>of target based on performance. Awards are <br>delivered in common stock. | •Drive long-term performance<br>•Align executive interests with <br>those of stockholders and <br>encourage an owner's mindset<br>•Actual payouts determined by <br>performance |
|  |  | **Performance**<br>**Share Units** <br>**(50%)** | ![CEO LTI Mix.jpg](ingr-20260402_g37.jpg) | Performance-based, overlapping three-year <br>performance cycles. Actual awards are determined <br>at the end of the performance cycle by evaluating <br>financial performance against predetermined <br>metrics and targets. Awards range from 0% - 200% <br>of target based on performance. Awards are <br>delivered in common stock. | •Drive long-term performance<br>•Align executive interests with <br>those of stockholders and <br>encourage an owner's mindset<br>•Actual payouts determined by <br>performance |
|  | LONG-TERM INCENTIVE COMPENSATION | **Performance**<br>**Share Units** <br>**(50%)** | ![CEO LTI Mix.jpg](ingr-20260402_g37.jpg) | Performance-based, overlapping three-year <br>performance cycles. Actual awards are determined <br>at the end of the performance cycle by evaluating <br>financial performance against predetermined <br>metrics and targets. Awards range from 0% - 200% <br>of target based on performance. Awards are <br>delivered in common stock. | •Drive long-term performance<br>•Align executive interests with <br>those of stockholders and <br>encourage an owner's mindset<br>•Actual payouts determined by <br>performance |
| VARIABLE | LONG-TERM INCENTIVE COMPENSATION | **Performance**<br>**Share Units** <br>**(50%)** | ![CEO LTI Mix.jpg](ingr-20260402_g37.jpg) | Performance-based, overlapping three-year <br>performance cycles. Actual awards are determined <br>at the end of the performance cycle by evaluating <br>financial performance against predetermined <br>metrics and targets. Awards range from 0% - 200% <br>of target based on performance. Awards are <br>delivered in common stock. | •Drive long-term performance<br>•Align executive interests with <br>those of stockholders and <br>encourage an owner's mindset<br>•Actual payouts determined by <br>performance |
| VARIABLE | LONG-TERM INCENTIVE COMPENSATION | **Performance**<br>**Share Units** <br>**(50%)** | ![CEO LTI Mix.jpg](ingr-20260402_g37.jpg) | Performance-based, overlapping three-year <br>performance cycles. Actual awards are determined <br>at the end of the performance cycle by evaluating <br>financial performance against predetermined <br>metrics and targets. Awards range from 0% - 200% <br>of target based on performance. Awards are <br>delivered in common stock. | •Drive long-term performance<br>•Align executive interests with <br>those of stockholders and <br>encourage an owner's mindset<br>•Actual payouts determined by <br>performance |
| VARIABLE | LONG-TERM INCENTIVE COMPENSATION | **Performance**<br>**Share Units** <br>**(50%)** | ![CEO LTI Mix.jpg](ingr-20260402_g37.jpg) | Performance-based, overlapping three-year <br>performance cycles. Actual awards are determined <br>at the end of the performance cycle by evaluating <br>financial performance against predetermined <br>metrics and targets. Awards range from 0% - 200% <br>of target based on performance. Awards are <br>delivered in common stock. | •Drive long-term performance<br>•Align executive interests with <br>those of stockholders and <br>encourage an owner's mindset<br>•Actual payouts determined by <br>performance |
| VARIABLE | LONG-TERM INCENTIVE COMPENSATION |  | ![CEO LTI Mix.jpg](ingr-20260402_g37.jpg) |  |  |
| VARIABLE | LONG-TERM INCENTIVE COMPENSATION |  | ![CEO LTI Mix.jpg](ingr-20260402_g37.jpg) |  |  |
| VARIABLE | LONG-TERM INCENTIVE COMPENSATION | **Restricted Stock**<br>**Units**<br>**(25%)** | ![CEO LTI Mix.jpg](ingr-20260402_g37.jpg) | Time-based equity awards that cliff vest after three <br>years. Awards are delivered in common stock.  | •Align executive interests with <br>those of stockholders and <br>encourage an owner's mindset<br>•Cliff vesting provides retention <br>value |
| VARIABLE | LONG-TERM INCENTIVE COMPENSATION | **Restricted Stock**<br>**Units**<br>**(25%)** | ![NEO LTI Mix.jpg](ingr-20260402_g38.jpg) | Time-based equity awards that cliff vest after three <br>years. Awards are delivered in common stock.  | •Align executive interests with <br>those of stockholders and <br>encourage an owner's mindset<br>•Cliff vesting provides retention <br>value |
|  | LONG-TERM INCENTIVE COMPENSATION | **Restricted Stock**<br>**Units**<br>**(25%)** | ![NEO LTI Mix.jpg](ingr-20260402_g38.jpg) | Time-based equity awards that cliff vest after three <br>years. Awards are delivered in common stock.  | •Align executive interests with <br>those of stockholders and <br>encourage an owner's mindset<br>•Cliff vesting provides retention <br>value |
|  | LONG-TERM INCENTIVE COMPENSATION |  | ![NEO LTI Mix.jpg](ingr-20260402_g38.jpg) |  |  |
|  | LONG-TERM INCENTIVE COMPENSATION |  | ![NEO LTI Mix.jpg](ingr-20260402_g38.jpg) |  |  |
|  | LONG-TERM INCENTIVE COMPENSATION | **Stock**<br>**Options** <br>**(25%)** | ![NEO LTI Mix.jpg](ingr-20260402_g38.jpg) | An appreciation-based vehicle that pro rata vests <br>over a three-year period. Intended to provide <br>performance-based compensation tied specifically <br>to increases in the price of common stock. | •Align executive interests with <br>those of stockholders and <br>encourage an owner's mindset<br>•Create value through stock price <br>appreciation |
|  | LONG-TERM INCENTIVE COMPENSATION | **Stock**<br>**Options** <br>**(25%)** | ![NEO LTI Mix.jpg](ingr-20260402_g38.jpg) | An appreciation-based vehicle that pro rata vests <br>over a three-year period. Intended to provide <br>performance-based compensation tied specifically <br>to increases in the price of common stock. | •Align executive interests with <br>those of stockholders and <br>encourage an owner's mindset<br>•Create value through stock price <br>appreciation |
|  |  | **Stock**<br>**Options** <br>**(25%)** | ![NEO LTI Mix.jpg](ingr-20260402_g38.jpg) | An appreciation-based vehicle that pro rata vests <br>over a three-year period. Intended to provide <br>performance-based compensation tied specifically <br>to increases in the price of common stock. | •Align executive interests with <br>those of stockholders and <br>encourage an owner's mindset<br>•Create value through stock price <br>appreciation |
|  |  | **Stock**<br>**Options** <br>**(25%)** | ![NEO LTI Mix.jpg](ingr-20260402_g38.jpg) | An appreciation-based vehicle that pro rata vests <br>over a three-year period. Intended to provide <br>performance-based compensation tied specifically <br>to increases in the price of common stock. | •Align executive interests with <br>those of stockholders and <br>encourage an owner's mindset<br>•Create value through stock price <br>appreciation |

---

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **31** |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

Additional elements of our executive compensation program include health, welfare, and retirement benefits, and limited

perquisites as appropriate to support our executive compensation philosophy.

**ELEMENTS OF COMPENSATION**

**Base Salary**

Base salary is the primary element of compensation that is fixed. In setting base salaries for each NEO, the PCC Committee uses

the same approach the Company uses to determine compensation for the broader employee population, including pay

competitiveness, which generally targets base salaries within a reasonable range around the median of comparable roles within

our Compensation Peer Group and the broader market. Specific NEO salaries vary based on level of job responsibility, years of

experience, time in position, internal equity considerations, and individual performance.

**2025 Compensation Actions**

In 2025, the CEO recommended base salary increases for the other NEOs, all of which were approved by the PCC Committee.

The PCC Committee recommended the base salary increase for the CEO, and the Board of Directors, without the participation

of the CEO, discussed and approved the final salary increase. Mr. Ritchie, in addition to his annual merit increase, received a

promotional increase, effective August 16, 2025. Base salaries for the NEOs and 2025 increases are shown in the table below:

---

| | | | |
|:---|:---|:---|:---|
| Name | 2024<br>Base<br>Salary<br>($)<br>| 2025<br>Base<br>Salary<br>($)<br>| Increase<br>(%)<br>|
| James Zallie | 1245600 | 1295050 | 4.0% |
| James Gray | 732900 | 762216 | 4.0% |
| Tanya Jaeger de Foras | 520245 | 538454 | 3.5% |
| Robert Ritchie | 520000 | 575000 | 10.6% |
| Eric Seip | 543375 | 561306 | 3.3% |

---

**Annual Incentive Plan**

We design our AIP to motivate our NEOs to achieve or exceed our annual financial, strategic, and individual goals. The PCC

Committee sets the formula and establishes target, threshold, and maximum annual incentive opportunities at the beginning of

each year. Target goals are based on the financial goals for the Company. The financial goals are recommended by Company

management and, after review and discussion, approved by our Board of Directors. The PCC Committee determines the actual

awards earned by each NEO based on Company annual financial results and individual performance against the pre-defined

strategic objectives for each executive, with the award for the CEO recommended by the PCC Committee to the board for

approval. Annual incentive award payouts can vary greatly from year to year based on actual financial performance relative to

the target goals.

**Annual Incentive Plan Target Opportunity**

The PCC Committee approves the cash, short-term incentive target opportunity for each NEO, other than the CEO, expressed as

a percentage of base salary. The Board of Directors approves the cash, short-term incentive target opportunity for the CEO,

which is also expressed as a percentage of base salary.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Base Salary as of** <br>**December 31, 2025**<br>| **X** | **Target AIP** <br>**Opportunity** <br>**(% of Base Salary)**<br>| **=**  | **Target AIP** <br>**Amount**<br>|

---

---

| | | |
|:---|:---|:---|
| **32** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

The PCC Committee approves the annual incentive targets for the NEOs, other than the CEO, considering both market data and

recommendations from the CEO. Target annual incentive opportunities are set within a reasonable range around the median of

our Compensation Peer Group and the broader market. The target award percentage was increased in 2025 for Messrs. Gray,

Ritchie, and Seip, and for Ms. Jaeger de Foras after considering a number of factors, including total cash compensation

positioning, individual contributions, Company performance, and internal equity. The PCC Committee agreed on a

recommendation for the CEO's 2025 AIP target that was approved by the Board of Directors. The annual incentive opportunity

for each NEO is shown in the table below.

---

| | | |
|:---|:---|:---|
| Name | 2024<br>Target <br>opportunity<br>as a % of salary<br>| 2025<br>Target <br>opportunity<br>as a % of salary<br>|
| James Zallie | 150% | 150% |
| James Gray | 95% | 100% |
| Tanya Jaeger de Foras | 70% | 75% |
| Robert Ritchie | 75% | 85% |
| Eric Seip | 70% | 75% |

---

**2025 AIP Design**

The 2025 AIP design consists of three financial metrics that constitute 80% of the plan, with the remaining 20% consisting of

personal objectives. The PCC Committee approves the individual personal objectives for the NEOs, other than the CEO. The

Board of Directors reviews and approves the individual personal goals and objectives for our CEO in light of the Company's

corporate financial goals and objectives.

---

| | | | |
|:---|:---|:---|:---|
|  | **80%** | | **20%** |
|  | **80%** |  | **20%** |
| **70%** | **15%** | **15%** | **Personal** <br>**Objectives** |
| **AIP**<br>**Adjusted** <br>**EBITDA** | **Working**<br>**Capital as a** <br>**% of Net Sales** | **Cost/**<br>**Productivity** | **Personal** <br>**Objectives** |

---

To be eligible to receive an incentive payment for the 2025 performance period, an NEO must:

• be an employee of the Company on the date the annual incentive is paid or have terminated employment during the

performance period due to retirement, disability, or death, and

• have been employed by the Company for more than three months of the performance period.

An NEO who is eligible to receive an incentive payment for the performance period, but who was not actively employed during

the entire performance period due to such NEO's retirement, disability, or death, will receive a pro rata payment determined in

accordance with rules approved by the PCC Committee.

**Financial Metrics**

The metrics used to determine the financial performance components and the rationale for choosing these metrics is described

below. In selecting metrics, the PCC Committee seeks to incentivize execution against our strategy. The PCC Committee

determined that each of the metrics described below incentivized a key component of our strategy and that our executives

have the ability to influence the Company's performance on each metric. Payouts for each metric can range from 0% to 200%.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **33** |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

---

| | |
|:---|:---|
| Financial Metric | Rationale |
| AIP Adjusted EBITDA<sup>(1)</sup> | Serves as a foundation for our growth and, as a result, shareholder value. |
| Working Capital ("WC") as a <br>Percentage of Net Sales<sup>(2)</sup><br>| A key financial metric to maximize the efficiency of our working capital; incentivizes <br>tightening working capital in periods when sales may decline. <br>|
| Cost/Productivity<sup>(3)</sup> | Focus and simplify to better execute, increase effectiveness/productivity and lower <br>costs.<br>|

---

(1)Adjusted EBITDA, which is a non-GAAP financial measure under SEC rules, is defined by the Company for these purposes as income before

income taxes, calculated in accordance with GAAP, as adjusted to exclude the following items: depreciation and amortization; financing

costs; other non-operating expense; restructuring and resegmentation costs; impairment charges; and certain other matters outside the

normal course of business that occurred during 2025 and is reported in our Annual Report on Form 10-K for the year ended December 31,

2025. AIP Adjusted EBITDA was further adjusted by the PCC Committee to exclude a historic expense item not associated with in-year

operating performance.

(2)Working capital as a percentage of net sales is defined as the 12-month average of trade accounts receivable plus inventory less trade

accounts payable and accrued expenses, divided by average monthly net sales.

(3)Cost/productivity is a cost-savings metric defined by Selling, General, and Administrative ("SG&A") expenses and Cost of Goods Sold

("COGS") targets, inclusive of procurement savings.

**2025 Financial Metrics, Targets, and Results**

The PCC Committee recognizes the importance of establishing realistic yet rigorous targets that continue to motivate and retain

executives. The AIP targets for each year are set, together with the Company budget, at the beginning of the current year,

taking into consideration prior year results, growth targets, and potential risks to achieving the target during the performance

period. The targets and performance scale for each metric are approved after thorough review and discussion at both the PCC

Committee and Board of Directors. The range of performance from threshold to maximum is intended to reflect the expected

variance of operating results. Details on the metrics, weightings, performance scale, and results for the 2025 AIP are shown

below:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Performance** <br>**Measure** | **Weight** | **Weight** | ![image007.jpg](ingr-20260402_g39.jpg) | ![image007.jpg](ingr-20260402_g39.jpg) | ![image007.jpg](ingr-20260402_g39.jpg) | **2025** <br>**Achievement** |
| **Performance** <br>**Measure** | **Weight** | **Weight** | **Threshold** | **Target** | **Maximum** | **2025** <br>**Achievement** |
| **AIP**<br>**Adjusted** <br>**EBITDA** | **80%** | **70%** |  |  |  | **93.1%** |
| **AIP**<br>**Adjusted** <br>**EBITDA** | **80%** | **70%** |  |  |  | **93.1%** |
| **AIP**<br>**Adjusted** <br>**EBITDA** | **80%** | **70%** | ![image006.jpg](ingr-20260402_g40.jpg) | ![image006.jpg](ingr-20260402_g40.jpg) | ![image006.jpg](ingr-20260402_g40.jpg) | **93.1%** |
| **AIP**<br>**Adjusted** <br>**EBITDA** | **80%** | **70%** | $1084.5 | $1275.9 | $1403.5 |  |
|  | **80%** |  |  |  |  |  |
|  | **80%** |  |  |  |  |  |
| **Working Capital** <br>**as a % of Net** <br>**Sales** | **80%** | **15%** | ![image006.jpg](ingr-20260402_g40.jpg) | ![image006.jpg](ingr-20260402_g40.jpg) | ![image006.jpg](ingr-20260402_g40.jpg) | **123.7%** |
| **Working Capital** <br>**as a % of Net** <br>**Sales** | **80%** | **15%** |  |  |  | **123.7%** |
| **Working Capital** <br>**as a % of Net** <br>**Sales** | **80%** | **15%** |  |  |  | **123.7%** |
| **Working Capital** <br>**as a % of Net** <br>**Sales** | **80%** | **15%** | 22.7% | 19.7% | 16.7% |  |
|  | **80%** |  |  |  |  |  |
| **Cost/**<br>**Productivity**<br>**(in millions)**  | **80%** | **15%** |  |  |  | **190.0%** |
| **Cost/**<br>**Productivity**<br>**(in millions)**  | **80%** | **15%** |  |  |  | **190.0%** |
| **Cost/**<br>**Productivity**<br>**(in millions)**  | **80%** | **15%** | ![image006.jpg](ingr-20260402_g40.jpg) | ![image006.jpg](ingr-20260402_g40.jpg) | ![image006.jpg](ingr-20260402_g40.jpg) | **190.0%** |
| **Cost/**<br>**Productivity**<br>**(in millions)**  | **80%** | **15%** | $42.5 | $50.0 | $60.0 |  |

---

![](ingr-20260402_g41.gif)

**$1,249.7**

![](ingr-20260402_g41.gif)

**19.0%**

![](ingr-20260402_g41.gif)

**$59.0**

---

| | | |
|:---|:---|:---|
| **34** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

**2025 Segment Targets and Financial Results**

To determine the Adjusted EBITDA portion of the AIP award for Mr. Ritchie, the 70% weighting for his Adjusted EBITDA was

allocated 15% to each of the two Food and Industrial Ingredients segments (US/Canada and LATAM) and the remaining 40%

was based upon the total Company Adjusted EBITDA as shown above. The US/Canada segment results were further adjusted as

described in footnote 1 to the table presented under "Financial Metrics" above.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  |  | Performance Scale | Performance Scale | Performance Scale | Results | Results |
| Financial Metric | Weighting | Threshold | Target | Maximum | Final Result | Payout |
| F&II US/Canada Adjusted EBITDA | 15% | $347.7 | $400.9 - $409.1 | $450 | $359.5 | 74% |
| F&II LATAM Adjusted EBITDA | 15% | $477.3 | $561.5 | $617.6 | $541.8 | 74% |

---

**Personal Objectives**

At the beginning of each year, based on the annual financial and strategic plan, our CEO and the other NEOs develop annual

quantitative and qualitative personal objectives. The personal objectives for the CEO are recommended by the PCC Committee

to the Board of Directors and, after review and discussion, are approved by the Board of Directors. The personal objectives for

the NEOs, other than the CEO, are recommended by the CEO to the PCC Committee and, after review and discussion, are

approved by the PCC Committee.

---

| | |
|:---|:---|
| For 2025, the personal objectives for all Ingredion <br>employees, including the CEO and all other NEOs, were <br>aligned with Ingredion's four strategic pillars (Business <br>Growth & Innovation, Cost Competitiveness, Commercial <br>Excellence and Strategy Execution, and Talent Development, <br>Inclusion & Belonging and Growth Culture) and the core <br>Company value of "Care First." Mr. Zallie's personal <br>objectives for 2025 focused on employee safety, execution <br>against the Company's strategy, delivery of strategic <br>business growth, innovation, cost competitiveness, <br>leadership development, and succession planning. | **Mr. Zallie's Personal Objectives for 2025** |
| For 2025, the personal objectives for all Ingredion <br>employees, including the CEO and all other NEOs, were <br>aligned with Ingredion's four strategic pillars (Business <br>Growth & Innovation, Cost Competitiveness, Commercial <br>Excellence and Strategy Execution, and Talent Development, <br>Inclusion & Belonging and Growth Culture) and the core <br>Company value of "Care First." Mr. Zallie's personal <br>objectives for 2025 focused on employee safety, execution <br>against the Company's strategy, delivery of strategic <br>business growth, innovation, cost competitiveness, <br>leadership development, and succession planning. | ![CEO Objectives 2025.jpg](ingr-20260402_g42.jpg) |

---

The personal objectives of the other NEOs were aligned with and supported Mr. Zallie's personal objectives and focused on the

same strategic categories with varying levels of emphasis and weighting. A maximum 200% payout on the personal objective

component is possible for exceptional performance, while a payout of 0% on the personal objectives is possible for poor

performance.

At the conclusion of the annual performance period:

• our CEO provides a detailed self-appraisal of his performance relative to the achievement of his annual personal

objectives and the quality of work performed, which is shared with the Board of Directors. Following a thorough review

and discussion of all information provided, the PCC Committee recommends a personal objective rating for the CEO to

the board, and the Board of Directors makes the final decision on the personal objective rating for the CEO, which is

then used to calculate his AIP payout.

• for each of the other NEOs, the CEO provides the PCC Committee with an individual performance assessment and rating

recommendation based on each NEO's contributions and achievements during the year. The PCC Committee reviews

and discusses the recommendations made by the CEO before approving the individual performance rating for each NEO.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **35** |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

• the PCC Committee retains discretion to adjust earned AIP awards up or down in extraordinary circumstances. No such

adjustments were made to earned AIP awards for 2025.

**2025 AIP Payouts**

After determining the 2025 financial achievement and individual performance achievement against the annual personal

objectives for each NEO, the PCC Committee approved the following annual incentive cash payments:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  | Financial Factors (80%) | Financial Factors (80%) | Personal Objectives (20%) | Personal Objectives (20%) | 2025 Aggregate<br>Payout | 2025 Aggregate<br>Payout |
| Name | Target<br>($)<br>| Earned <br>Payout <br>(%)<br>| Earned <br>Payout <br>($)<br>| Earned Payout <br>(%)<br>| Earned Payout <br>($)<br>| Earned <br>Payout <br>(%)<br>| Earned <br>Payout <br>($)<br>|
| James Zallie | 1942575 | 112.2% | 1744044 | 113.75% | 441936 | 112.5% | 2185980 |
| James Gray | 762216 | 112.2% | 684317 | 122.50% | 186743 | 114.3% | 871060 |
| Tanya Jaeger de Foras | 403841 | 112.2% | 362569 | 116.25% | 93893 | 113.0% | 456462 |
| Robert Ritchie<sup>(1)</sup> | 458434 | 106.5% | 390513 | 106.25% | 97417 | 106.4% | 487930 |
| Eric Seip | 420980 | 112.2% | 377955 | 101.25% | 85248 | 110.0% | 463203 |

---

(1)AIP target and payout for Mr. Ritchie reflect proration based on his salary and AIP target from January 1 through August 15, 2025 and,

following his promotion, his increased salary and AIP target from August 16, 2025 through December 31, 2025.

**Long-term Incentive Compensation**

We design our annual long-term incentive program ("LTIP") to provide variable compensation in the form of equity that

rewards executives when we achieve long-term results that align with stockholder interests. Our LTIP incentivizes our NEOs to

focus on important performance objectives that we believe will translate into sustainable stockholder returns over the long

term. For 2025, we continued with the same mix of awards used in prior years, as shown in the table below, to provide a

balance of performance- and retention-based compensation to support our long-term strategy. This mix of awards, consisting

of performance share units ("PSUs"), restricted stock units ("RSUs"), and stock options, is designed to tie executive

compensation to TSR, balance performance focus with the ability to retain executives, and mitigate the risk of over-focusing on

a single metric.

---

| | | | |
|:---|:---|:---|:---|
| Vehicle | Weight | Structure | Purpose |
| PSUs | 50% | •Number of shares earned may range from <br>0%- 200% of the target number of PSUs <br>granted based on the business performance <br>rating for the performance cycle<br>•3-year performance cycle<br>| •Strengthens retention<br>•Promotes focus on specific performance <br>goals critical to the success of the business <br>•Facilitates stock ownership when earned<br>•Aligns long-term interests with those of <br>stockholders<br>|
| RSUs | 25% | •Value of award depends on our stock price at <br>time of vesting<br>•3-year cliff vesting from date of grant<br>| •Strengthens retention<br>•Facilitates stock ownership<br>|
| Stock <br>Options<br>| 25% | •3-year ratable vesting<br>•10-year term<br>| •Requires stock price appreciation for value <br>creation<br>•Facilitates stock ownership<br>•Aligns long-term interests with those of <br>stockholders<br>|

---

---

| | | |
|:---|:---|:---|
| **36** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

**2025 Annual Equity Grants to NEOs**

The table below shows the 2025 annual equity grants to our NEOs. In determining each grant, the PCC Committee considered

the executive's level of responsibility, individual and Company performance, external market positioning, and

recommendations from the CEO (for the other NEOs). We approve long-term incentive grants at the PCC Committee's first

meeting of each fiscal year, typically in February, at the same time other elements of compensation are determined so that we

can consider all elements of compensation simultaneously when making decisions.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | 2025 Annual Equity Grants<sup>(1),(2)</sup> | 2025 Annual Equity Grants<sup>(1),(2)</sup> | 2025 Annual Equity Grants<sup>(1),(2)</sup> | 2025 Annual Equity Grants<sup>(1),(2)</sup> |
| Name | PSUs ($) | RSUs ($) | Stock Options ($) | Total Equity Grant ($) |
| James Zallie | 4000000 | 2000000 | 2000000 | 8000000 |
| James Gray | 900000 | 450000 | 450000 | 1800000 |
| Tanya Jaeger de Foras | 475000 | 237500 | 237500 | 950000 |
| Robert Ritchie | 600000 | 300000 | 300000 | 1200000 |
| Eric Seip | 412500 | 206250 | 206250 | 825000 |

---

(1)Grant date for the annual equity grants was February 26, 2025. Value of PSUs is reflected at target (100% achievement) since actual

value of grant/shares earned, if any, will be determined after the three-year performance cycle ending on December 31, 2027.

(2)Represents the dollar amount approved by the PCC Committee. This amount differs from the value in the "2025 Grants of Plan-Based

Awards" table on page <u>[49](#iafcd580ce31344a8a23a91f06fc3939f_2402)</u>, which represents the accounting value of the award.

**Performance Share Units**

The PCC Committee approves performance targets for a three-year performance cycle when it grants PSUs. At the end of the

three-year performance cycle, grants will vest only if the PCC Committee certifies that Company results meet or exceed the

applicable performance thresholds set at the beginning of the cycle. Vested PSUs are settled in shares of common stock in the

first quarter following the end of the performance cycle. Dividend equivalents accrue during the performance period and are

paid in cash based on the actual number of shares earned. However, if no PSUs are earned for a performance cycle, no

dividends are paid on those PSUs.

The table below outlines the performance measures, weightings, and performance scale for the February 2025 annual PSU

grant and outlines the rationale for selecting each metric. In selecting the metrics, the PCC Committee sought to incentivize

behavior consistent with achieving our long-term growth objectives and to align the interests of our executives with the

interests of our stockholders.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  |  | Performance Scale (2025 - 2027) | Performance Scale (2025 - 2027) | Performance Scale (2025 - 2027) |
| Metric | Weighting | Rationale | Threshold | Target | Maximum |
| Adjusted Return on <br>Invested Capital <br>("Adjusted ROIC")<sup>(1)</sup><br>| 50% | Focuses on profitability and value-<br>creating potential while also taking <br>into account the amount of capital <br>invested.<br>| <8.5% | 11.5% | ≥14.75% |
| Relative Total <br>Shareholder Return <br>("rTSR")<sup>(2)</sup><br>| 50% | Directly link awards to shareholder <br>value creation and performance <br>versus peers.<br>| <25<sup>th</sup><br>percentile<br>| 50<sup>th</sup><br>percentile<br>| ≥75<sup>th</sup><br>percentile<br>|

---

(1)Adjusted ROIC is a financial performance ratio not defined under GAAP. The Company defines Adjusted ROIC as adjusted operating

income, net of tax, divided by average end-of-year balances for the current year and prior year total net debt and equity. Adjusted

operating income, net of tax, is a non-GAAP financial measure under SEC rules. The Company defines adjusted operating income, net of

tax, as net income, calculated in accordance with GAAP, as adjusted to exclude acquisition and integration costs, impairment and

restructuring costs, and certain other matters outside the normal course of business that may occur during the applicable year.

(2)rTSR measures our stock performance relative to a 23-company performance peer group that was selected prior to the start of the

performance period. This metric measures how well our stock has performed compared to the Performance Peer Group over the

performance period.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **37** |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

**2023 – 2025 Performance Share Plan Results** 

The following chart shows:

• the key financial metrics, weighting, and performance goals the PCC Committee set in 2023,

• our actual performance over the 2023 – 2025 performance cycle, and

• the final performance results approved by the PCC Committee at the end of the 2023 – 2025 performance cycle.

Based on three-year results that exceeded the pre-established maximum performance levels, the 2023 – 2025 PSU awards paid

out at 183.4% of target. Actual results for the 2023 – 2025 performance cycle are shown below:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | 2023 – 2025 Performance Cycle Results | 2023 – 2025 Performance Cycle Results | 2023 – 2025 Performance Cycle Results | 2023 – 2025 Performance Cycle Results | 2023 – 2025 Performance Cycle Results | 2023 – 2025 Performance Cycle Results |
| Performance Metric | Weighting | Threshold | Target | Maximum | Actual | Payout |
| Adjusted ROIC<sup>(1)</sup> | 50% | <8% | 10.0% | ≥11.5% | 14.5% | 200.0% |
| rTSR (percentile rank)<sup>(2)</sup> | 50% | <25<sup>th</sup> | 50<sup>th</sup> | ≥75<sup>th</sup> | 67<sup>th</sup> | 166.7% |
| **Final Performance Rating** |  |  |  |  |  | **183.4%** |

---

(1)Adjusted ROIC, which is a financial performance ratio not defined under GAAP, is defined by the Company in the manner specified in

footnote 1 to the table presented under "Performance Share Units" above and is reported in our Annual Report on Form 10-K for the year

ended December 31, 2025.

(2)rTSR measured our stock performance relative to a 20-company performance peer group that was selected prior to the start of the

performance period (per the terms of the award agreement, two companies were removed before the end of the performance period due

to acquisition so ultimately ended with 18 peers). This metric measures how well our stock has performed compared to the Performance

Peer Group over the performance period.

**Stock Options**

Of our NEOs' long-term incentive, 25% is delivered in the form of nonqualified stock options that vest ratably over three years

and have a term of ten years. The exercise price of stock options is the Closing Price of our common stock on the grant date.

Stock options have no realizable value at the time of grant. NEOs will realize value from stock options only if the Company's

share price has appreciated above the exercise price as of the option exercise date.

**Restricted Stock Units**

We grant RSUs to align the interests of our NEOs with the interests of our stockholders and to promote retention of critical

talent. These awards also help to balance the long-term incentive compensation mix for our NEOs to minimize risk-taking.

RSUs granted to the NEOs in February 2025 cliff vest on the third anniversary of the grant date. As of each dividend payable

date, additional RSUs equivalent to the value of the dividend are credited to the award. The additional RSUs credited are

subject to the same terms and conditions as the underlying award.

---

| | | |
|:---|:---|:---|
| **38** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

**OTHER COMPENSATION ELEMENTS**

**Limited Perquisites**

We provide limited perquisites to our NEOs. The table below identifies and provides the business rationale for each perquisite

provided to the NEOs in 2025. The PCC Committee believes offering certain limited perquisites is important for executive

retention and recruitment and that the perquisites offered to the Company's NEOs are similar in scope and value to those

offered by companies with which we compete for talent.

---

| | |
|:---|:---|
| Category | Business Rationale |
| Choice of Car Allowance or <br>Automobile Lease<br>| To allow the NEO the convenience of using a vehicle for business purposes without having <br>to track and submit expenses or, in the case of a lease, take time for maintenance of a <br>vehicle, ultimately saving time and allowing the NEO to be more productive.<br>|
| Financial Planning and Tax <br>Preparation<br>| To address complex tax and financial situations and assist in compliance with local state <br>and country tax laws for our executives with dual nationalities or work histories in multiple <br>states and countries.<br>|
| Executive Physical | To promote the health and well-being of our NEOs and to minimize time away from work <br>through a single coordinated and comprehensive medical evaluation.<br>|

---

Each of the NEOs is subject to income tax on the imputed income resulting from his or her perquisites and each is responsible

for payment of any resulting taxes. We do not provide our NEOs with tax gross-ups on perquisites. The value of these limited

perquisites is included in the "2025 Summary Compensation Table" on page <u>[47](#ie7e472361805446c8b302de30ed47fbf_55)</u> in the "All Other Compensation" column.

---

| |
|:---|
| **Retirement and Separation Benefits** |
| Our U.S.-based NEOs are eligible for broad-based U.S. employee benefit plans on the same terms and conditions as U.S. <br>salaried employees, including medical, dental, and life insurance as well as disability and accidental death and <br>dismemberment coverage.<br>•All eligible employees in the U.S., including the NEOs, may purchase additional life, dependent life, and accidental <br>death and dismemberment coverage as part of their active employee benefit plans.<br>•All salaried employees in the U.S. are eligible to participate in our salaried Retirement Savings Plan.<br>•In the past, all salaried employees in the U.S., subject to certain service requirements, were also eligible to participate <br>in the Cash Balance Plan Component of the Ingredion Pension Plan (the "Cash Balance Plan") and our Master Retiree <br>Welfare Plan (also known as Retiree Health Care Spending Accounts or "RHCSA"). Both of these plans were closed to <br>new participants as of December 31, 2014.<br>|

---

**Retirement Savings Plan**

Our Retirement Savings Plan is a tax-qualified 401(k) savings plan that offers U.S. salaried employees the opportunity to

contribute up to 75% of their respective eligible compensation on either a before-tax or after-tax basis.

• The Company matches 100% of employee contributions up to the first 6% of eligible compensation contributed.

• Employee contributions are fully vested upon contribution.

• Company contributions are vested after three years of qualified employment with the Company.

• Employees not eligible to participate in the Cash Balance Plan are eligible for an additional Company contribution of 3%

of eligible compensation contributed to their Retirement Savings Plan account.

Because Ms. Jaeger de Foras and Mr. Seip are not eligible to participate in the Cash Balance Plan, they each receive the

additional Company contribution of 3% of eligible compensation, as referenced above.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **39** |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

---

| |
|:---|
| **Cash Balance Plan** |
| Messrs. Zallie, Gray, and Ritchie participate in the Cash Balance Plan. The Cash Balance Plan is a defined benefit qualified <br>pension plan which was available to all U.S. salaried employees hired before January 1, 2015.<br>•Participant accounts accrue pay credits based on years of service and monthly interest credits using a rate equal to <br>a specified amount above the interest rate on short-term U.S. Treasury notes.<br>•Pay credits are calculated as a percentage (3% to 10%) of a salaried employee's eligible compensation (defined as <br>base salary, overtime, and earned AIP award).<br>•Pay credit percentage is determined by the employee's years of service and reaches and remains at 10% after 35 <br>years of service (with the plan frozen at 2017 levels for purposes of calculating the pay credit percentage).<br>•The value of a participant's account at retirement is paid out either as a life or a joint and survivor annuity or in an <br>optional form, such as a lump sum, if certain funding conditions are met.<br>•The Cash Balance Plan provides for a three-year vesting period, with all eligible participants currently vested in their <br>accounts.<br>|

---

**Retiree Health Care Spending Account**

Messrs. Zallie and Ritchie are both retirement-eligible and will each be provided with a Retiree Health Care Spending Account

("RHCSA") account when their respective employment with the Company terminates. The RHCSA account aids in purchasing

pre-age 65 retiree medical and dental coverage from the Company and in reimbursing for a Medicare supplement policy for

coverage at age 65 or older. At termination, qualified employees have access to a RHCSA account for themselves and a RHCSA

account in an equal amount for their then-qualified dependents. The balances in these accounts may be used by the pre-age 65

retiree and dependents to purchase from the Company, at the full cost, medical and dental benefits that mirror those provided

by the Company to active employees.

Balances in these notional accounts are forfeited if the eligible employee terminates employment prior to age 55 with ten years

of service at the time of termination. The accounts otherwise terminate on the death of the employee for the employee's

RHCSA and upon the death of the qualified dependent in the case of the dependent's RHCSA or when the balance in the

account is depleted.

Although Mr. Gray is retirement-eligible, the RHCSA plan was frozen as of December 31, 2014, and he did not meet the age and

service requirements to be grandfathered into the program.

---

| | | |
|:---|:---|:---|
| **40** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

---

| | |
|:---|:---|
| **Non-Qualified Deferred Compensation Plan** | **Non-Qualified Deferred Compensation Plan** |
|  | Certain of our U.S.-based eligible employees, including all NEOs, are entitled to participate in our Non-Qualified Deferred <br>Compensation Plan (formerly called the Supplemental Executive Retirement Plan ("SERP")). The purpose of this nonqualified, <br>unfunded plan is to:<br>•permit certain key executives to defer receipt of a portion of current compensation, including short- and long-term <br>incentive payments, until a later year,<br>•provide participants and their beneficiaries with the amount of retirement income that is not provided under the <br>Cash Balance Plan or the Retirement Savings Plan by reason of statutory limits on eligible compensation under <br>tax-qualified plans, and<br>•preserve the opportunity for executives to continue to defer compensation that was deferred under previously <br>maintained plans.<br>To the extent that an employee's annual retirement income benefit under the Cash Balance Plan exceeds the limitations <br>imposed by the U.S. Internal Revenue Code, additional benefits are provided through our Non-Qualified Deferred <br>Compensation Plan ("NQDCP") via an account referred to as a Cash Balance Make-up Account to which we contribute the <br>amounts that we would have contributed to the Cash Balance Plan absent those statutory limitations. Messrs. Zallie, <br>Gray, and Ritchie are the only NEOs who have Cash Balance Make-up Accounts.<br>Participants are entitled to participate in annual deferral accounts and accounts referred to as Savings Plan Make-up <br>Accounts under the NQDCP. To the extent that benefits are limited under the Retirement Savings Plan due to statutory <br>limits on compensation and deferral under tax-qualified plans, participants are permitted to defer compensation through <br>the NQDCP. In addition, we make matching contributions on voluntary contributions to the Savings Plan Make-up <br>Accounts in the amount that we would have contributed to the Retirement Savings Plan absent those statutory <br>limitations. A participant is vested in his or her Savings Plan Make-up Account to the extent that the participant is vested <br>in the Retirement Savings Plan matching contributions. NQDCP participants are general, unsecured creditors of the <br>Company.<br>|

---

**Post-Termination Compensation** 

The NEOs are covered by arrangements, under either an executive severance agreement or certain plans that specify payments

in the event the executive's employment is terminated. These severance benefits are payable if and only if the executive's

employment is terminated by the Company under certain circumstances, including termination without cause. Severance plans,

consisting of the Ingredion Executive Severance Pay Plan and the Executive Change In Control Severance Pay Plan, have been

created to attract and retain talented and experienced executives and further motivate them to contribute to our short- and

long-term success.

Messrs. Zallie, Gray, and Seip are covered by individual executive severance agreements that provide for benefits in the event

of a change in control of the Company ("CIC"). These agreements are intended to align executive and stockholder interests by

enabling executives to consider corporate transactions that are in the best interests of stockholders and other stakeholders of

the Company without undue concern over whether the transactions may jeopardize the NEO's own employment. The

agreements require us or a successor company to make certain payments and provide certain benefits if employment is

terminated by us or a successor company other than because of death, "Disability" or "Cause," or by the NEO for "Good

Reason," in each case, within two years of a CIC. Disability, Cause, and Good Reason are defined in the executive severance

agreements.

Ms. Jaeger de Foras and Mr. Ritchie are covered by the executive severance plans, which provide for cash severance payable in

a multiple of current annual base salary and current target annual incentive award based on the executive's position in

Ingredion and whether termination involves a CIC event. The terms of the executive severance plans are similar to those

provided by other companies, and we offer them in part to provide a competitive compensation package. Information regarding

potential payments under the individual executive severance agreements or the executive severance plans is provided under

"Potential Payments Upon Termination or Change in Control" beginning on page <u>[54](#ie7e472361805446c8b302de30ed47fbf_73)</u>.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **41** |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

**HOW COMPENSATION DECISIONS ARE MADE**

**Role of Peer Groups**

The PCC Committee uses two different groups of companies to (i) benchmark executive compensation, market practices, and

compensation design and (ii) assess relative performance.

**Compensation Peer Group**

The PCC Committee annually reviews compensation data from a comparator group of companies as one reference point when

making compensation decisions for all executive pay, including CEO pay, and when benchmarking compensation plan designs.

With the assistance of its independent executive compensation consultant, the PCC Committee reviewed peer group market

data from public filings and proprietary survey sources to determine the competitiveness of target pay levels. Other factors

considered in NEO compensation decisions include individual performance, job responsibilities, leadership, years of experience,

Company performance, and long-term growth potential.

We routinely review the selection criteria and companies in our Compensation Peer Group to ensure all companies are still

meeting the original criteria for selection. The PCC Committee, with input from the independent executive compensation

consultant, determined that no updates to the Compensation Peer Group were necessary for 2025. In total, the 2025

Compensation Peer Group consists of 18 companies with a median revenue of $8.8 billion.

The table below shows our criteria for choosing the Compensation Peer Group and how it is used:

---

| | | |
|:---|:---|:---|
| **How the Compensation**<br>**Peer Group Was Chosen**<br>| **2025 Compensation**<br>**Peer Group**<br>| **How We Use the Compensation**<br>**Peer Group**<br>|
| •Revenue size: 1/3x – 3x Ingredion <br>revenue<br>•Strong focus in the food product and <br>beverage industry<br>•U.S. publicly traded companies<br>•Global footprint with sales and <br>operations outside of the United <br>States<br>•Similar business structure<br>•Also considered market cap, gross <br>margin and capital intensity, as well <br>as peers identified by proxy advisory <br>firms<br>| •The Campbell's Company<br>•The Clorox Company<br>•Conagra Brands, Inc.<br>•Constellation Brands Inc.<br>•Darling Ingredients Inc.<br>•Eastman Chemical Company<br>•Flowers Foods, Inc.<br>•Fresh Del Monte Produce Inc.<br>•The Hershey Company<br>•Hormel Foods Corporation<br>•The J.M. Smucker Company<br>•Kellanova<br>•Keurig Dr Pepper Inc.<br>•Lamb Weston Holdings, Inc.<br>•McCormick & Company, Inc.<br>•Molson Coors Beverage Company<br>•Post Holdings, Inc.<br>•TreeHouse Foods, Inc.<br>| •For benchmarking the following:<br>i.Annual and long-term incentive <br>plan design<br>ii.Total direct compensation (at <br>target levels), including base <br>salary, and annual and long-term <br>incentive awards<br>iii. Stock ownership requirements<br>iv. Perquisites<br>v.Severance benefits<br>vi.Non-employee director <br>compensation<br>•Compare pay-for-performance <br>alignment<br>|

---

We review all elements of compensation annually to consider the relationships between all compensation elements as well as

to assess the appropriateness of the total compensation package for each NEO. We also consider the strength of our financial

performance, the NEO's position and level of responsibility, internal comparisons, individual performance, and competitive

market data for the Compensation Peer Group. In addition, we supplement data collected from the Compensation Peer group

with broader, general industry data from nationally recognized survey providers.

---

| | | |
|:---|:---|:---|
| **42** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

**Performance Peer Group**

We compare our TSR performance against our Performance Peer Group, which allows us to structure long-term incentive

compensation linked directly to the performance of our peers. This group of companies is less relevant as a comparator for

compensation levels for executive positions because of differences in company size, market capitalization, scope, business

structure, and geographic footprint. We consider these companies industry competitors, so we believe that comparing our

performance against this peer group provides a valuable measure of our performance. We also believe investors are more likely

to consider the stocks of the Performance Peer Group as alternatives to an investment in our stock than the companies in the

Compensation Peer Group, in part because their business operations are more similar to ours.

We also routinely review the selection criteria and companies in our Performance Peer Group to ensure all companies are still

meeting the original criteria for selection. The PCC Committee, with input from its independent executive compensation

consultant, made several changes to the Performance Peer Group for 2025 to enhance the comparability of the companies to

Ingredion for purposes of the rTSR assessment. The committee removed Associated British Foods PLC, Tyson Foods, Inc., and

Unilever PLC and added Ashland, Inc., Bunge Global SA, Corteva, Inc., Eastman Chemical Company, FMC Corporation, and

International Flavors and Fragrances, Inc. The 2025 Performance Peer Group consists of 23 companies.

The table below shows our criteria for choosing the Performance Peer Group and how it is used.

---

| | |
|:---|:---|
| **How the Performance**<br>**Peer Group Was Chosen**<br>| **How We Use the Performance**<br>**Peer Group**<br>|
| •Focused on basic ingredient, food <br>additives, and midstream <br>manufacturing<br>•Market capitalization between $1 <br>billion and $50 billion<br>•Correlation in stock price and <br>volatility<br>•Business cyclicality and comparable <br>commodity price sensitivity<br>•Overseas operations<br>•AAK AB<br>•Archer Daniels-Midland Company<br>•Ashland Inc.<br>•Bunge Global SA<br>•Celanese Corporation<br>•Corteva, Inc.<br>•Danone S.A.<br>•DSM-Firmenich AG<br>•Eastman Chemical Company<br>•Ecolab Inc.<br>•FMC Corporation<br>•General Mills, Inc.<br>•Huntsman Corporation<br>•International Flavors and <br>Fragrances, Inc.<br>•Kellanova<sup>(1)</sup><br>•Kerry Group plc<br>•The Kraft Heinz Company<br>•McCormick & Company, Inc.<br>•Mondelēz International, Inc.<br>•Novonesis A/S<br>•Sealed Air Corporation<br>•Sensient Technologies Corporation<br>•Tate & Lyle plc<br>| •Compare annualized TSR to assess <br>our results against the TSR <br>performance measure for PSUs<br>|

---

(1)Included through December 11, 2025 when it was acquired by Mars, Inc.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **43** |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

**DECISION-MAKING PROCESS**

**Role of the Compensation Consultant**

The PCC Committee retains an independent executive compensation consultant to assist in evaluating executive compensation

programs. The consultant advises the PCC Committee regarding the amount and form of executive and director compensation,

pay-for-performance alignments, and plan design to support the strategic and financial goals of the Company. The committee

believes that conferring with a consultant provides additional assurance that our executive and director compensation

programs are reasonable, market-competitive, and aligned with our objectives.

The PCC Committee has engaged Meridian as its independent executive compensation consultant. For additional information

regarding the PCC Committee's use of an independent executive compensation consultant, see "Proposal 1. Election of

Directors—The Board and Committees—People, Culture, and Compensation Committee" on page <u>[14](#ib074b4e47f704a23a3698e9789e4e5f6_31854)</u>.

**Compensation Consultant Responsibilities:**<br>•Regularly update the PCC Committee on executive compensation market trends, incentive practices, and legislation <br>pertaining to executive compensation<br>•Attend all PCC Committee meetings, including executive sessions without management present<br>•Provide guidance on executive compensation programs to promote market competitiveness<br>•Provide research, data, survey information and design expertise in support of the development of compensation <br>programs for executives and the design of incentive programs for all eligible employees<br>•Review and recommend compensation of non-employee directors<br>•Conduct a pay-for-performance assessment<br>•Perform an annual compensation program risk assessment<br>•Advise the PCC Committee on the appropriate comparator peer groups for compensation and performance<br>•Provide guidance to the PCC Committee on CEO compensation<br>•Provide an independent assessment of the CEO's recommendations on NEO compensation to the PCC Committee<br>

**Role of the PCC Committee**

The PCC Committee is accountable for ensuring executive compensation decisions are made in the best long-term interests of

our stockholders and for administering the compensation program for Ingredion's executive officers, including the NEOs,

accordingly. Annually, the PCC Committee reviews and approves each element of compensation and, if warranted, the PCC

Committee recommends adjustments to individual elements of compensation to achieve an overall total targeted

compensation that it believes is market-competitive and consistent with our compensation philosophy and objective to attract,

retain, and motivate a talented workforce. In its deliberations, the PCC Committee reviews data prepared by the independent

consultant on pay levels in our Compensation Peer Group (as described above) and reviews NEO, other than the CEO,

performance based on the evaluations presented by the CEO.

Additionally, the PCC Committee reviews and approves management's recommendations for equity grants made annually

under our Stock Incentive Plan during its first meeting of the fiscal year, which is typically held in February. The PCC Committee

approves grants of equity awards to NEOs, other than the CEO, at the same time it approves grants of equity awards to all other

eligible employees. In addition, the PCC Committee approves grants of equity awards to the CEO, subject to approval by the

non-employee directors of the board.

The PCC Committee approves performance measures and payout ranges for both AIP and LTIP metrics and, at year end, certifies

levels of achievement of Company and segment performance for each program, as applicable.

---

| | | |
|:---|:---|:---|
| **44** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

**Role of Management**<br>The compensation of every employee, including each NEO, is influenced in large part by the responsibilities of the position <br>and the need to ensure that employees having similar job responsibilities are paid equitably, with consideration for individual <br>performance. The CEO makes compensation recommendations to the PCC Committee for base salary and annual and long-<br>term incentive compensation for the NEOs, other than himself, and considers pay competitiveness as well as both individual <br>and Company performance when making his recommendations. For 2025, based on the NEO's contributions throughout the <br>year, the CEO provided the PCC Committee with an individual performance assessment and rating recommendation as well a <br>compensation recommendation (including base salary and long-term incentive recommendation) for each NEO.<br>The PCC Committee considers the CEO's analysis and direct knowledge of each NEO's performance and contributions when <br>determining the individual performance rating for each NEO and when approving compensation decisions.<br>

**COMPENSATION GOVERNANCE**

**How the PCC Committee Manages Compensation-Related Risk**

We believe that the design and objectives of our executive compensation programs provide an appropriate balance of

incentives for our executive officers and discourage our executive officers and other employees from taking excessive risks for

short-term benefits that may harm the Company and our stockholders in the long term. As described throughout this CD&A

section, we design our compensation program to incentivize executive officers and other employees to achieve the Company's

financial and strategic goals as well as individual performance goals that promote long-term stockholder returns. Specifically,

the compensation program includes, among other features, several risk-mitigating elements, including:

• a balanced pay mix with:

(i) a mix of short-term and long-term incentives,

(ii) variable compensation based on a variety of performance goals, including Company, segment, and individual

performance goals, and

(iii) the use of multiple relevant performance measures in our incentive plan designs, so executives do not place undue

importance on one measure, which could distort the results we are looking to incentivize,

• payout caps on incentive plans,

• weighting of executive compensation heavily toward long-term incentives to encourage sustainable

stockholder value creation and accountability for long-term results, and

• requiring our executive officers to hold a significant multiple of their compensation in the Company's common

stock and prohibiting them from hedging or pledging their common stock.

In 2025, consistent with its annual practice, the PCC Committee evaluated whether our compensation designs and practices

operate to discourage our executive officers and other employees from taking unnecessary or excessive risks. Based upon the

information provided by management and Meridian, the PCC Committee concluded that our compensation programs and

processes do not incentivize risk-taking that is likely to have a material adverse effect on the Company.

**Stock Ownership Requirements**

To further align NEO and stockholder interests, NEOs are required to establish and maintain a significant level of direct stock

ownership. The following chart summarizes our requirements, which are comparable to the requirements of the majority of

companies in our Compensation Peer Group.

---

| | |
|:---|:---|
| Key Provision | Explanation of Key Provision |
| Ownership Requirement | •CEO: 6 times salary<br>•Other NEOs: 3 times salary<br>|
| Time to Meet Requirement | •5 years from the date the ownership requirement becomes applicable whether <br>through new hire or promotion<br>|

---

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **45** |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

---

| | |
|:---|:---|
| Shares Counted Toward Ownership | •Includes direct and indirect ownership of common stock, including shares <br>owned outright, unvested RSUs, shares held through the Ingredion 401(k) plan, <br>and phantom stock units held in the NQDCP<br>•Excludes unexercised stock options and unvested PSUs<br>|
| Additional Requirements | •Prior to attaining their ownership requirement, NEOs are not permitted to sell <br>shares of common stock, other than to fund the payment of the exercise price <br>of stock options or to fund the payment of taxes upon the exercise of stock <br>options or vesting of PSU or RSU awards<br>|

---

The PCC Committee monitors NEO compliance with the stock ownership requirements. As of December 31, 2025, all NEOs have

either exceeded their stock ownership requirements or are within the five-year compliance window in which to meet their

ownership requirement.

---

| |
|:---|
| **Timing of Equity Grants** |
| The PCC Committee's practice is to grant annual equity awards, including stock options, to employees, including NEOs, in <br>February each year based on a schedule set at least one year in advance on a date that occurs after our year-end earnings <br>have been announced. The timing of grants is in accordance with the Company's compensation cycle, to incentivize the <br>executives to deliver on the Company's strategic objectives for the new year. The PCC Committee has delegated limited <br>authority to the CEO to grant equity awards outside of our annual cycle for new hires, promotions, recognition, retention, or <br>other purposes. These awards are only granted in the form of RSUs.<br>|
| The PCC Committee does not grant equity awards in anticipation of the release of material nonpublic information and does <br>not time the release of material nonpublic information based on equity award grant dates or vesting events. The Company has <br>no program, plan, or practice to time the grant of equity awards for the purpose of affecting the value of executive <br>compensation. <br>|
| Equity grants are made annually on the fourth Wednesday of February after they have been approved by the PCC Committee, <br>a meeting that generally occurs in mid-February.<br>|

---

**Clawback Policy**

The Board of Directors has adopted an incentive compensation recoupment policy to incorporate the NYSE standards adopted

in connection with the SEC's final rule implementing the mandatory clawback provision of the Dodd-Frank Wall Street Reform

and Consumer Protection Act. The policy requires the Company (subject to certain exemptions if recovery would be

"impracticable," as defined by the SEC in the final rule) to recover excess cash and equity-based incentive compensation

received by a current or former Section 16 executive officer (based on a three-year lookback period) that was based upon the

achievement of certain financial results in the event of any financial restatement. Actions under the policy to recover incentive

compensation include, as required by the NYSE standards (as applicable) and to the extent permitted by applicable law:

• seeking reimbursement of the incremental portion of incentive-based awards paid to executive officers in excess of the

awards that would have been paid based on the restated financial results, with all forms of incentive-based

compensation subject to this policy,

• looking back over the three-year period prior to the restatement for recoupment, including recoupment of

compensation paid to both current and former executives, and

• in the PCC Committee's discretion, recoupment of amounts of excess incentive-based compensation paid to any

executive officer in conjunction with any incorrect financial results (even if not resulting in a restatement), or

misconduct on the part of the officer, constituting fraud, commission of a felony, material violation of any written

agreement with or policies of the Company, or any other material breach of fiduciary duty injurious to the Company.

In addition, our CEO and CFO are subject to any clawbacks that may be required under the Sarbanes-Oxley Act of 2002.

---

| | | |
|:---|:---|:---|
| **46** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

**Insider Trading Policy, Including the Hedging and Pledging of** <br>**Company Stock**<br>The Company has adopted and maintains an insider trading policy governing the purchase, sale, or other disposition of its <br>common stock and other securities by its directors, officers, employees, and other designated persons. We believe our insider <br>trading policy is reasonably designed to promote compliance with insider trading laws, rules, and regulations and NYSE listing <br>standards applicable to the Company. We have filed a copy of the insider trading policy as Exhibit 19.1 to our Annual Report <br>on Form 10-K. It is the Company's policy to engage in transactions in its own securities in compliance with insider trading <br>laws, rules, and regulations.<br>In addition to directors, officers, and employees, the insider trading policy also applies to family members who reside with <br>any director or employee, any other person who lives in the director's or employee's household, and any other family <br>members whose transactions in securities are directed by, or subject to the influence or control of, the director or employee, <br>as well as entities, such as a corporation, partnership, or trust, controlled by the director or employee.<br>The policy prohibits directors and executive officers, and strongly discourages other employees, from engaging in hedging <br>and monetization transactions that would permit any such person to continue to own the securities without the full risks and <br>rewards of ownership, including the use of financial instruments such as prepaid variable forwards, equity swaps, collars, and <br>exchange funds.<br>The policy also generally prohibits directors and executive officers from holding Company securities in a margin account or <br>otherwise lending or pledging Company securities as collateral for a loan. An exception to the prohibition on pledging may be <br>granted where a director or officer wishes to pledge Company securities for a loan (not involving margin debt) and clearly <br>demonstrates the financial capacity to repay the loan without recourse to the pledged securities.<br>The provisions of the policy apply to transactions in all equity and other securities, including awards granted under equity <br>compensation plans, issued by the Company that are held by any person covered by the policy. Securities subject to the <br>policy also include derivative securities that are not issued by the Company, such as exchange-traded put or call options or <br>swaps relating to Company securities.<br>The administrator of the policy has the discretion, on a case-by-case basis and in appropriate circumstances, to waive or <br>modify the restrictions and prohibitions on the hedging and other transactions described above.<br>

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **47** |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

**2025 Summary Compensation Table**

The following table presents information about the total compensation paid or granted for the fiscal years indicated by the

Company to the 2025 named executive officers.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Name and<br>Principal Position<br>| Year | Salary ($) | Bonus <br>($)<br>| Stock <br>Awards<sup>(1)</sup> <br>($)<br>| Option <br>Awards<sup>(2)</sup><br>($)<br>| Non-Equity <br>Incentive Plan <br>Compensation<sup>(3)</sup> <br>($)<br>| Change in <br>Pension Value <br>and <br>Nonqualified <br>Deferred <br>Compensation <br>Earnings<sup>(4)</sup>($)<br>| All Other <br>Compensation<sup>(5)</sup><br>($)<br>| Total ($) |
| James Zallie<br>President and CEO | 2025 | 1290929 |  | 6509237 | 1999964 | 2185980 | 665369 | 280755 | 12932234 |
| James Zallie<br>President and CEO | 2024 | 1241800 |  | 5663846 | 1699996 | 2704247 | 365233 | 228559 | 11903681 |
| James Zallie<br>President and CEO | 2023 | 1195600 |  | 5182466 | 1599741 | 2363400 | 557470 | 203315 | 11101992 |
| James Gray<br>EVP and Chief Financial <br>Officer | 2025 | 759773 |  | 1464555 | 450006 | 871060 | 102616 | 128744 | 3776754 |
| James Gray<br>EVP and Chief Financial <br>Officer | 2024 | 729992 |  | 1374343 | 412512 | 999029 | 86363 | 114505 | 3716744 |
| James Gray<br>EVP and Chief Financial <br>Officer | 2023 | 695667 |  | 1153956 | 356191 | 771884 | 76853 | 102467 | 3157018 |
| Tanya Jaeger de Foras<br>SVP and Chief Legal <br>Officer, Corporate <br>Secretary and Chief <br>Compliance Officer | 2025 | 536937 |  | 772995 | 237493 | 456462 | 5228 | 135409 | 2144524 |
| Tanya Jaeger de Foras<br>SVP and Chief Legal <br>Officer, Corporate <br>Secretary and Chief <br>Compliance Officer | 2024 | 518141 |  | 749643 | 224990 | 516163 | 4480 | 115494 | 2128911 |
| Tanya Jaeger de Foras<br>SVP and Chief Legal <br>Officer, Corporate <br>Secretary and Chief <br>Compliance Officer |  |  |  |  |  |  |  |  |  |
| Robert Ritchie<br>SVP, Food and Industrial <br>Ingredients Americas | 2025 | 556877 |  | 976409 | 299993 | 487930 | 125776 | 160106 | 2607091 |
| Robert Ritchie<br>SVP, Food and Industrial <br>Ingredients Americas | 2024 | 518333 |  | 666341 | 200003 | 575088 | 96987 | 109321 | 2166073 |
| Robert Ritchie<br>SVP, Food and Industrial <br>Ingredients Americas |  |  |  |  |  |  |  |  |  |
| Eric Seip<br>SVP Global Operations <br>and Chief Supply Chain <br>Officer | 2025 | 559812 |  | 671288 | 206243 | 463203 | 15646 | 138004 | 2054196 |
| Eric Seip<br>SVP Global Operations <br>and Chief Supply Chain <br>Officer | 2024 | 541844 |  | 666341 | 200003 | 531504 | 19283 | 111907 | 2070882 |
| Eric Seip<br>SVP Global Operations <br>and Chief Supply Chain <br>Officer | 2023 | 523292 |  | 587015 | 181213 | 481058 | 13551 | 103800 | 1889929 |

---

(1)Amounts reflect the aggregate grant date fair value of PSUs and RSUs granted in the current and prior years, computed in accordance with

Accounting Standards Codification Topic 718 ("FASB ASC Topic 718") of the Financial Accounting Standards Board. Additional information

regarding the awards is set forth in the "2025 Grants of Plan-Based Awards" table on page <u>[49](#iafcd580ce31344a8a23a91f06fc3939f_2402)</u> and the "2025 Outstanding Equity Awards at

Fiscal Year-End" table on page <u>[50](#i6426160d02fa42f783577c589be2c5d6_713)</u>. The assumptions used in determining the fair value of the awards are set forth in note 11 (Equity) to our

consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2025. The actual

amounts ultimately realized from the disclosed PSUs and RSUs will likely vary from the disclosed amounts based on a number of factors,

including the amounts of the actual awards, our actual operating performance, stock price fluctuations, differences from the valuation

assumptions used, and the timing of exercise or vesting of the awards. The actual value an NEO receives will depend on the number of

shares earned and the Closing Price of our common stock on the vesting date. Because the accounting valuation for the PSUs is calculated

using a Monte Carlo simulation model, the target value utilized by the PCC Committee to determine the number of PSUs to grant differs

from the valuation used for accounting purposes.

For PSUs granted in 2025, the table above includes the grant date fair value based on the probable outcome of the performance

conditions. Assuming that the highest level of performance conditions will be achieved, the maximum grant date value would be as

follows: Mr. Zallie, $8,990,650; Mr. Gray, $2,022,954; Ms. Jaeger de Foras, $1,067,581; Mr. Ritchie, $1,348,539; and Mr. Seip, $927,102.

(2)This column represents the grant date fair value of stock option awards granted in the current and prior years, computed in accordance

with FASB ASC Topic 718. Additional information regarding the awards is set forth in the "2025 Grants of Plan-Based Awards" table on

page <u>[49](#iafcd580ce31344a8a23a91f06fc3939f_2402)</u> and the "2025 Outstanding Equity Awards at Fiscal Year-End" table on page <u>[50](#i6426160d02fa42f783577c589be2c5d6_713)</u>. The assumptions used in determining the fair

value of the awards are set forth in note 11 (Equity) to our consolidated financial statements contained in our Annual Report on Form 10-K

for the year ended December 31, 2025. The actual amounts ultimately realized by the NEOs from the disclosed option awards will likely

vary based on a number of factors, including our actual operating performance, stock price fluctuations, differences from the valuation

assumptions used and the timing of exercise or vesting of the awards. Because we consider vesting restrictions and forfeiture assumptions

to determine the grant date fair value of stock option awards, the target value utilized by the PCC Committee to determine the number of

stock options to grant differs from the valuation used for accounting purposes and disclosed in this column. Stock options granted in 2023,

2024, and 2025 vest in three equal installments on the first three anniversaries of their respective grant dates.

(3)Amounts reflect awards made under our 2025 AIP that were paid in March 2026.

(4)Amounts reflect the aggregate actuarial increase in the present value of benefits under all our pension plans. Amounts were determined

by using interest rate and mortality rate assumptions consistent with those used in our consolidated financial statements. In 2025, for

Messrs. Zallie, Gray, and Ritchie, the amounts consist of the actuarial increase in the value of the Cash Balance Plan and respective

nonqualified Cash Balance Make-up Accounts. Ms. Jaeger de Foras and Mr. Seip do not participate in the Cash Balance Plan. Amounts

include actual earnings in the NQDCP in excess of the 120% applicable federal rate for 2025.

---

| | | |
|:---|:---|:---|
| **48** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

(5)Amounts shown in the "All Other Compensation" column for 2025 reflect the following:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Named<br>Executive Officer<br>| Company<br>Contributions<br>to Qualified and<br>Nonqualified<br>Savings Plans<sup>(a)</sup><br>($)<br>| Perquisites<sup>(b)</sup>($) | Tax Equalization<sup>(c)</sup>($) | Other<sup>(d)</sup>($) | Total All<br>Other<br>Compensation<br>($)<br>|
| James Zallie | 240084 | 31671 |  | 9000 | 280755 |
| James Gray | 103659 | 15625 |  | 9460 | 128744 |
| Tanya Jaeger de Foras | 95794 | 29920 |  | 9695 | 135409 |
| Robert Ritchie | 68178 | 31416 | 59552 | 960 | 160106 |
| Eric Seip | 105338 | 24010 |  | 8656 | 138004 |

---

(a)Reflects matching contributions by the Company for compensation contributed by participants under our Retirement Savings Plan

(with an additional 3% contribution for Ms. Jaeger de Foras and Mr. Seip, as they do not participate in the Cash Balance Plan) and, if

applicable, to nonqualified Cash Balance Make-up Accounts and Savings Plan Make-up Accounts.

(b)Amounts include the costs of providing a leased automobile or the use of a Company automobile or automobile allowance to each of

our NEOs, the cost of financial planning and tax preparation services, and the cost of an executive physical.

(c)Mr. Ritchie was previously an expatriate on assignment in Mexico. To offset taxes related to taxable expenses in his 2023

compensation, a tax equalization was completed in 2025 in accordance with the long-term assignment policy. The expenses include

tax equalization payments or repayments, imputed compensation for the tax preparation fee, and corresponding federal, state, and

FICA tax gross-ups on those items.

(d)Reports the total amount of other benefits provided, none of which individually exceeded the greater of $25,000 or 10% of the total

amount of perquisites and such other benefits. The amounts reported may include, as applicable for each NEO: "Bring Your Own

Device" allowance payments, reimbursements for gym memberships, and wellness program credits received during 2025, all of

which are reimbursements under programs available to all employees. The amounts reported also include matching contributions

made by the Company for applicable NEOs under the Company's charitable matching gift program, which provides for matching

contributions consisting of a $2 match for every $1 of the first $1,000 contributed and a $1 match for every $1 of the next $6,500

contributed.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **49** |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

## 2025 Grants of Plan-Based Awards
The following table presents information related to awards paid under our AIP and grants of PSUs, RSUs, and stock options

received under our Stock Incentive Plan during 2025.

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  |  | Estimated Future Payouts<br>Under Non-Equity<br>Incentive Plan Awards<sup>(1)</sup> | Estimated Future Payouts<br>Under Non-Equity<br>Incentive Plan Awards<sup>(1)</sup> | Estimated Future Payouts<br>Under Non-Equity<br>Incentive Plan Awards<sup>(1)</sup> | Estimated Future Payouts<br>Under Equity Incentive<br>Plan Awards<sup>(2)</sup> | Estimated Future Payouts<br>Under Equity Incentive<br>Plan Awards<sup>(2)</sup> | Estimated Future Payouts<br>Under Equity Incentive<br>Plan Awards<sup>(2)</sup> |  |  |  |  |
| Name | Grant<br>Date<br>| Grant<br>Type<br>| Threshold<br>($)<br>| Target<br>($)<br>| Maximum<br>($)<br>| Threshold<br>(#)<br>| Target<br>(#)<br>| Maximum<br>(#)<br>| All <br>Other<br>Stock<br>Awards:<br>Number<br>of Shares<br>of Stock<br>or Units<br>| All Other<br>Option<br>Awards:<br>Number of<br>Securities<br>Underlying<br>Options<br>| Exercise<br>or Base<br>Price<br>of Stock<br>Option<br>Awards<sup>(3)</sup><br>($/Sh)<br>| Grant<br>Date Fair<br>Value of<br>Stock and<br>Option<br>Awards<sup>(4)</sup><br>($)<br>|
| James <br>Zallie |  | AIP | 971288 | 1942575 | 3885150 |  |  |  |  |  |  |  |
| James <br>Zallie | 2/26/2025 | Stock Options |  |  |  |  |  |  |  | 59647 | 130.57 | 1999964 |
|  | 2/26/2025 | Restricted Stock Units |  |  |  |  |  |  | 15424 |  |  | 2013912 |
|  | 2/26/2025 | Performance Share <br>Units<br>|  |  |  | 15424 | 30848 | 61696 |  |  |  | 4495325 |
| James <br>Gray  |  | AIP | 381108 | 762216 | 1524432 |  |  |  |  |  |  |  |
| James <br>Gray  | 2/26/2025 | Stock Options |  |  |  |  |  |  |  | 13421 | 130.57 | 450006 |
|  | 2/26/2025 | Restricted Stock Units |  |  |  |  |  |  | 3470 |  |  | 453078 |
|  | 2/26/2025 | Performance Share <br>Units<br>|  |  |  | 3471 | 6941 | 13882 |  |  |  | 1011477 |
| Tanya <br>Jaeger de <br>Foras  |  | AIP | 201921 | 403841 | 807682 |  |  |  |  |  |  |  |
| Tanya <br>Jaeger de <br>Foras  | 2/26/2025 | Stock Options |  |  |  |  |  |  |  | 7083 | 130.57 | 237493 |
| Tanya <br>Jaeger de <br>Foras  | 2/26/2025 | Restricted Stock Units |  |  |  |  |  |  | 1832 |  |  | 239204 |
|  | 2/26/2025 | Performance Share <br>Units<br>|  |  |  | 1832 | 3663 | 7326 |  |  |  | 533791 |
| Robert <br>Ritchie |  | AIP | 229217 | 458434 | 916868 |  |  |  |  |  |  |  |
| Robert <br>Ritchie | 2/26/2025 | Stock Options |  |  |  |  |  |  |  | 8947 | 130.57 | 299993 |
|  | 2/26/2025 | Restricted Stock Units |  |  |  |  |  |  | 2314 |  |  | 302139 |
|  | 2/26/2025 | Performance Share <br>Units<br>|  |  |  | 2314 | 4627 | 9254 |  |  |  | 674270 |
| Eric <br>Seip |  | AIP | 210490 | 420980 | 841960 |  |  |  |  |  |  |  |
| Eric <br>Seip | 2/26/2025 | Stock Options |  |  |  |  |  |  |  | 6151 | 130.57 | 206243 |
|  | 2/26/2025 | Restricted Stock Units |  |  |  |  |  |  | 1591 |  |  | 207737 |
|  | 2/26/2025 | Performance Share <br>Units<br>|  |  |  | 1591 | 3181 | 6362 |  |  |  | 463551 |

---

(1)Amounts shown reflect the possible range of payouts under our 2025 AIP, which are payable in cash. The AIP is the Company's annual

bonus plan that is based on achievement of financial performance and strategic objectives. For the actual amounts earned pursuant to

the AIP for 2025, see the "Non-Equity Incentive Plan Compensation" column in the "2025 Summary Compensation Table" on page <u>[47](#ie7e472361805446c8b302de30ed47fbf_55)</u>.

For a detailed discussion of the AIP, including targets and plan mechanics, see "Elements of Compensation – Annual Incentive Plan" in

the Compensation Discussion and Analysis section of this proxy statement. Payouts can range from 0% -200%. Awards under the AIP for

NEOs are determined using their annual base salary and individual incentive target percentage for the plan year.

(2)Amounts reflect the terms of grants of PSUs under our Stock Incentive Plan. The grant date fair value of these shares is included in

the "Stock Awards" column in the "2025 Summary Compensation Table" on page <u>[47](#ie7e472361805446c8b302de30ed47fbf_55)</u>.

(3)Exercise price for these options is the Closing Price of our common stock on the grant date.

(4)Column shows the grant date fair value of stock awards and option awards under FASB ASC Topic 718. Generally, the full grant date fair

value is the amount the Company would expense in its financial statements over the award's vesting schedule. For stock options, fair

value is calculated based on the grant date fair value estimated using the Black-Scholes option pricing model for financial reporting

purposes, which was $33.53 for the grants on February 26, 2025. For additional information on the valuation assumptions, see note 11

(Equity) to our consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2025. Actual

amounts ultimately realized by the NEOs from the disclosed stock and option awards will likely vary based on a number of factors,

including the amounts of the actual awards, our actual operating performance, stock price fluctuations, differences from the valuation

assumptions used, and the timing of exercise of the awards. Stock options vest in three equal installments on the first three anniversaries

of their respective grant dates.

---

| | | |
|:---|:---|:---|
| **50** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

## 2025 Outstanding Equity Awards at Fiscal Year-End
The following table presents information relating to stock options, RSUs, and PSUs held by our NEOs on December 31, 2025.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  | Option Awards | Option Awards | Option Awards | Option Awards | Stock Awards | Stock Awards | Stock Awards | Stock Awards |
|  |  | Number of Securities<br>Underlying Unexercised Options | Number of Securities<br>Underlying Unexercised Options | Number of Securities<br>Underlying Unexercised Options | Number of Securities<br>Underlying Unexercised Options | Shares or Units of Stock<br>That Have Not Vested | Shares or Units of Stock<br>That Have Not Vested | Equity Incentive Plan <br>Awards:<br>Unearned Shares, Units <br>or Other<br>Rights That Have Not <br>Vested | Equity Incentive Plan <br>Awards:<br>Unearned Shares, Units <br>or Other<br>Rights That Have Not <br>Vested |
| Name | Grant Date | Exercisable<br>(#)<br>| Unexercisable<sup>(1)</sup><br>(#)<br>| Option <br>Exercise<br>Price ($)<br>| Option <br>Expiration<br>Date<br>| (#)<sup>(1)</sup> | Market <br>Value<sup>(2)</sup><br>| (#)<sup>(1),(3)</sup> | Market or<br>Payout <br>Value<sup>(4)</sup><br>|
| James Zallie | 2/7/2017 | 25043 |  | 118.97 | 2/7/2027 |  |  |  |  |
|  | 1/1/2018 | 74858 |  | 139.80 | 1/1/2028 |  |  |  |  |
|  | 2/9/2021 | 131869 |  | 87.12 | 2/9/2031 |  |  |  |  |
|  | 2/16/2022 | 103890 |  | 88.66 | 2/16/2032 |  |  |  |  |
|  | 2/15/2023 | 44811 | 22405 | 98.69 | 2/15/2033 | 17035 | 1878277 |  |  |
|  | 2/13/2024 | 21522 | 43043 | 108.38 | 2/13/2034 | 15865 | 1749319 | 31093 | 3428314 |
|  | 2/26/2025 |  | 59647 | 130.57 | 2/26/2035 | 15083 | 1663106 | 30848 | 3401300 |
| James Gray | 2/4/2020 | 26358 |  | 88.35 | 2/4/2030 |  |  |  |  |
|  | 2/9/2021 | 27938 |  | 87.12 | 2/9/2031 |  |  |  |  |
|  | 2/16/2022 | 21609 |  | 88.66 | 2/16/2032 |  |  |  |  |
|  | 2/15/2023 | 9977 | 4989 | 98.69 | 2/15/2033 | 3794 | 418278 |  |  |
|  | 2/13/2024 | 5222 | 10445 | 108.38 | 2/13/2034 | 3850 | 424448 | 7545 | 831912 |
|  | 2/26/2025 |  | 13421 | 130.57 | 2/26/2035 | 3390 | 373785 | 6941 | 765315 |
| Tanya Jaeger de Foras | 2/16/2022 | 10805 |  | 88.66 | 2/16/2032 |  |  |  |  |
|  | 2/15/2023 | 5426 | 2713 | 98.69 | 2/15/2033 | 2063 | 227462 |  |  |
|  | 2/13/2024 | 2848 | 5697 | 108.38 | 2/13/2034 | 2151 | 237128 | 4115 | 453720 |
|  | 2/26/2025 |  | 7083 | 130.57 | 2/26/2035 | 1867 | 205840 | 3663 | 403882 |
| Robert Ritchie | 2/7/2017 | 3454 |  | 118.97 | 2/7/2027 |  |  |  |  |
|  | 2/6/2018 | 4484 |  | 130.30 | 2/6/2028 |  |  |  |  |
|  | 2/4/2020 | 5010 |  | 88.35 | 2/4/2030 |  |  |  |  |
|  | 2/9/2021 | 5588 |  | 87.12 | 2/9/2031 |  |  |  |  |
|  | 2/16/2022 | 4156 |  | 88.66 | 2/16/2032 |  |  |  |  |
|  | 2/15/2023 | 1855 | 928 | 98.69 | 2/15/2033 | 706 | 77797 |  |  |
|  | 5/2/2023 |  |  |  | 5/2/2033 | 3077 | 339228 |  |  |
|  | 2/13/2024 | 2532 | 5064 | 108.38 | 2/13/2034 | 1866 | 205769 | 3658 | 403331 |
|  | 2/26/2025 |  | 8947 | 130.57 | 2/26/2035 | 2280 | 251396 | 4627 | 510173 |
| Eric Seip | 2/9/2021 | 11175 |  | 87.12 | 2/9/2031 |  |  |  |  |
|  | 2/16/2022 | 10389 |  | 88.66 | 2/16/2032 |  |  |  |  |
|  | 2/15/2023 | 5076 | 2538 | 98.69 | 2/15/2033 | 1930 | 212756 |  |  |
|  | 2/13/2024 | 2532 | 5064 | 108.38 | 2/13/2034 | 1911 | 210742 | 3658 | 403331 |
|  | 2/26/2025 |  | 6151 | 130.57 | 2/26/2035 | 1621 | 178762 | 3181 | 350737 |

---

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **51** |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

(1)The vesting schedule for all outstanding unvested stock and stock options is as follows:

---

| | | |
|:---|:---|:---|
| Grant Date | Grant Type | Vesting Schedule |
| 2/15/2023 | PSUs | 100% of the grant vests upon approval of the PCC Committee, subject to the satisfaction <br>of the performance criteria. Distribution of vested shares occurred on 2/9/2026.<br>|
| 2/15/2023 | RSUs | 100% of the grant vested on 02/15/2026. |
| 2/15/2023 | Stock Options | First tranche (33%) vested on 02/15/2024, second tranche (33%) vested on 02/15/2025 <br>and last tranche (34%) vested on 02/15/2026.<br>|
| 5/2/2023 | RSUs | 100% of the grant will vest on 5/02/2026. |
| 2/13/2024 | PSUs | 100% of the grant vests upon approval of the PCC Committee, subject to the satisfaction <br>of the performance criteria.<br>|
|  |  | Distribution of any shares awarded will be no later than 03/15/2027. |
| 2/13/2024 | RSUs | 100% of the grant will vest on 02/13/2027. |
| 2/13/2024 | Stock Options | First tranche (33%) vested on 02/13/2025, second tranche (33%) vested on 02/13/2026 <br>and last tranche (34%) will vest on 02/13/2027.<br>|
| 2/26/2025 | PSUs | 100% of the grant vests upon approval of the PCC Committee, subject to the satisfaction <br>of the performance criteria.<br>|
|  |  | Distribution of any shares awarded will be no later than 03/15/2028. |
| 2/26/2025 | RSUs | 100% of the grant will vest on 2/26/2028 |
| 2/26/2025 | Stock Options | First tranche (33%) vested on 02/26/2026, second tranche (33%) will vest on 02/26/2027 <br>and last tranche (34%) will vest on 02/26/2028.<br>|

---

(2)Value is the number of unvested RSUs multiplied by the Closing Price of our common stock on December 31, 2025 ($110.26).

(3)Amounts reflect unearned PSUs from the 2024 and 2025 PSUs (at target performance level).

(4)Value is the number of unearned PSUs from the 2024 and 2025 PSUs (at target performance level) multiplied by the Closing Price of our

common stock on December 31, 2025 ($110.26).

**2025 Option Exercises and Stock Vested**

The following table presents information regarding stock options that were exercised by our NEOs and shares of stock acquired

upon vesting of PSU and RSU awards by each NEO in 2025.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Option Awards | Option Awards | Stock Awards | Stock Awards |
|  | Number of<br>Shares <br>Acquired<br>on Exercise<br>| Value Realized<br>on Exercise<sup>(1)</sup><br>| Number of<br>Shares <br>Acquired<br>on Vesting<br>| Value Realized<br>on Vesting<sup>(2),(3)</sup><br>|
| Name | (#) | ($) | (#) | ($) |
| James Zallie | 224838 | 8241752 | 76728 | 9831300 |
| James Gray |  |  | 16811 | 2154342 |
| Tanya Jaeger de Foras |  |  | 8972 | 1150060 |
| Robert Ritchie | 6684 | 284361 | 3151 | 403793 |
| Eric Seip |  |  | 8443 | 1082186 |

---

(1)The value realized on exercise of option awards is equal to the number of stock options exercised multiplied by the difference between

the price at which the option is exercised and the Closing Price of our common stock on the grant date of the applicable stock option.

(2)Represents the vesting of RSU awards granted in 2022 that vested in February 2025 and the PSUs awarded for the 2023 – 2025

performance cycle based on actual performance for the cycle, which ended on December 31, 2025.

(3)Amounts shown are calculated based on the Closing Price of our common stock on the date of vesting. The amounts also include earned

dividend equivalents for RSUs. PSUs are earned based on achievement against pre-defined performance metrics, targets, and ranges set

for the performance period. Performance against rTSR and Adjusted ROIC was above target, resulting in a performance achievement level

of 183.4% (see "2023 – 2025 Performance Share Plan Results" on page <u>[37](#idbd8228798374a95ab5d4e1f889f4e94_42815)</u> for details).

---

| | | |
|:---|:---|:---|
| **52** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

**2025 Pension Benefits**

We have several pension benefit plans available to U.S. salaried employees.

**CASH BALANCE PLAN**

Our Cash Balance Plan is a defined benefit qualified pension plan that is available to all U.S. salaried employees hired before

January 1, 2015. Participant accounts accrue pay credits based on years of service and monthly interest credits using a rate

equal to a specified amount above the interest rate on short-term U.S. Treasury notes. Pay credits are calculated as a

percentage (3% to 10%) of a salaried employee's eligible compensation (defined as base salary, overtime, and earned AIP

award). The pay credit percentage is determined by the employee's years of service, but no additional service on or after

January 1, 2017 is taken into account for purposes of determining the pay credit percentage since a participant's pay credit

percentage was frozen as of January 1, 2017. The value of a participant's account at retirement is paid out either as a life or

joint and survivor annuity or in an optional form, such as a lump sum, if certain funding conditions are met. The Cash Balance

Plan provides for a three-year vesting period. Messrs. Zallie, Gray, and Ritchie are all participants in the Cash Balance Plan.

Additionally, Mr. Zallie participated in the National Starch LLC Pension Plan during his employment with National Starch until

Ingredion acquired that company in October 2010. The National Starch LLC Pension Plan was frozen effective December 31,

2010, and Mr. Zallie ceased to accrue benefits under this plan. Mr. Zallie had 27 years of credited service under the plan when it

was frozen.

**NONQUALIFIED CASH BALANCE MAKE-UP ACCOUNTS**

To the extent that an employee is a participant in the Cash Balance Plan and such employee's annual retirement income benefit

under the plan exceeds the limitations imposed by the Internal Revenue Code, additional benefits are provided through our

NQDCP via a Cash Balance Make-up Account. Messrs. Zallie, Gray, and Ritchie have nonqualified Cash Balance Make-up

Accounts. Mr. Seip and Ms. Jaeger de Foras are not eligible for the Cash Balance Plan and therefore do not have a nonqualified

Cash Balance Make-up Account.

The following table shows the actuarial present value of each named executive officer's accumulated benefit under each of our

pension plans.

**2025 PENSION BENEFITS**

---

| | | | | |
|:---|:---|:---|:---|:---|
| Name | Plan Name | Number of<br>Years<br>Credited<br>Service<br>| Present<br>Value of<br>Accumulated<br>Benefit<sup>(1)</sup><br>($)<br>| Payments <br>During<br>Last Fiscal Year<br>|
| James Zallie | Cash Balance Plan | 33 | 512971 |  |
|  | Nonqualified Cash Balance Make-up Account | 33 | 2709397 |  |
|  | National Starch LLC Pension Plan | 27 | 1096143 |  |
|  | National Starch Excess Pension Plan | 27 | 1656087 |  |
| James Gray | Cash Balance Plan | 3 | 140344 |  |
|  | Nonqualified Cash Balance Make-up Account | 3 | 322003 |  |
| Robert Ritchie | Cash Balance Plan | 20 | 507135 |  |
|  | Nonqualified Cash Balance Make-up Account | 20 | 248705 |  |

---

(1)The present value of the accumulated benefit reflects current vested balances in the Cash Balance Plan, which will be distributed upon

termination, regardless of the age of the participant at termination, and balances in the nonqualified Cash Balance Make-up Accounts,

which will be distributed in accordance with individual elections. For Mr. Zallie, the present value includes the accumulated benefits in the

National Starch LLC Pension Plan and the National Starch Excess Pension Plan. See note 10 (Pension and Other Postretirement Benefits) to

our consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2025 for a discussion of the

assumptions used to determine the present value of accumulated benefits under our pension plans.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **53** |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

**2025 Nonqualified Deferred Compensation**

The Ingredion Incorporated NQDCP provides participants with an elective deferral opportunity and is designed to satisfy the

requirements of Section 409A of the Internal Revenue Code. Under our NQDCP, NEOs may defer up to (i) 20% of their annual

base salary, (ii) 75% of their AIP award, and (iii) 75% of any earned PSUs under our LTIP. Our NQDCP is an unfunded plan and is

not regulated or protected under the Employee Retirement Income Security Act of 1974 ("ERISA"). The NQDCP is a combination

of plans that mirror plans being operated by our former parent company at the time we became an independent public

company. NQDCP participants are general, unsecured creditors of the Company.

The NQDCP is designed to provide participants with the benefit of the Company non-elective contributions that could not be

made to their accounts under the 401(k) plan due to Internal Revenue Code limitations. Such contributions are made on behalf

of all eligible participants, including our NEOs, and are equal to the amount of the non-elective contributions that a participant

would have otherwise received under the 401(k) plan and the Cash Balance Plan on the portion of their salary that exceeded

the applicable Internal Revenue Code limits.

Amounts deferred are, at the election of each NEO, deemed to be invested in a cash account at a prime interest rate or in

phantom units of our common stock, provided that, if deferred, earned PSUs must be deferred into phantom units of our

common stock. Deemed investment earnings are credited at the monthly compound equivalent of the prime rate, which is

adjusted quarterly based upon the published prime rate, or the increase or decrease of the fair market value of the applicable

number of shares of our common stock. When dividends are paid on our common stock, deemed investments in common stock

are credited with the amount of the dividends, which are deemed to be invested in additional phantom stock units at the fair

market value of a share of our common stock on the dividend payment date. Phantom stock units are paid through the issuance

of shares of common stock at the time of distribution equal to the number of phantom stock units owned at that time.

**2025 NONQUALIFIED DEFERRED COMPENSATION**

The following table shows contributions, earnings, withdrawals, and distributions during fiscal 2025 and the account balances as

of December 31, 2025, for our NEOs.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Name | Executive<br>Contributions <br>in<br>2025<sup>(1)</sup><br>($)<br>| Company<br>Contributions <br>in<br>2025<sup>(2)</sup><br>($)<br>| Aggregate<br>Earnings<br>in 2025<sup>(3)</sup><br>($)<br>| Aggregate<br>Withdrawal/<br>Distributions<br>in 2025<br>($)<br>| Aggregate <br>Balance<br>on December 31,<br>2025<sup>(3)</sup><br>($)<br>|
| James Zallie | 239711 | 222632 | 371238 |  | 5367440 |
| James Gray | 144366 | 84528 | (100669) |  | 1807619 |
| Tanya Jaeger de Foras | 57892 | 63279 | 20502 |  | 340415 |
| Robert Ritchie | 113196 | 48758 | 53160 |  | 810646 |
| Eric Seip | 551483 | 69298 | (129765) |  | 1932174 |

---

(1)Employee contributions include any deferrals of annual compensation, including earned awards under the AIP and any earned PSUs.

These amounts are included in the NEOs' compensation in the columns captioned "Salary," "Bonus," "Stock Awards," or "Non-Equity

Incentive Plan Compensation" in the "2025 Summary Compensation Table" on page <u>[47](#ie7e472361805446c8b302de30ed47fbf_55)</u>.

(2)Amounts represent Company matching contributions for compensation contributed by participants under our NQDCP (with an additional

3% contribution for eligible earnings over the IRS qualified compensation limit for Ms. Jaeger de Foras and Mr. Seip, as they do not

participate in the Cash Balance Plan) and, if applicable, nonqualified Cash Balance Make-up Accounts and Savings Plan Make-up Accounts.

These amounts are also included in each NEO's compensation in the "All Other Compensation" column in the "2025 Summary

Compensation Table" on page <u>[47](#ie7e472361805446c8b302de30ed47fbf_55)</u>.

(3)Deemed investment earnings are credited at the monthly compound equivalent of the prime rate, which is adjusted quarterly based upon

the published prime rate, or the increase or decrease of the fair market value of the applicable number of shares of our common stock.

Amounts calculated using rates in excess of 120% of the prime rate appear in the "2025 Summary Compensation Table" in the "Change in

Pension Value and Nonqualified Deferred Compensation Earnings" column on page <u>[47](#ie7e472361805446c8b302de30ed47fbf_55)</u>.

---

| | | |
|:---|:---|:---|
| **54** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

**Potential Payments Upon Termination or Change** 

**in Control**

Our NEOs may receive compensation in connection with their termination of employment. Most of our plans and programs,

including our executive severance agreements and executive severance plans, contain specific provisions detailing how

payments are treated upon termination or a change in control. The specific termination and CIC provisions under these

agreements and plans apply to all participants under each agreement or plan. In 2024, we changed some of the terms and

conditions of our equity grants for NEOs, including removing the one-year post-grant employment requirement and adding a

six-month notice period of the intent to retire for the NEOs to receive retirement treatment for outstanding equity awards.

The narrative and tables below describe the potential payments to each NEO upon certain terminations, including following a

CIC. In accordance with SEC rules, all information described in this section is presented as if the triggering events had occurred

on December 31, 2025. The following description of Mr. Gray's rights upon an assumed termination or change in control

accordingly is presented as of December 31, 2025, when Mr. Gray served as the Company's CFO. Mr. Gray retired from that

position effective March 31, 2026 without providing six months notice of the intent to retire.

**INVOLUNTARY TERMINATION WITHOUT CAUSE** 

**(NON-CHANGE IN CONTROL EVENT)**

For an involuntary termination without a CIC, under the terms of the executive severance agreements, NEOs are not entitled to

receive any benefits that would not be otherwise available to other salaried employees. Benefits applicable to all employees

may include:

• distributions under the Cash Balance Plan and the Retirement Savings Plan,

• a lump sum payment equal to accrued but unused vacation pay,

• health benefits for the remainder of the calendar month of departure, and

• outplacement services.

Severance payments may be payable to executive officers upon termination of employment without cause, in addition to any

payments to which the NEO is otherwise entitled, in exchange for confidentiality, non-compete, non-solicitation, or other

agreements. In exchange for an NEO's entry into an agreement with a one-year term, the executive severance agreement

provides for a severance payment of one times the NEO's base salary in effect on the date of such officer's termination of

employment in the event of a termination of employment other than within two years of a CIC.

For an involuntary termination without a CIC, under the terms of the Ingredion Executive Severance Pay Plan (the "ESP Plan"), in

exchange for confidentiality, non-compete, non-solicitation, and other agreements, NEOs are entitled to:

• a multiple of annual base salary and target annual bonus payable in installments,

• a prorated portion of their annual bonus for the year of termination only if the company pays bonuses under the Annual

Incentive Plan for that year,

• health benefits through COBRA for the lesser of 18 months or the length of the severance period, and

• outplacement services.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **55** |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

**POTENTIAL PAYOUT UPON OTHER TYPES OF SEPARATIONS**

**Potential Payout Upon Death or Disability**

If employment terminates due to death or disability, all outstanding unvested equity would be treated as follows:

---

| | |
|:---|:---|
| Grant Year | Treatment  |
| 2023 | •Unvested Stock Options: after 1 year from grant date; continue to vest |
|  | •RSUs after 1 year from grant date: continue to vest |
|  | •RSUs less than 1 year from grant date: pro rata accelerated vesting based on number of full months <br>active during vesting period<br>|
|  | •PSUs if actively employed for the first year of the performance period: pro rata vesting at time of <br>event based on target performance and number of full months active during performance period<br>|
|  | •PSUs if not actively employed for the first year of the performance period: forfeit |
| 2024 and 2025 | •Unvested Stock Options: fully vest on date of termination |
|  | •Vested Stock Options: exercisable for 3 years from the date of the event  |
|  | •RSUs: fully vest on date of termination |
|  | •PSUs: pro rata accelerated vesting based on target (100%) performance and the number of days <br>active during vesting period<br>|

---

In addition, the following benefits would also be payable:

• in the event of a termination of employment due to total and permanent disability, a monthly payment equal to the

lesser of 66.67% of monthly covered earnings or the maximum disability benefit of $15,000 per month until age 65, and

• in the event of death before termination or retirement, a basic life insurance benefit of one and one-half times of annual

base salary up to a maximum of $1,000,000.

---

| | | |
|:---|:---|:---|
| **56** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

**Potential Payout Upon Retirement**

As of December 31, 2025, Messrs. Zallie, Gray, and Ritchie are eligible for retirement. The following table summarizes the

treatment of awards upon termination of employment due to retirement and assumes that the NEO provided six months notice

of the intent to retire to receive the treatment listed below specific to unvested equity. Six months notice of the intent to retire

is not applicable to the AIP.

---

| | |
|:---|:---|
| AIP | Eligible for a prorated award under AIP. |
| Unvested PSUs | PSUs will vest pro rata based on the number of full months actively employed <br>during the applicable performance period, subject to actual Company <br>performance.<br>|
| Unvested RSUs | Shares from the 2023 RSU grant will continue to vest per the original vesting <br>schedule provided the NEO has been actively employed for at least one year <br>following grant date. If an NEO retires less than one year from the grant date, <br>awards will vest pro rata based on the number of full months actively <br>employed during the vesting period.<br>2024 and 2025 RSU awards will continue to vest per the original vesting <br>schedule. <br>|
| Unvested Stock Options | Unvested options from the 2023 stock option grant will continue to vest per <br>the original vesting schedule if the NEO has been actively employed for at <br>least one year following grant date. If an NEO retires less than one year <br>following grant date, unvested stock options forfeit.<br>Unvested stock options granted in 2024 and 2025 will continue to vest per the <br>original vesting schedule. <br>|

---

**TERMINATION FOLLOWING A CHANGE IN CONTROL**

NEOs are not eligible for any benefit solely upon a CIC, as our executive severance agreements ("Agreements") and the

Ingredion Change in Control Executive Severance Pay Plan ("CIC Plan") each require a double-trigger event in order for CIC

severance provisions to become payable. The Agreements and the CIC Plan each require us to make certain payments and

provide certain benefits if the NEO's employment is terminated by us other than because of death, disability, or "Cause" or is

terminated by the NEO for "Good Reason" within two years of a CIC. Additionally, the Stock Incentive Plan provides for the

treatment of unassumed outstanding equity grants following a CIC and assumed outstanding equity grants upon an involuntary

termination of employment without Cause or voluntary termination for Good Reason within two years following a CIC.

The key elements of the executive severance agreements, the CIC Plan and the Stock Incentive Plan assuming a double-trigger

CIC event are described in the narrative and table below.

---

| | |
|:---|:---|
| Plan Element | Description |
| Definition of "CIC" | As defined in the Agreements, results from any of the following: |
|  | •Acquisition by an individual, entity, or group of persons of beneficial ownership of 20% or <br>more of our common stock,<br>•Change in composition of the board such that the individuals who, as of the effective <br>date of the CIC Plan, constitute the board cease for any reason to constitute at least a <br>majority of the board during any 12-month period, provided, however, that any <br>individual who becomes a member of the board subsequent to the effective date of the <br>CIC Plan and was approved by a majority vote of the board shall be considered as though <br>such individual were a member of the board,<br>|

---

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **57** |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

---

| | |
|:---|:---|
|  | •A merger or sale of substantially all of our assets except where owners of our shares own <br>a majority of the voting shares of the surviving corporation or purchaser of the assets, <br>and no person other than us or our benefits plans who owned 15% of our stock before <br>the transaction owns 25% or more of the stock of the survivor or purchaser, and the <br>directors who must be a majority under the preceding provision are a majority of the <br>directors of the surviving corporation or purchaser, or<br>•The consummation of a plan of our complete liquidation or dissolution.<br>|
|  | As defined in the CIC Plan, results from any of the following: |
|  | •Acquisition by any one person, or more than one person acting as a group, of ownership <br>of equity of the Company possessing more than 30% of the total voting power of the <br>equity of the Company,<br>|
|  | •Acquisition by any one person, or more than one person acting as a group, of ownership <br>of equity of the Company that, together with equity held by such person or group, <br>constitutes more than 50% of the total fair market value or total voting power of the <br>equity of the Company,<br>|
|  | •Acquisition by any one person, or more than one person acting as a group, of all or <br>substantially all of the assets of the Company, or<br>|
|  | •Change in composition of the board such that the individuals who, as of the effective <br>date of the CIC Plan, constitute the board cease for any reason to constitute at least a <br>majority of the board during any 12-month period, provided, however, that any <br>individual who becomes a member of the board subsequent to the effective date of the <br>CIC Plan and was approved by a majority vote of the board shall be considered as though <br>such individual were a member of the board.<br>|
| Definition of "Cause" | Under the Agreements, the occurrence of one of the conditions below with respect to the NEO:<br>•Willful engagement in conduct which involves dishonesty or moral turpitude which <br>either:<br>|
|  | (i) results in substantial personal enrichment of the NEO at our expense, or<br>(ii)is demonstrably and materially injurious to our financial condition or reputation,<br>|
|  | •Willful violation of the provisions of the confidentiality or non-competition agreement <br>entered into between the Company or any of its subsidiaries and the NEO, or<br>•Commitment of a felony.<br>|
|  | Under the CIC Plan, the occurrence of one of the conditions below with respect to the NEO:<br>•Willful engagement in conduct which involves dishonesty or moral turpitude which <br>either:<br>|
|  | (i) results in substantial personal enrichment of the NEO at our expense, <br>(ii)is demonstrably and materially injurious to our financial condition or reputation, or<br>(iii)is a material violation of the Company's Code of Conduct,<br>|
|  | •Willful violation of the provisions of the confidentiality, non-competition or other <br>material agreement entered into between the Company or any of its subsidiaries and the <br>NEO, <br>•Commitment of a felony, or <br>•the NEO's failure or refusal to perform the duties or responsibilities of their position or as <br>otherwise assigned within ten days after written notice. <br>|
| Definition of "Good <br>Reason"<br>| Under the Agreements:<br>•Material reduction in base salary,<br>•Relocation beyond 35 miles from office location immediately prior to the CIC,<br>•Material reduction in job title, job authorities, or responsibilities immediately prior to the <br>CIC, or<br>•Taking of certain other actions as specified in the definition.<br>|

---

---

| | | |
|:---|:---|:---|
| **58** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

---

| | |
|:---|:---|
| Definition of "Good <br>Reason" (continued)<br>| Under the CIC Plan:<br>•Material reduction in base salary,<br>•Change in the geographic location of more than a 50 mile radius from the participant's <br>designated office location, and that also substantially increases the commute time to the <br>new geographic location, <br>•Material reduction in the participant's duties or responsibilities, excluding any change in <br>title, or<br>•Taking of certain other actions as specified in the definition.<br>|
| Severance and Benefits<sup>(1)</sup> | Under the terms of their respective agreements, Messrs. Zallie and Gray are eligible to receive: |
|  | (i)Three times the sum of (a) highest base salary in effect during any consecutive 12-<br>month period within the 36 months immediately preceding the date of termination <br>plus (b) target AIP payment for the year in which the termination occurs, paid in a <br>lump sum, and<br>(ii)Continued health and welfare benefit coverage at the same cost and coverage level <br>as in effect as of the date of termination of employment for 36 months.<br>|
|  | Under the terms of his agreement, Mr. Seip is eligible to receive: |
|  | (i) Two times the sum of (a) highest base salary in effect during any consecutive 12-<br>month period within the 36 months immediately preceding the date of termination <br>plus (b) target AIP payment for the year in which the termination occurs, paid in a <br>lump sum, and<br>(ii)Continued health and welfare benefit coverage at the same cost and coverage level <br>as in effect as of the date of termination of employment for 24 months.<br>|
|  | Under the terms of their respective agreements, Messrs. Zallie, Gray, and Seip are eligible to <br>receive: <br>•Outplacement services for twelve months following termination,<br>•Lump sum amount equivalent to the same level of personal allowances for the period of <br>three months, and<br>•Continued payment of lease payments for three months for any NEO participating in the <br>car lease programs.<br>|
|  | Under the terms of the CIC Plan, Ms. Jaeger de Foras and Mr. Ritchie are eligible to receive:  |
|  | (i)Two times annual base salary and target annual bonus paid in a lump sum,<br>(ii)Full cost of COBRA coverage for 18 months or if earlier, until the NEO ceases to be <br>eligible for COBRA, and <br>(iii)Outplacement services for twelve months following termination.<br>|
| Treatment of AIP awards <br>and Equity Grants<sup>(2)</sup><br>| All NEOs would receive:<br>•Target annual bonus under the AIP reduced pro rata for any portion of the plan year in <br>which the NEO is not employed with the Company; assumes target performance level <br>was achieved, and<br>•All outstanding stock options and stock appreciation rights immediately become <br>exercisable in full, all other awards immediately vest, all performance periods will lapse, <br>each performance period will be deemed satisfied at the target level and each option, <br>stock appreciation right, and other award will represent a right to acquire the <br>appropriate number of shares of common stock received in the merger or similar <br>transaction.<br>|

---

(1)Such continued insurance and other benefits are provided only until the NEO reaches age 65.

(2)Such treatment is afforded to grants to executive officers who are members of our Executive Leadership Team only in the event that the

NEO terminates employment for "Good Reason" or is terminated by the Company without "Cause" within two years of a CIC.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **59** |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

**Form of Release and Restrictive Covenants**

Each executive severance agreement and the CIC Plan require, as a condition to the receipt of payments, that the NEO sign a

standard form of release in which the NEO waives all claims that the NEO might have against the Company and certain

associated individuals and entities. The agreements contain confidentiality provisions that apply for an unlimited period of time

following termination of employment.

The executive severance agreements of Messrs. Zallie and Gray each include three-year non-compete and non-solicitation

covenants in the event employment is terminated within two years of a CIC. Mr. Seip's executive severance agreement and the

CIC Plan both include a two-year non-compete and non-solicitation covenant in the event employment is terminated within two

years of a CIC.

**TREATMENT OF RETIREMENT BENEFITS UPON CHANGE IN** 

**CONTROL**

**Cash Balance Plan and Nonqualified Cash Balance Make-Up Accounts**

For Messrs. Zallie and Gray, the executive severance agreements provide for the terminated NEO to receive three additional

years of service credit under our Cash Balance Plan and our nonqualified Cash Balance Make-up Account, provided, that if the

NEO is at least 62 years old, the NEO will receive a prorated amount of additional service credits based on the number of full

months until he reaches age 65. The additional years of service credit will be calculated consistently with and be based on the

NEO's total target cash compensation. The agreements also provide for vesting of each NEO's account under the Cash Balance

Plan and nonqualified Cash Balance Make-up Accounts if not already vested.

While Mr. Seip has an executive severance agreement, he is not a participant in the Cash Balance Plan and, accordingly, does

not have a nonqualified Cash Balance Make-Up Account.

**Retirement Savings Plan and Savings Plan Make-Up Accounts**

In addition, Messrs. Zallie and Gray will receive nonqualified plan credits equal to three times the sum of the employer

matching contributions (and Mr. Seip will receive nonqualified plan credits equal to two times the sum of the employer

matching contributions) made to each NEO's account under the Company's Retirement Savings Plan and, if applicable, the

Savings Plan Make-up Accounts for the most recent plan year that ended before the date of the CIC, or, if higher, for the most

recent plan year that ended after the date of the CIC (calculated on an annualized basis) as well as the continuation of vesting

over the severance period, provided, that if the NEO is at least 62 years old, the NEO will receive a prorated amount of

additional service credits based on the number of full months until the NEO reaches age 65. The agreements also provide for

vesting of each NEO's account under the Retirement Savings Plan and the Savings Plan Make-up Accounts if not already vested.

**Retirement Health Care Savings Account**

Messrs. Zallie and Ritchie will also receive the cash value of their current RHCSA and related dependent accounts. To the extent

the payments may not be paid from a qualified plan, such amounts will be paid from our general assets.

---

| | | |
|:---|:---|:---|
| **60** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

**ESTIMATE OF POTENTIAL PAYMENTS UPON TERMINATION OR** 

**CHANGE IN CONTROL**

The following table shows the potential payments to the NEOs upon termination of employment or a change in control of the

Company as of December 31, 2025.

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | | Cash | Cash | Equity | Equity | Equity | Benefits and Perquisites | Benefits and Perquisites | Benefits and Perquisites | Benefits and Perquisites | |
| | <br>Scenario | Severance<br>Payments<br>($)<br>| AIP Award<sup>(1)</sup><br>($)<br>| Stock <br>Options<sup>(2)</sup><br>($)<br>| Restricted <br>Stock<br>Units<sup>(3)</sup><br>($)<br>| Performance<br>Share Units<sup>(4)</sup><br>($)<br>| Health and<br>Welfare<sup>(5)</sup><br>($)<br>| Retirement<sup>(6)</sup><br>($)<br>| Perquisites<sup>(7)</sup><br>($)<br>| Outplacement<br>($)<br>| <br>TOTAL<br>($)<br>|
| James Zallie | Retirement |  | 2185980 | 340147 | 5290702 | 3419310 | 106767 |  |  |  | 11342906 |
|  | Death/<br>Disability<br>|  | 2185980 | 340147 | 5186353 | 3419310 | 106767 |  |  |  | 11238557 |
|  | Involuntary <br>Termination <br>Without <br>Cause<br>| 1295050 | 2185980 | 340147 | 5290702 | 3419310 |  |  |  |  | 12531189 |
|  | Change in <br>Control<br>| 9712875 | 1942575 | 340147 | 5290702 | 6829615 | 161348 | 812592 | 6844 | 11500 | 25108198 |
| James Gray | Retirement |  | 871060 | 77359 | 1216510 | 809713 |  |  |  |  | 2974642 |
|  | Death/<br>Disability<br>|  | 871060 | 77359 | 1193273 | 809713 |  |  |  |  | 2951405 |
|  | Involuntary <br>Termination <br>Without <br>Cause<br>| 762216 | 871060 | 77359 | 1216510 | 809713 |  |  |  |  | 3736858 |
|  | Change in <br>Control<br>| 4573296 | 762216 | 77359 | 1216510 | 1597226 | 72515 | 459609 | 3906 | 11500 | 8774137 |
| Tanya <br>Jaeger de <br>Foras | Retirement |  |  |  |  |  |  |  |  |  |  |
| Tanya <br>Jaeger de <br>Foras | Death/<br>Disability<br>|  | 456462 | 42100 | 657793 | 437107 |  |  |  |  | 1593462 |
|  | Involuntary <br>Termination <br>Without <br>Cause<br>| 942295 | 456462 |  |  |  | 27054 |  |  | 11500 | 1437311 |
|  | Change in <br>Control<br>| 1884589 | 403841 | 42100 | 670430 | 857602 | 27054 |  |  | 11500 | 3897116 |
| Robert <br>Ritchie | Retirement |  | 487930 | 20257 | 874191 | 438945 | 46863 |  |  |  | 1868186 |
| Robert <br>Ritchie | Death/<br>Disability<br>|  | 487930 | 20257 | 822754 | 438945 | 46863 |  |  |  | 1816749 |
|  | Involuntary <br>Termination <br>Without <br>Cause<br>| 1063750 | 487930 | 20257 | 874191 | 438945 | 84094 |  |  | 11500 | 2980667 |
|  | Change in <br>Control<br>| 2127500 | 488750 | 20257 | 874191 | 913504 | 84094 | 127650 |  | 11500 | 4647446 |
| Eric Seip | Retirement |  |  |  |  |  |  |  |  |  |  |
|  | Death/<br>Disability<br>|  | 463203 | 38885 | 590440 | 385800 |  |  |  |  | 1478328 |
|  | Involuntary <br>Termination <br>Without <br>Cause<br>| 561306 |  |  |  |  |  |  |  |  | 561306 |
|  | Change in <br>Control<br>| 1964571 | 420980 | 38885 | 602260 | 754068 | 49585 | 210676 | 4929 | 11500 | 4057454 |

---

(1)Amounts reflect the actual 2025 AIP award, paid in March 2026. Amount for CIC reflects a target AIP payment as provided under the

executive severance agreements.

(2)Amounts reflect the value of the unvested outstanding stock options based on the Closing Price of our common stock on December 31,

2025 ($110.26), minus the applicable exercise price. Stock option treatment varies based on termination scenario. See description in

"Potential Payout Upon Other Types of Separations" above.

(3)Amounts reflect the value of unvested RSUs multiplied by the Closing Price of our common stock on December 31, 2025 ($110.26). RSU

treatment varies based on termination scenario. See description in "Potential Payout Upon Other Types of Separations" above.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **61** |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

(4)Amounts for retirement, death and disability reflect the value of unvested PSUs multiplied by the Closing Price of our common stock on

December 31, 2025 ($110.26). PSU treatment varies based on termination scenario. See description in "Potential Payout Upon Other

Types of Separations" above.

(5)In the event Mr. Zallie or Ritchie terminates his employment due to retirement, death, or disability, amount includes the value of the

RHCSA benefit. In the event of a termination due to a CIC, amounts reflect the value of the RHCSA benefit as well as cost of COBRA

coverage for Messrs. Zallie and Ritchie and, for remaining NEOs, the cost of COBRA coverage. See description in "Potential Payout Upon

Other Types of Separations" above.

(6)Amounts reflect additional employer contributions to the defined contribution plans based on three times (for Messrs. Zallie and Gray)

and two times (for Mr. Seip) the sum of the employer matching contributions made to the executive's accounts under the qualified and

nonqualified plans for the most recent plan year that ended before the date of the CIC, or, if higher, for the most recent plan year that

ended after the date of the CIC (calculated on an annualized basis), as well as the continuation of vesting over the severance period.

Amounts for Messrs. Zallie, Gray, and Ritchie also reflect additional amounts earned under the Cash Balance Plan and nonqualified Cash

Balance Make-up Accounts upon a CIC, as well as the continuation of vesting over the severance period.

(7)For Messrs. Zallie, Gray, and Seip, the amounts reflect the Company cost related to three months of financial planning services and

Company car lease or car allowance payments.

In accordance with SEC rules, the foregoing presentation of potential payments to Mr. Gray upon an assumed termination or

change in control is as of December 31, 2025, when Mr. Gray served as the Company's CFO. Mr. Gray retired from that position

effective March 31, 2026 without giving six months notice of intent to retire.

**Pay Ratio Disclosure**

As required by Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and SEC rules adopted

thereunder, we are providing the following disclosure regarding the relationship of the annual total compensation of our

employees to the annual total compensation of Mr. Zallie, our CEO.

To understand this disclosure, we believe it is important to give context to our operations. Our corporate headquarters are in

Westchester, Illinois, and, as of March 1, 2026, we operate 15 U.S. manufacturing facilities in 13 states and have an additional

26 manufacturing facilities globally. As a global organization, we maintain a workforce with approximately 76% of our

employees located outside of the U.S. To attract, retain, and motivate talent, we use local compensation benchmark data to

maintain a competitive level of compensation for our employees. Accordingly, our pay structures vary based on position and

geographic location.

There has been no change in our employee population or employee compensation arrangements in 2025 that we believe would

significantly impact the pay ratio disclosure. As a result, we are using the same individual we identified as our median employee

last year, a full-time employee working in Pakistan.

For the purposes of preparing this disclosure, in accordance with Item 402(c)(2)(x) of Regulation S-K, we converted the median

employee's compensation paid in Pakistan rupees to U.S. dollars using the currency exchange rate as of December 31, 2025.

This calculation is the same calculation used to determine total compensation for purposes of the Summary Compensation

Table with respect to each of the NEOs.

The 2025 total compensation for Mr. Zallie, as reported in the "Total" column of the "2025 Summary Compensation Table," was

$12,932,234. For the median employee, 2025 total compensation was $57,174. The resulting ratio of total compensation for

Mr. Zallie to this median employee's total compensation was 226 to 1.

---

| | | |
|:---|:---|:---|
| **62** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

**Pay Versus Performance Disclosure**

In accordance with rules adopted by the SEC pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act, we

provide the following disclosure regarding executive compensation for our principal executive officer ("PEO") and Non-PEO

NEOs and Company performance for our five most recent fiscal years. The PCC Committee did not consider the pay versus

performance disclosure below in making its pay decisions for any of the years presented. See the "Compensation Discussion

and Analysis" section of this proxy statement beginning on page <u>[26](#ie7e472361805446c8b302de30ed47fbf_49)</u> for information about the decisions made by the PCC

Committee with respect to our NEO compensation for 2025.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  |  |  |  | Value of Initial Fixed $100<br>Investment Based On: | Value of Initial Fixed $100<br>Investment Based On: |  |  |
| Year<br>(a)<br>| Summary<br>Compensation<br>Table Total<br>for<br>PEO<sup>(1)</sup> ($)<br>(b)<br>| Compensation<br>Actually Paid<br>to PEO<sup>(2)</sup> ($)<br>(c)<br>| Average <br>Summary<br>Compensation<br>Table Total for<br>Non-PEO <br>NEOs<sup>(3)</sup> ($)<br>(d)<br>| Average<br>Compensation<br>Actually Paid<br>to Non-PEO<br>NEOs<sup>(2)</sup> ($)<br>(e)<br>| Total <br>Shareholder<br>Return<sup>(4)</sup> ($)<br>(f)<br>| PvP Peer <br>Group<br>Total <br>Shareholder<br>Return<sup>(5)</sup> ($)<br>(g)<br>| Net Income<sup>(6)</sup><br>($ in millions)<br>(h)<br>| Adjusted <br>EBITDA<sup>(7)</sup><br>($ in millions)<br>(i)<br>|
| 2025 | 12932234 | 5262717 | 2645641 | 1399068 | 159.83 | 133.94 | 729 | 1244 |
| 2024 | 11903681 | 26604006 | 2520653 | 4499692 | 194.60 | 124.65 | 647 | 1230 |
| 2023 | 11101992 | 19410647 | 2255416 | 3342377 | 150.60 | 120.71 | 643 | 1189 |
| 2022 | 9476866 | 14451217 | 2416154 | 3050919 | 132.01 | 125.53 | 492 | 1002 |
| 2021 | 10326083 | 14161465 | 2715632 | 2883921 | 126.35 | 115.83 | 117 | 896 |

---

(1)Dollar amounts shown are the amounts reported for the PEO under the "Total" column of the Summary Compensation Table ("SCT") for

the years presented (the "Covered Years"). James Zallie was our PEO for each Covered Year.

(2)Dollar amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not

reflect the actual compensation earned by or paid to the applicable NEO for any Covered Year. The table below reflects adjustments to

our calculation for all years covered by the disclosure. Compensation Actually Paid reflects the following adjustments to the SCT amounts

for equity awards and pension benefits reported for the PEO and the Non-PEO NEOs. Stock option grant date fair values are calculated

based on the Black-Scholes option pricing model as of the grant date. Adjustments have been made to the inputs in the Black-Scholes

option pricing model to determine the fair value as of each measurement date. Performance stock unit grant date fair values are

calculated using a Monte Carlo simulation model for the TSR-based potion of the award (where applicable) and Adjusted ROIC for the

Adjusted ROIC-based portion of the award. Adjustments have been made to the inputs into the Monte Carlo simulation and Adjusted ROIC

calculation as of the measurement date. In 2022, the PCC Committee approved the payment of dividends in cash on PSUs at the time of

vesting based on actual performance achieved for performance cycles including calendar year 2023 and subsequent years, and this is

reflected in the applicable Compensation Actually Paid amounts. RSU grant date fair values are calculated using the Closing Price of the

Company's common stock as of the grant date. Adjustments have been made using the Closing Price of the Company's common stock as

of the measurement date.

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Adjustments to <br>Determine<br>Compensation <br>"Actually Paid" | PEO | PEO | PEO | PEO | PEO | Non-PEO NEOs | Non-PEO NEOs | Non-PEO NEOs | Non-PEO NEOs | Non-PEO NEOs |
| Adjustments to <br>Determine<br>Compensation <br>"Actually Paid" | 2025<br>($)<br>| 2024<br>($)<br>| 2023<br>($)<br>| 2022<br>($)<br>| 2021<br>($)<br>| 2025<br>($)<br>| 2024<br>($)<br>| 2023<br>($)<br>| 2022<br>($)<br>| 2021<br>($)<br>|
| Deduction for <br>Change in the <br>Actuarial <br>Present Values <br>reported under <br>the "Change in <br>Pension Value <br>and <br>Nonqualified <br>Deferred <br>Compensation <br>Earnings" <br>Column in the <br>SCT<br>| -665369 | -365233 | -557470 | -29572 | -356593 | -62317 | -51778 | -23224 | -9063 | -12655 |
| Deduction for <br>Amounts <br>Reported <br>under the <br>"Stock Awards" <br>Column in the <br>SCT<br>| -6509237 | -5663846 | -5182466 | -4756723 | -5402825 | -971312 | -864167 | -756709 | -762884 | -1090714 |

---

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **63** |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Adjustments to <br>Determine<br>Compensation <br>"Actually Paid" | PEO | PEO | PEO | PEO | PEO | Non-PEO NEOs | Non-PEO NEOs | Non-PEO NEOs | Non-PEO NEOs | Non-PEO NEOs |
| Adjustments to <br>Determine<br>Compensation <br>"Actually Paid" | 2025<br>($)<br>| 2024<br>($)<br>| 2023<br>($)<br>| 2022<br>($)<br>| 2021<br>($)<br>| 2025<br>($)<br>| 2024<br>($)<br>| 2023<br>($)<br>| 2022<br>($)<br>| 2021<br>($)<br>|
| Deduction for <br>Amounts <br>Reported <br>under the <br>"Option <br>Awards" <br>Column in the <br>SCT<br>| -1999964 | -1699996 | -1599741 | -1562393 | -1622964 | -298434 | -259377 | -221840 | -229671 | -229691 |
| Increase for <br>"Service Cost" <br>for Pension <br>Plans<br>| 170106 | 125112 | 130733 | 147024 | 159382 | 28766 | 15417 | 7105 | 8345 | 6863 |
| Fair value of <br>equity <br>compensation <br>granted in <br>current year<br>| 9022363 | 13517537 | 10011282 | 9980318 | 10371863 | 1350569 | 2065622 | 1427945 | 1533228 | 1632198 |
| Change in fair <br>value from end <br>of prior fiscal <br>year to end of <br>current fiscal <br>year for awards <br>made in prior <br>fiscal years that <br>were unvested <br>at end of <br>current fiscal <br>year<br>| -4165768 | 5695450 | 2931627 | 1207751 | 1558116 | -627231 | 716838 | 372424 | 127162 | 142575 |
| Change in fair <br>value from end <br>of prior fiscal <br>year to vesting <br>date for <br>awards made <br>in prior fiscal <br>years that <br>vested during <br>current fiscal <br>year<br>| -3521648 | 3091301 | 2574690 | -12054 | -871597 | -666615 | 356485 | 281260 | -32353 | -46623 |
| Fair value of <br>forfeited <br>awards <br>determined at <br>end of prior <br>year for awards <br>made in prior <br>fiscal years that <br>were forfeited <br>during current <br>fiscal year<br>|  |  |  |  |  |  |  |  |  | -233665 |
| Total <br>Adjustments <br>| -7669517 | 14700325 | 8308655 | 4974351 | 3835382 | -1246573 | 1979040 | 1086961 | 634765 | 168289 |

---

(3)Dollar amounts shown represent the average of the total compensation amounts reported in the SCT for the Non-PEO NEOs for the

Covered Years. The following executive officers served as the Non-PEO NEOs for the following years: (i) for 2025, James Gray, Tanya Jaeger

de Foras, Robert Ritchie, and Eric Seip; (ii) for 2024, James Gray, Tanya Jaeger de Foras, Robert Ritchie, and Eric Seip; (iii) for 2023, James

Gray, Eric Seip, Nancy Wolfe, and Jeremy Xu; (iv) for 2022, James Gray, Jorgen Kokke, Nancy Wolfe, and Jeremy Xu; and (v) for 2021, James

Gray, Jorgen Kokke, Janet Bawcom, Eric Seip, and Jeremy Xu.

(4)The cumulative TSR for the Company is calculated by dividing the sum of the cumulative amount of dividends for the measurement

period, assuming dividend reinvestment, and the difference between the Company's share price at the end and the beginning of the

measurement period by the Company's share price at the beginning of the measurement period. Each of these yearly percentage changes

was applied to a deemed fixed investment of $100 at the beginning of the measurement period to produce the Covered Year-end values

of such investment as of the end of 2025, 2024, 2023, 2022, and 2021.

(5)The cumulative PVP Peer Group TSR utilizes the S&P 1500 Food, Beverage, and Tobacco Index (the "PVP Peer Group"), which we also

utilize in the stock performance graph required by Item 201(e) of Regulation S-K to be included in our annual report for the year ended

December 31, 2025. For each Covered Year, our PVP Peer Group TSR was calculated based on a deemed fixed investment of $100 through

the measurement period, assuming dividend reinvestment for the peer group, weighted according to the respective companies' stock

market capitalization at the beginning of the measurement period.

---

| | | |
|:---|:---|:---|
| **64** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

(6)Amounts reported represent Net Income attributable to Ingredion as presented in the Company's audited financial statements for the

applicable Covered Year.

(7)We determined Adjusted EBITDA to be the most important performance measure used to link Company performance to Compensation

Actually Paid to our PEO and Non-PEO NEOs for 2025. Adjusted EBITDA was the highest-weighted financial metric used to determine NEO

performance under our Annual Incentive Plan for 2025, as discussed under "Financial Metrics" on page <u>[32](#idbd8228798374a95ab5d4e1f889f4e94_42811)</u> of the Compensation Discussion

and Analysis section of this proxy statement. This performance measure may not have been the most important performance measure for

any other Covered Year. We may determine that a different performance measure will be the most important performance measure for

future years. Adjusted EBITDA is defined under "Financial Metrics" on page <u>[33](#idbd8228798374a95ab5d4e1f889f4e94_42808)</u> of the Compensation Discussion and Analysis section of this

proxy statement. The Adjusted EBITDA shown in the table above and the "Compensation Actually Paid and Company Adjusted EBITDA"

section below is the same as reported in our Annual Report on Form 10-K for the year ended December 31, 2025.

**ANALYSIS OF INFORMATION PRESENTED IN THE PAY VERSUS** 

**PERFORMANCE TABLE**

While we utilize several performance measures to align executive compensation with Company performance, not all incentive

measures are presented in the pay versus performance table above. We generally seek to incentivize long-term performance

and therefore do not specifically align performance measures with compensation that is actually paid (as computed in

accordance with Item 402(v) of Regulation S-K) for a particular year.

We provide information below about the relationship between the compensation actually paid to our PEO and Non-PEO NEOs

for the Covered Years as shown in the pay versus performance table above and:

• our cumulative TSR,

• our net income, and

• our Adjusted EBITDA.

**Compensation Actually Paid and Company Total Shareholder Return**

The chart below illustrates for the Covered Years the Compensation Actually Paid to our PEO and Non-PEO NEOs in relation to

our TSR, as well as our TSR compared to our PVP Peer Group TSR over the same period. In 2025, our TSR exceeded our PVP Peer

Group TSR. For 2025, based on our relative percentile ranking with respect to TSR and our performance against our Adjusted

ROIC metric, our PEO and non-PEO NEOs earned PSUs awarded for the 2023 – 2025 performance period at a performance level

of 166.7%.

![2025 CAP and TSR Graph.jpg](ingr-20260402_g43.jpg)

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **65** |

---

**<u>**Table of Contents**</u>**

Executive Compensation<br>

**Compensation Actually Paid and Company Net Income**

The chart below illustrates for the Covered Years the Compensation Actually Paid to our PEO and Non-PEO NEOs in relation to

Company net income. Our 2021 net income was negatively impacted by an impairment of $340 million related to net assets

contributed to a joint venture in South America.

![2025 CAP to Net Income.jpg](ingr-20260402_g44.jpg)

**Compensation Actually Paid and Company Adjusted EBITDA**

The chart below illustrates for the Covered Years the Compensation Actually Paid to our PEO and Non-PEO NEOs in relation to

our Adjusted EBITDA.

![2025 CAP and Adj EBITDA.jpg](ingr-20260402_g45.jpg)

**MOST IMPORTANT FINANCIAL PERFORMANCE MEASURES**

We set forth below the three financial performance measures that represented the most important measures used to link

Compensation Actually Paid to our PEO and Non-PEO NEOs (as calculated in accordance with Item 402(v) of Regulation S-K) to

Company performance for 2025. The measures in this table are not ranked.

---

| |
|:---|
| Adjusted EBITDA |
| Adjusted ROIC |
| Relative Total Shareholder Return versus PVP Peer Group |

---

As discussed in the Compensation Discussion and Analysis section of this proxy statement under "Elements of Compensation"

beginning on page <u>[31](#idbd8228798374a95ab5d4e1f889f4e94_42814)</u>, these measures were used to evaluate the performance of our NEOs under both our annual incentive

plan and our long-term incentive plan and to incentivize our NEOs to increase long-term value for our stockholders. See that

discussion for a description of how we calculate Adjusted EBITDA and Adjusted ROIC from our audited financial statements.

---

| | | |
|:---|:---|:---|
| **66** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Compensation Committee Report; Compensation Committee Interlocks and Insider Participation<br>

**Compensation Committee Report**

The People, Culture, and Compensation Committee of the Board of Directors reports that it has reviewed and discussed with

the Company's management the section of this proxy statement headed "Compensation Discussion and Analysis" and, on the

basis of that review and discussion, recommended that such section be included in this proxy statement and incorporated by

reference into our Annual Report on Form 10-K for the year ended December 31, 2025.

People, Culture, and Compensation Committee

R. L. Jordan, Chair

D. B. Fischer

C. V. Magro

**Compensation Committee Interlocks and** 

**Insider Participation**

None of the PCC Committee members:

• has ever been an officer or employee of the Company, or

• had a relationship during 2025 that is required to be disclosed under SEC rules relating to disclosure of transactions with

related persons.

In 2025, none of our executive officers served on the board of directors or compensation committee of any entity that had one

or more of its executive officers serving on our Board of Directors or our PCC Committee.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **67** |

---

**<u>**Table of Contents**</u>**

Proposal 2. Advisory Vote on Compensation of Our Named Executive Officers<br>

**Proposal 2. Advisory Vote on Compensation of** 

**Our Named Executive Officers**

In this Proposal 2, in accordance with Section 14A of the Exchange Act and the SEC's rules thereunder, the Board of Directors is

asking the stockholders to approve, on an advisory basis, the compensation of the Company's named executive officers as

described in this proxy statement, other than the information presented under "Pay Versus Performance Disclosure" in the

"Executive Compensation" section of this proxy statement. The Board of Directors has determined to seek such a vote annually

until the next required stockholder vote on the frequency of stockholder votes on executive compensation in May 2029.

In the discussion in the "Compensation Discussion and Analysis" section of this proxy statement beginning on page <u>[26](#ie7e472361805446c8b302de30ed47fbf_49)</u>, we

discuss in detail how our compensation programs support our business and financial objectives, how they work, how they are

administered under the direction of our PCC Committee, and how the PCC Committee's decisions concerning the 2025

compensation of our named executive officers were directly tied to our performance.

At our 2025 annual meeting, 94% of the shares voted were cast in support of the compensation of our named executive officers

as described in the proxy statement for that meeting. We ask that you again support the compensation of our named executive

officers, as described in this proxy statement for this annual meeting. Because your vote is advisory, it will not be binding on the

board or the Company. The board and the PCC Committee, however, will review the voting results and take them into

consideration when making future decisions regarding executive compensation.

We have a long-standing record of delivering strong performance for our stockholders. Our executive compensation programs

have played an important role in our ability to achieve strong financial results and attract, retain, and motivate a highly

experienced, successful team to manage the Company.

We believe that our executive compensation programs are well informed by market practices and structured to effectively align

compensation with the Company's business and talent strategies.

• Our compensation programs are substantially tied to key strategic business objectives and the creation of long-term

shareholder value. If the value we deliver to our stockholders declines, so does the compensation we deliver to our

executives.

• We maintain a high level of corporate governance over our executive pay programs.

• We closely monitor our compensation programs and the pay levels of executives of companies of similar size and

complexity so that we may ensure that our compensation programs are within the norm of a range of market practices.

**The Board of Directors unanimously recommends that you vote FOR the following** <br>**proposal:**<br>

RESOLVED, that the stockholders approve, on an advisory basis, the compensation of the Company's named executive officers

as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, the accompanying

compensation tables, and the related narrative disclosures in the proxy statement for the Company's 2026 annual meeting of

stockholders.

---

| | | |
|:---|:---|:---|
| **68** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>**Table of Contents**</u>**

Review and Approval of Transactions with Related Persons<br>

**Review and Approval of Transactions with** 

**Related Persons**

The Board of Directors has adopted a written policy and procedures for review, approval, and monitoring of transactions

involving the Company and "related persons" that generally would be subject to disclosure by the Company under SEC rules

requiring disclosure of transactions with related persons.

Under the policy, "related persons" consist of the following:

• directors or nominees for directors,

• executive officers,

• beneficial owners of more than 5% of the Company's outstanding common stock,

• the immediate family members of any of the above persons, and

• an entity in which any of the above persons acts as an officer or general partner or otherwise controls, or in which such

person, together with any other persons referred to above, holds an ownership interest of at least 10%.

The policy covers any transaction with related persons involving amounts exceeding $120,000 in which a related person has a

direct or indirect material interest.

**Policy**<br>Transactions with related persons must be approved by the Audit Committee of the Board of Directors or if a related person <br>involved is a member of the Board of Directors or a nominee to become a director, by all of the disinterested and <br>independent members of the board. In considering the transaction, the Audit Committee or disinterested and independent <br>directors will consider all relevant factors, including, as applicable:<br>•the size of the transaction and the amount payable, directly or indirectly, to a related person,<br>•the nature of the interest or involvement of the related person in the transaction,<br>•whether the transaction creates an appearance of a conflict of interest or unfair dealing,<br>•whether the rates or charges and other key terms involved in the transaction were determined by competitive bids,<br>•whether the transaction involves the provision of goods or services to the Company that are available from <br>unaffiliated third parties and, if so, whether the transaction is on terms and made under circumstances that are at <br>least as favorable to the Company as would be available in comparable transactions with or involving unaffiliated third <br>parties, and<br>•the impact of the transaction on the Company and its stockholders.<br>

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **69** |

---

**<u>**Table of Contents**</u>**

Review and Approval of Transactions with Related Persons<br>

**Procedures**

The evaluation and approval of transactions with related persons under the policy are required to be conducted in accordance

with the following procedures:

• The CFO will advise the Chair of the Audit Committee of any related-person transaction of which the CFO becomes

aware.

• The Audit Committee will consider such related-person transaction at its next regularly scheduled meeting or, if it deems

it advisable, prior thereto at an interim meeting called for such purpose. If approval or, to the extent permissible under

applicable standards, ratification of the related-person transaction requires consideration by all of the disinterested and

independent members of the Board of Directors, the related-person transaction will be considered at the board's next

regularly scheduled meeting or, if the disinterested and independent directors deem it advisable, prior thereto at an

interim meeting called for such purpose.

• Except as set forth below, any related-person transaction not approved in advance by the Audit Committee or a majority

of the disinterested and independent directors will not be entered into by the Company unless the consummation of the

transaction, to the extent permissible under applicable standards, is expressly subject to ratification by the Audit

Committee or a majority of the disinterested and independent directors. If the transaction is not so ratified, the

Company will not consummate the transaction. It is the responsibility of management to notify the CFO of all potential

related-person transactions in advance, so as to allow appropriate review under the Company's guidelines.

• If the Company enters into a transaction that (i) the Company was not aware constituted a related-person transaction at

the time it was entered into but which it subsequently determines is a related-person transaction prior to full

performance thereof or (ii) did not constitute a related-person transaction at the time such transaction was entered into

but thereafter becomes a related-person transaction prior to full performance thereof, then in either such case the

related-person transaction will be presented for ratification in the manner set forth above. If the related-person

transaction is not ratified, then the Company will take all reasonable actions to attempt to terminate its participation in

the transaction. Reasonable steps will not be deemed to require that the Company act in breach of any contractual

obligations or otherwise expose itself to legal liability.

• The CFO will update the Audit Committee or the board, as applicable, on the status of any approved related-person

transaction not less frequently than annually, or upon termination of or anticipated significant change in the related-

person transaction. Anticipated significant changes will be subject to the approval procedures required for initial

approval of a related-person transaction.

Since January 1, 2025, there have been no related-person transactions subject to approval under the foregoing policy and

procedures.

---

| | | |
|:---|:---|:---|
| **70** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

Equity Compensation Plan Information as of December 31, 2024; Audit Committee Report<br>

**Equity Compensation Plan Information as of** 

**December 31, 2025**

The following table provides information about our equity compensation plans as of December 31, 2025.

---

| | | | |
|:---|:---|:---|:---|
| Plan Category | Number of <br>securities<br>to be issued<br>upon exercise of<br>outstanding <br>options,<br>warrants and <br>rights<br>| Weighted-<br>average<br>exercise price of<br>outstanding<br>options,<br>warrants and<br>rights<br>| Number of securities<br>remaining available <br>for<br>future issuance <br>under<br>equity compensation<br>plans (excluding<br>securities reflected<br>in the first column)<br>|
| Equity compensation plans approved by security holders | 2142211<sup>(1)</sup> | $105.75<sup>(2)</sup> | 4569234 |
| Equity compensation plans not approved by security <br>holders<br>| 35694<sup>(3)</sup> | N/A | N/A |
| Total | 2177904 | $105.75<sup>(4)</sup> | 4569234 |

---

(1)Amount shown includes an aggregate of 151,570 shares of common stock representing outstanding PSUs that will vest only upon

completion of the relevant long-term incentive performance cycle and will be payable, if earned, by the Company in shares of common

stock. This amount assumes all such performance awards vest at 100%. Amount shown also includes 510,000 RSUs outstanding as of

December 31, 2025.

(2)Price shown excludes the 151,570 PSUs and 510,000 RSUs referenced in footnote 1 to this table because those awards have no exercise

price.

(3)Amount shown assumes that all 479 phantom stock units credited to the Director Deferred Compensation Plan and all 35,215 phantom

stock units in the NQDCP accounts of the participating directors and executive officers will be paid in the form of shares of common stock.

(4)Price shown represents the weighted-average exercise price of outstanding options. It excludes the phantom stock units referenced in

footnote 3 to this table and the 151,570 PSUs and 510,000 RSUs referenced in footnote 1 to this table because those awards have no

exercise price.

**Audit Committee Report**

The Audit Committee of the Board of Directors reports that it has: (i) reviewed and discussed with management the audited

financial statements of the Company for the fiscal year ended December 31, 2025; (ii) discussed with KPMG LLP ("KPMG"), the

independent registered public accounting firm serving as the Company's independent auditors, the matters required to be

discussed by the applicable requirements of the Public Company Accounting Oversight Board and the U.S. Securities and

Exchange Commission ("SEC"); and (iii) received the written disclosures and the letter from KPMG required by applicable

requirements of the Public Company Accounting Oversight Board regarding KPMG's communications with the Audit Committee

concerning independence, and has discussed with KPMG their independence. Based on such review and discussions, the Audit

Committee recommended to the Board of Directors that the audited financial statements of the Company for the fiscal year

ended December 31, 2025 be included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025,

for filing with the SEC.

Audit Committee

C. A. Suever, Chair

V. J. Reich

D. A. Wilson

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **71** |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

Proposal 3. Ratification of Appointment of KPMG as Our Independent Registered Public Accounting Firm<br>

**Proposal 3. Ratification of Appointment of** 

**KPMG as Our Independent Registered Public** 

**Accounting Firm**

In this Proposal 3, the Board of Directors is asking stockholders to ratify the Audit Committee's appointment of KPMG LLP

("KPMG") as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

Although the Company is not required to seek stockholder approval of this appointment, the board is submitting a proposal for

stockholders to ratify such approval as a matter of good corporate governance. If the appointment is not ratified, the Audit

Committee will evaluate the reasons for stockholder rejection and will reconsider the appointment. Even if the appointment is

ratified, the Audit Committee, in its discretion, may appoint a different independent registered public accounting firm at any

time during the year if the Audit Committee determines that such an appointment would be in the best interests of the

Company and its stockholders.

KPMG has served as the Company's independent auditor since 1997. KPMG also performs certain audit-related and non-audit

tax services for the Company.

Representatives of KPMG are expected to attend the annual meeting and will be available to respond to appropriate questions

and to make a statement if they so desire.

**The Board of Directors unanimously recommends that you vote FOR the** <br>**ratification of the appointment of KPMG LLP as the Company's independent** <br>**registered public accounting firm for the fiscal year ending December 31, 2026.**<br>

The following is a summary of professional services provided by KPMG during the years ended December 31, 2025 and 2024,

and the fees paid by the Company for such services.

---

| | | |
|:---|:---|:---|
| | 2025 | 2024 |
| Audit Fees<sup>(1)</sup> | $4743000 | $4900000 |
| Audit-Related Fees<sup>(2)</sup> | $76400 | $7000 |
| Tax Fees<sup>(3)</sup> | $85700 | $16000 |
| All Other Fees<sup>(4)</sup> | $— | $— |
| Total | $4905100 | $4923000 |

---

(1)Audit Fees include fees for services related to the annual consolidated financial statements and internal control over financial reporting,

completion of limited reviews of quarterly financial information, and foreign statutory audits.

(2)Audit-Related Fees include fees for services related to benefit plan audits, review of government filings, attestation, and compliance

reports.

(3)Tax Fees primarily relate to tax compliance and consultation services in the various countries in which the Company operates.

(4)All Other Fees are fees for products or services other than Audit Fees, Audit-Related Fees, or Tax Fees. There were no such fees paid to

KPMG in 2024 or 2025.

As part of its assessment of auditor independence, the Audit Committee has considered and determined the compatibility of

the audit-related and non-audit tax services provided by KPMG.

---

| | | |
|:---|:---|:---|
| **72** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

Proposal 3. Ratification of Appointment of KPMG as Our Independent Registered Public Accounting Firm<br>

**Pre-Approval of Services**

The Audit Committee pre-approves KPMG's performance of the foregoing services in accordance with its policy requiring

committee pre-approval of all audit and non-audit services by KPMG. In accordance with that policy, the Audit Committee has

given its pre-approval for the provision of audit services by KPMG for fiscal year 2026, including KPMG's audit fees, and has also

given its pre-approval for up to one year in advance for the provision by KPMG of specified types of audit-related, tax, and other

permitted non-audit services. In circumstances in which the services proposed to be provided by KPMG are not covered by one

of these pre-approvals, the Audit Committee may subsequently pre-approve such services or delegate authority to the Chair or

other designated members of the committee to pre-approve such services. Any pre-approvals under this delegated authority

must be communicated to the full Audit Committee.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **73** |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

Questions and Answers About This Proxy Statement and Our 2025 Annual Meeting<br>

**Questions and Answers About This Proxy** 

**Statement and Our 2026 Annual Meeting**

**Why am I receiving these materials?**

The Board of Directors of Ingredion Incorporated is soliciting proxies to be voted at the 2026 Annual Meeting of Stockholders to

be held on Wednesday, May 20, 2026, and at any adjournment or postponement thereof. When we ask you for your proxy, we

must provide you with a proxy statement and an annual report to stockholders that contain certain information specified by

SEC rules. Our Board of Directors has made these materials available to most of our stockholders via the Internet or, if you have

previously requested to receive paper copies or you are a participant in one of the Ingredion Incorporated Retirement Savings

Plans, has delivered paper copies of these materials to you by mail. Our stockholders are invited to attend the annual meeting

at *www.virtualshareholdermeeting.com/INGR2026* and are requested to vote on the proposals described in this proxy

statement.

**What is included in these materials?**

These materials include:

• this proxy statement for the annual meeting, and

• our 2025 Annual Report to Stockholders, which includes our audited consolidated financial statements.

If you received paper copies of these materials by mail, these materials also include the proxy card for the annual meeting.

**Why did I receive a notice in the mail regarding the Internet** 

**availability of proxy materials instead of a paper copy of the proxy** 

**materials?**

As in previous years, we are furnishing proxy materials to our stockholders primarily through the Internet. We are mailing to

most of our stockholders a notice of Internet availability of proxy materials ("notice of availability") instead of a paper copy of

the proxy materials. All stockholders receiving the notice of availability will have the ability to access the proxy materials over

the Internet. In addition, they have the ability to request a paper copy of the proxy materials by mail. Instructions on how to

access the proxy materials over the Internet or to request a paper copy are included in the notice of availability. In addition, this

proxy statement contains instructions on how stockholders may request to receive proxy materials over the Internet or in paper

form by mail on an ongoing basis.

**Why didn't I receive a notice of Internet availability of proxy** 

**materials?**

If you have previously requested to receive a paper copy of the proxy materials or are a stockholder who is a participant in one

of the Ingredion Incorporated Retirement Savings Plans, you were sent a paper copy of the proxy materials instead of a notice

of availability.

**How can I access the proxy materials over the Internet and how can I** 

**switch to electronic delivery in the future?**

Your notice of availability, e-mail notification, proxy card, or voting instruction form contains instructions on how to view our

proxy materials for the annual meeting via the Internet. Our proxy materials are also available on our investor relations website

at *https://ir.ingredionincorporated.com/financial-information/sec-filings*.

---

| | | |
|:---|:---|:---|
| **74** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

Questions and Answers About This Proxy Statement and Our 2025 Annual Meeting<br>

If you received your proxy materials in the mail, on the SEC Filings section of our investor relations website you can instruct us

to send future proxy materials to you via electronic delivery. Choosing to receive your future proxy materials by electronic

delivery will help us conserve natural resources and reduce the costs of printing and distributing our proxy materials. If you

choose to receive future proxy materials via electronic delivery, you will receive an e-mail with instructions containing a link to

the website where those materials are available and a link to the proxy voting website. Your election to receive proxy materials

via electronic delivery will remain in effect until you terminate it.

**How can I obtain a paper copy of the proxy materials?**

Stockholders receiving a notice of Internet availability of proxy materials will find instructions in their notice about how to

obtain a paper copy of the proxy materials. All stockholders who do not receive the notice of availability and have not elected to

receive proxy materials via electronic delivery will receive a paper copy of the proxy materials by mail.

**What does it mean if I receive more than one notice of availability or** 

**proxy card?**

It means that you hold shares in more than one account. To ensure that all your shares are voted, if you submit proxy or voting

instructions via the Internet or by telephone, you will need to submit such instructions once for each notice of availability, e-

mail notification, proxy card, or voting instruction form you receive. To ensure that all your shares are voted, if you received

more than one proxy card, sign, date and return each card or submit voting instructions once for each card via the Internet or

by telephone.

**What will the stockholders vote on at the annual meeting?**

The stockholders will vote on three proposals:

• in accordance with Proposal 1, election to the board of the 11 director nominees who are named in this proxy

statement, each to serve for a term of one year,

• in accordance with Proposal 2, approval, by advisory vote, of the compensation of the Company's named executive

officers as described in this proxy statement, and

• in accordance with Proposal 3, ratification of the appointment of KPMG as our independent registered public accounting

firm for the fiscal year ending December 31, 2026.

**Will there be any other items of business on the agenda?**

We do not expect any other items on the agenda because the deadlines for stockholder proposals and notices to present

business at the annual meeting, including director nominations, have passed. Nonetheless, if there should be an unforeseen

matter or item of business to be presented or acted upon at the annual meeting, the accompanying proxy gives discretionary

authority to the persons named in the proxy to vote the proxy as to such matters or items of business in accordance with their

best judgment.

**How does the Board of Directors recommend that I vote on the** 

**proposals?**

The Board of Directors unanimously recommends that you vote your shares:

• ***FOR*** the election of each of the board's 11 director nominees, as described in Proposal 1,

• ***FOR*** approval of the compensation of the Company's named executive officers as described in this proxy statement, as

described in Proposal 2, and

• ***FOR*** ratification of the appointment of KPMG as our independent registered public accounting firm for the fiscal year

ending December 31, 2026, as described in Proposal 3.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **75** |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

Questions and Answers About This Proxy Statement and Our 2025 Annual Meeting<br>

**Who is entitled to vote?**

Only stockholders as of the close of business on March 23, 2026, which is the record date for the annual meeting fixed by the

Board of Directors (the "record date"), and those who hold valid proxies from such stockholders may vote at the annual

meeting. You have one vote for each share of common stock you held on the record date, including shares:

• held directly in your name as a stockholder of record,

• held in your account with a bank, broker, or other holder of record, or

• allocated to your account(s) in the Ingredion Incorporated Stock Fund in one of the Company's Retirement Savings Plans.

A list of the stockholders entitled to vote at the meeting will be open to examination by any stockholder for any purpose

germane to the meeting for ten days prior to the meeting during ordinary business hours at the Company's offices at

5 Westbrook Corporate Center, Westchester, Illinois 60154. In addition, the list will be available to any stockholder during the

annual meeting on the meeting website set forth above using the 16-digit control number provided on your notice of

availability of proxy materials, e-mail notification, proxy card or voting instruction form.

**What constitutes a quorum for the annual meeting?**

The holders of a majority of the voting power of the outstanding shares of our common stock entitled to vote and present or

represented by proxy at the annual meeting will constitute a quorum for the transaction of business at the annual meeting. As

of the record date, 63,054,170 shares of our common stock were issued and outstanding.

**How many votes are required for the approval of each proposal and** 

**what is the effect of abstentions?**

A summary of our 2026 annual meeting proposals and applicable vote standards is as follows:

---

| | | | |
|:---|:---|:---|:---|
| Proposal | Voting Options | Vote Required for Approval | Effect of an<br>Abstention<br>|
| Election of Directors | FOR,<br>AGAINST,<br>ABSTAIN<br>| Majority of the votes cast | None — does not count as a vote <br>cast on this proposal<br>|
| Approval of Named Executive <br>Officer Compensation<br>| FOR,<br>AGAINST,<br>ABSTAIN<br>| Majority of voting power of <br>shares present at the meeting <br>and entitled to vote thereat<br>| Treated as a vote AGAINST |
| Ratification of Appointment of <br>KPMG as Our Independent <br>Registered Public Accounting Firm<br>| FOR,<br>AGAINST,<br>ABSTAIN<br>| Majority of voting power of <br>shares present at the meeting <br>and entitled to vote thereat<br>| Treated as a vote AGAINST |

---

**What is the effect of broker non-votes?**

Under NYSE rules, if you hold your shares through a record holder such as a broker, the broker will not be able to vote your

shares on Proposal 1 (election of directors) or Proposal 2 (advisory vote to approve named executive officer compensation as

described in this proxy statement) unless it receives specific instructions from you. We strongly encourage you to submit your

voting instructions on Proposals 1 and 2.

Your broker is able to submit voting instructions for Proposal 3 (ratification of appointment of KPMG as our independent

registered public accounting firm), even in the absence of instructions from you. If a broker submits a vote on Proposal 3 and

leaves Proposals 1 and 2 blank, this is a "broker non-vote" with respect to Proposals 1 and 2. Broker non-votes will be counted

for purposes of establishing a quorum for the annual meeting, will have no effect on the outcome of the vote on Proposal 1,

and will be treated as a vote against Proposal 2.

---

| | | |
|:---|:---|:---|
| **76** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

Questions and Answers About This Proxy Statement and Our 2025 Annual Meeting<br>

**What should I do if I want to attend the annual meeting in person?**

This year's annual meeting will be conducted exclusively via the Internet without an option to attend in person.

**Why did the Company decide to hold its annual meeting exclusively** 

**via the Internet?**

We decided to hold the 2026 Annual Meeting in a virtual format as we believe it facilitates stockholder access by enabling all

stockholders to participate equally from any location around the world. We remain committed to ensuring that stockholders

will have the same rights and opportunities to participate online as they would at an in-person meeting.

For example, both before and during the annual meeting, you will have the ability to vote your shares (other than as described

below in "How can I vote my shares in the Ingredion Incorporated Stock Fund in one of the Company's Retirement Savings

Plans?") and ask questions of Company management and the Chairman of the Board. Prior to the meeting, you can do this via

*www.proxyvote.com* and during the virtual annual meeting via *www.virtualshareholdermeeting.com/INGR2026*. In order to do

so, you will need your 16-digit control number. If you attend the virtual annual meeting as a guest, you will not be permitted to

ask questions. Shortly after the annual meeting, we will post the questions submitted in accordance with the meeting rules of

conduct and procedures and the associated answers on our Investor Relations website, *https://ir.ingredionincorporated.com/*

*events-and-presentations*. Similar questions on the same topic may be answered as a group.

If you encounter any difficulties accessing the virtual annual meeting during the check-in or meeting time, please call the

technical support number that will be posted on the virtual annual meeting login page.

**Will there be a question-and-answer session during the annual** 

**meeting?**

As part of the annual meeting, we will hold a live question-and-answer session via the Internet, during which we intend to

answer questions submitted during or prior to the meeting that are pertinent to the Company and the business of the annual

meeting. Each stockholder is limited to no more than two questions. Each question should be succinct and cover only a single

topic. Similar questions on the same topic may be answered as a group. We will not address questions that, among other

things:

• are irrelevant to the business of the Company or to the business of the annual meeting,

• are related to material nonpublic information of the Company,

• are related to personal grievances,

• contain derogatory references to individuals or that are otherwise in bad taste,

• repeat questions already asked by another stockholder,

• relate to the stockholder's personal interests and are not of general concern to all stockholders, or

• are out of order or not otherwise suitable for the conduct of the annual meeting as determined by the chair of the

meeting or the meeting secretary in their reasonable judgment.

Shortly after the annual meeting, we will post the questions submitted in accordance with the meeting rules of conduct and

procedures and the associated answers on our Investor Relations website, *https://ir.ingredionincorporated.com/events-and-*

*presentations*. If there are any matters of individual concern to a stockholder and not of general concern to all stockholders, or

if a question posed was not otherwise answered, such matters may be raised separately after the annual meeting by contacting

the Company's Investor Relations department at (708) 551-2600.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **77** |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

Questions and Answers About This Proxy Statement and Our 2025 Annual Meeting<br>

**How can I vote at the annual meeting?**

Whether you hold your shares of record or in street name, we encourage you to submit proxy or voting instructions in advance

the annual meeting via the Internet, by telephone, or by mail.

The annual meeting will be conducted exclusively via the Internet.

• If you are a stockholder of record as of the record date, you may vote your shares through the online voting platform

during the meeting or submit proxy or voting instructions in advance of the meeting, as described below in "How do I

submit proxy or voting instructions if I will not vote at the annual meeting?",

• If you are the beneficial owner of shares as of the record date, and hold the shares in street name, you may vote the

shares you beneficially own by following the instructions provided to you by your bank, broker, or other holder of

record, as described below in "How can I submit voting instructions for shares that are held by my bank, broker, or other

holder of record?", and

• If you have shares allocated to your account via the Ingredion Incorporated Stock Fund in one of the Company's

Retirement Savings Plans, you must vote their shares on or before May 15, 2026, as described below in "How can I vote

my shares in the Ingredion Incorporated Stock Fund in one of the Company's Retirement Savings Plans?".

If you wish to vote your shares of record or in street name (but not through one of the Company's Retirement Savings Plans) via

the Internet during the annual meeting, please follow the instructions at *www.virtualshareholdermeeting.com/INGR2026*. You

will need the 16-digit control number contained on your notice of availability, e-mail notification, proxy card, or voting

instruction form. If you encounter any difficulties voting during the meeting, please call the technical support number that will

be posted on the virtual annual meeting login page.

**How can I submit proxy or voting instructions if I will not vote at the** 

**annual meeting?**

If you are a stockholder of record, you may vote at the virtual annual meeting as described above. If you do not wish to vote at

the annual meeting or if you will not be attending the meeting, you may vote by proxy. Before the annual meeting, you may

submit your proxy or voting instructions via the Internet or by telephone by following the instructions provided in the notice of

availability of proxy materials, or, if you received these materials electronically, by following the instructions in the e-mail

message that notified you of their availability. If you received paper copies of the proxy materials by mail, you may submit your

proxy or voting instructions via the Internet, by telephone, or by mail by following the instructions on the enclosed proxy card.

You may utilize the following methods to submit your proxy or voting instructions before the annual meeting:

**By the Internet**

You may submit your proxy or voting instructions online at *www.proxyvote.com* by following the instructions provided in the

notice of availability of proxy materials or, if you received these materials electronically, by following the instructions in the e-

mail message that notified you of their availability, or, if you received these materials by mail, by following the instructions in

the enclosed proxy card. You will need your 16-digit control number contained on your notice of availability, e-mail notification,

or proxy card in order to submit your instructions. Submitting proxy or voting instructions via the Internet has the same effect

as submitting such instructions by mail or telephone. You may submit your proxy or voting instructions via the Internet until

11:59 p.m., Eastern Daylight Time, on May 19, 2026.

**By telephone**

You may submit your proxy or voting instructions by telephone at 1 (800) 690-6903. You will need the 16-digit control number

contained on your notice of availability, e-mail notification, or proxy card in order to vote by telephone. Submitting proxy or

voting instructions by telephone has the same effect as submitting such instructions by mail or the Internet. You may submit

your proxy or voting instructions by telephone until 11:59 p.m., Eastern Daylight Time, on May 19, 2026.

---

| | | |
|:---|:---|:---|
| **78** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

Questions and Answers About This Proxy Statement and Our 2025 Annual Meeting<br>

**By mail**

If you received a paper copy of the proxy materials, you may submit your proxy or voting instructions by signing and dating each

proxy card you received and returning each of them to us in the prepaid envelope provided. You should sign your name exactly

as it appears on the proxy. If you are signing in a representative capacity (for example, as an attorney-in-fact, executor,

administrator, guardian, trustee or the officer, agent or partner of a corporation or partnership), please indicate your name and

your title or capacity. If the stock is held in custody for a minor (for example, under the Uniform Transfers to Minors Act), the

custodian should sign, not the minor. If you submit your proxy or voting instructions by mail, it must be received by 11:59 p.m.,

Eastern Daylight Time, on May 19, 2026.

**May I revoke my proxy or voting instructions before my shares are** 

**voted at the annual meeting?**

Yes, you may revoke your proxy or voting instructions before your shares are voted at the annual meeting. You may submit your

proxy or voting instructions again at a later date via the Internet or by telephone or by signing and returning a new proxy card

with a later date, or you may attend the virtual annual meeting and vote during the meeting. Only your latest Internet,

telephone, or written proxy submitted prior to the meeting will be counted.

You may revoke your proxy at any time before the meeting by (i) notifying the Company's Corporate Secretary of the revocation

in writing or (ii) delivering a later-dated proxy via the Internet or by telephone or in writing. Your attendance at the virtual

annual meeting, however, will not automatically revoke your proxy unless you vote at the meeting or specifically request in

writing that your prior proxy be revoked. Any written notice revoking a proxy should be sent to Corporate Secretary, Ingredion

Incorporated, 5 Westbrook Corporate Center, Westchester, Illinois 60154 and must be received by 11:59 p.m., Eastern Daylight

Time, on May 19, 2026.

**How can I submit voting instructions for shares that are held by my** 

**bank, broker, or other holder of record?**

If you have shares held of record by a bank, broker, or other holder of record, you may instruct your bank, broker, or other

holder of record to vote your shares by following the instructions that such holder of record provides for you. Most banks and

brokers permit beneficial owners of shares to submit voting instructions via the Internet, by telephone, and by mail. If you do

not have your 16-digit control number, please contact your bank, broker, or other holder of record.

**How will the proxies be voted?**

The shares represented by valid proxies received by Internet, by telephone, or by mail will be voted in the manner specified in

such proxies. If you fail to indicate your voting preferences, the persons named in the proxy will vote on your behalf **FOR** 

election of the 11 nominees for director named in this proxy statement (Proposal 1), **FOR** approval of the compensation of the

Company's named executive officers as described in this proxy statement (Proposal 2), and **FOR** ratification of the appointment

of KPMG as our independent registered public accounting firm for the fiscal year ending December 31, 2026 (Proposal 3).

Should any matter not described above be properly presented at the meeting, each of the persons named in the proxy will vote

on such matter in accordance with such person's best judgment.

**How can I vote my shares in the Ingredion Incorporated Stock Fund in** 

**one of the Company's Retirement Savings Plans?**

You may instruct the plan trustee on how to vote your shares in the Ingredion Incorporated Stock Fund via the Internet, by

telephone, or by mail as described above in "How can I submit proxy or voting instructions if I will not vote at the annual

meeting?". You must provide your instruction via the Internet or by telephone no later than 11:59 p.m., Eastern Daylight Time,

on May 15, 2026, or by mail received no later than 11:59 p.m., Eastern Daylight Time, on May 15, 2026, in order to have your

shares in the Ingredion Incorporated Stock Fund voted at the annual meeting.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **79** |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

Questions and Answers About This Proxy Statement and Our 2025 Annual Meeting<br>

**How many shares in the Ingredion Incorporated Stock Fund in one of** 

**the Company's Retirement Savings Plans may I vote?**

You may vote all the shares allocated to your account on the record date.

**What happens if I do not instruct the plan trustee to vote my** 

**Retirement Savings Plans shares?**

Your shares will not be voted. The plan trustee will not vote shares held in the Retirement Savings Plans as to which it does not

receive timely directions.

**Who tabulates the votes?**

An independent inspector of election tabulates the votes.

**Is my vote confidential?**

As a matter of policy, proxies, ballots, and voting tabulations that identify individual stockholders are held confidential by the

Company. Such documents are available for examination only by any independent tabulation agents, the independent inspector

of election, and certain employees associated with tabulation of the vote. The identity of the vote of any stockholder is not

disclosed except as may be necessary to meet legal requirements.

**Where can I find the voting results of the annual meeting?**

We will report the voting results by filing a current report on Form 8-K with the SEC within four business days after the date of

the annual meeting.

**Who is paying the costs of this proxy solicitation?**

Ingredion is paying the costs of the solicitation of proxies. We have retained a proxy soliciting firm to assist in the solicitation of

proxies for a fee, plus reimbursement of certain out-of-pocket expenses. We will pay brokerage firms and other persons

representing beneficial owners of shares held in street name certain fees associated with:

• forwarding the notice of availability to beneficial owners,

• forwarding paper proxy materials by mail to beneficial owners, and

• obtaining beneficial owners' voting instructions.

In addition to soliciting proxies by the Internet and mail, our board members, officers, and employees may solicit proxies on our

behalf, without additional compensation, personally, by e-mail, or by telephone.

---

| | | |
|:---|:---|:---|
| **80** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

Questions and Answers About This Proxy Statement and Our 2025 Annual Meeting<br>

**How can I submit a stockholder proposal for the 2027 annual** 

**meeting?**

**Proposals for Inclusion in Next Year's Proxy Statement**

Our 2027 annual meeting is scheduled to be held on Wednesday, May 19, 2027. If a stockholder intends to present a proposal

pursuant to Rule 14a-8 under the Exchange Act at the 2027 annual meeting and wishes to have the proposal included in the

Company's proxy statement for the 2027 annual meeting, the stockholder must submit the proposal in writing so that we

receive it by December 9, 2026, unless the date of our 2027 annual meeting is more than 30 days before or after May 20, 2027

(the one-year anniversary of this year's annual meeting), in which case the proposal must be received a reasonable time before

we begin to print and mail our proxy materials for our 2027 annual meeting. Proposals should be addressed to our Corporate

Secretary, Ingredion Incorporated, 5 Westbrook Corporate Center, Westchester, Illinois 60154. Any stockholder proposal

submitted for inclusion must be eligible for inclusion in our proxy statement in accordance with the rules and regulations

promulgated by the SEC.

Pursuant to our bylaws, stockholders may submit director nominees to be included in our annual proxy statement in a process

known as "proxy access." Stockholders who intend to submit director nominees for inclusion in our proxy materials for the 2027

annual meeting must comply with the requirements of proxy access as set forth in our bylaws. The stockholder or group of

stockholders who wish to submit director nominees pursuant to proxy access must deliver the required materials to the

Company:

• not less than 120 nor more than 150 days prior to the anniversary of the date on which the proxy statement was

released for the prior year's annual meeting (for the 2027 annual meeting, between November 9, 2026 and December 9,

2026), or

• if the date of the annual meeting has been changed by more than 30 days from the date contemplated at the time of

the previous year's proxy statement, not less than 90 days before the date of the applicable annual meeting, or, if later,

the tenth day following the day on which notice of the date of the annual meeting was mailed or public disclosure of the

date of the annual meeting was given, whichever occurs first.

**Other Proposals for Consideration at the 2027 Annual Meeting**

In addition, our bylaws provide that any stockholder wishing to present any other business for consideration at the annual

meeting, including the nomination of directors for election, without including such matters in the Company's proxy materials

must give the Company written notice:

• not less than 90 nor more than 120 days in advance of the date which is the anniversary of the date of the previous

year's annual meeting (for the 2027 annual meeting, between January 20, 2027 and February 19, 2027), or

• if the date of the applicable annual meeting is more than 30 days prior to, or more than 60 days after, the first

anniversary of the date of the previous year's annual meeting, or, if later, the tenth day following the day on which

notice of the date of the annual meeting was mailed or public disclosure of the date of the annual meeting was given,

whichever occurs first.

The notice must provide certain other information as described in our bylaws.

There are other procedural requirements in our bylaws pertaining to stockholder nominations and proposals. A copy of the

bylaws is available online in the "Corporate Governance" section of our investor relations website at *https://*

*ir.ingredionincorporated.com/corporate-governance/highlights*. Any stockholder may also obtain a current copy of our bylaws,

without charge, by writing to our Corporate Secretary.

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **81** |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

Questions and Answers About This Proxy Statement and Our 2025 Annual Meeting<br>

**What other notice requirements must I satisfy if I intend to solicit** 

**proxies in connection with the 2027 annual meeting in support of** 

**director nominees other than the Company's nominees?**

In addition to satisfying the advance notice requirements under our bylaws described in the response to the prior question, to

comply with the universal proxy rules under the Exchange Act, stockholders who intend to solicit proxies in connection with the

2027 annual meeting in support of director nominees other than the Company's nominees must provide the Company no later

than March 19, 2027 with a notice that contains the information specified in Rule 14a-19 under the Exchange Act.

**I share an address with another stockholder and received one paper** 

**copy of the proxy materials. How can I obtain an additional copy of** 

**the proxy materials?**

The SEC's rules permit us to deliver a single set of annual meeting materials to one address that is shared by two or more of our

stockholders. This delivery method is referred to as "householding" and can result in significant cost savings for the Company

with respect to holders who want to receive paper materials.

To take advantage of this opportunity, we have delivered only one proxy statement and annual report to multiple stockholders

who share an address, unless we received contrary instructions from the affected stockholders prior to the mailing date. This

procedure saves the Company printing and postage costs by reducing duplicative mailings. We agree to deliver promptly, upon

written or oral request, a separate copy of the annual meeting materials to any stockholder at the shared address to which a

single copy of these documents was delivered. If you prefer to receive separate copies of the proxy statement or annual report,

you should contact Broadridge Financial Solutions, Inc. at (866) 540-7095 or in writing at Broadridge Householding Department,

51 Mercedes Way, Edgewood, New York 11717. Please also keep in mind that this proxy statement and the accompanying 2025

Annual Report to Stockholders will be filed or furnished with the SEC and available for viewing and copying in the "SEC Filings"

section of our investor relations website at *https://ir.ingredionincorporated.com/financial-information/sec-filings*, in addition to

being available at the site stated in the notice of availability.

If you are currently a stockholder sharing an address with another stockholder and wish to receive only one copy of future

proxy statements and annual reports for your household, please contact Broadridge Financial Solutions at the above telephone

number or address. Stockholders who participate in householding and request to receive paper copies of the proxy materials

will continue to receive separate proxy cards. Householding will not affect dividend check mailings.

Beneficial stockholders may request information about householding from their banks, brokers, or other holders of record.

---

| | | |
|:---|:---|:---|
| **82** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

Other Matters; Other Information<br>

**Other Matters**

We do not know of any other matters or items of business to be presented or acted upon at the annual meeting. If other

proposals are properly presented, each person named in the proxy is authorized to vote on them using such person's best

judgment.

**Other Information**

Any stockholder who wishes to receive a separate copy of this proxy statement or our 2025 Annual Report to Stockholders can

do so by contacting the Company's Corporate Secretary by telephone at (708) 551-2600 or by mail at the Company's principal

executive office, the address of which is Ingredion Incorporated, 5 Westbrook Corporate Center, Westchester, Illinois 60154.

Alternatively, you can access our 2025 Annual Report to Stockholders, which includes our 2025 Annual Report on Form 10-K for

the year ended December 31, 2025, and other financial information, on our investor relations website at: *https://*

*ir.ingredionincorporated.com/financial-information/annual-reports*.

To the extent that this proxy statement is incorporated by reference into any filing by the Company under the Securities Act of

1933, as amended, or the Exchange Act, the sections of this proxy statement entitled "Pay Versus Performance Disclosure"

under "Executive Compensation," "Compensation Committee Report," and "Audit Committee Report," to the extent permitted

by SEC rules, will not be deemed incorporated in such a filing, unless specifically provided otherwise in the filing. In addition,

such sections will not be deemed to be soliciting material for purposes of the solicitation of proxies in connection with the

annual meeting.

All website addresses contained in this proxy statement are intended to be inactive, textual references only. The information

on, or accessible through, any website (including the Company's website) identified in this proxy statement or any

accompanying materials is not a part of, and is not incorporated by reference into, this proxy statement.

Please submit your proxy or voting instructions via the Internet or by telephone as soon as possible, or if you received a paper

copy of the proxy materials and wish to submit your proxy or voting instructions by mail, please complete the accompanying

proxy card and mail it in the enclosed, postage-paid envelope as soon as possible. If you have received a voting instruction form

from a bank, broker, or other holder of record, please submit your voting instructions by following the directions provided on

that form.

By order of the Board of Directors,

Tanya Jaeger de Foras

Senior Vice President, Chief Legal Officer,

Corporate Secretary, and Chief Compliance Officer

April 8, 2026

---

| | | |
|:---|:---|:---|
| INGREDION INCORPORATED | 2026 PROXY STATEMENT | **A-1** |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

Appendix A<br>

**Appendix A: Reconciliation of Non-GAAP** 

**Financial Measure**

To supplement the consolidated financial results prepared in accordance with generally accepted accounting principles

("GAAP"), the Company uses non-GAAP historical financial measures, which exclude specified GAAP items. The Company uses

the term "adjusted" when referring to these non-GAAP amounts.

Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results, and

evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a

more meaningful, consistent comparison of the Company's operating results and trends for the periods presented. These non-

GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and reflect

an additional way of viewing aspects of our operations that, when viewed with our GAAP results, provide a more complete

understanding of factors and trends affecting our business. These non-GAAP measures should be considered as a supplement

to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with generally accepted

accounting principles.

Non-GAAP financial measures are not prepared in accordance with GAAP, so such measures are not necessarily comparable to

similarly titled non-GAAP financial measures presented by other companies.

A reconciliation of adjusted diluted earnings per share to diluted earnings per share as calculated in accordance with GAAP is

provided in the table below.

**Reconciliation of Adjusted Diluted EPS to Diluted EPS**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Year Ended | Year Ended | Year Ended | Year Ended |
|  | December 31, 2025 | December 31, 2025 | December 31, 2024 | December 31, 2024 |
| | (in millions) | Diluted EPS | (in millions) | Diluted EPS |
| Net income attributable to Ingredion | $729 | $11.18 | $647 | $9.71 |
| Adjustments: |  |  |  |  |
| Restructuring and resegmentation costs (i) | 11 | 0.17 | 13 | 0.20 |
| Net (gain) on sale of business (ii) |  |  | (86) | (1.29) |
| Impairment charges (iii) | 7 | 0.11 | 109 | 1.63 |
| Other matters (iv) | (7) | (0.11) | 5 | 0.07 |
| Tax item—Mexico (v) | (14) | (0.22) | 18 | 0.27 |
| Other tax matters (vi) |  |  | 4 | 0.06 |
| Non-GAAP adjusted net income attributable to <br>Ingredion<br>| $726 | $11.13 | $710 | $10.65 |

---

Amounts shown for net income and EPS may not sum or recalculate due to rounding.

<u>Notes</u>

(i)During 2025, we recorded pre-tax restructuring charges of $13 million, primarily related to decommissioning costs for

previously announced plant closures and restructuring activities that occurred during the year. During 2024, we recorded

pre-tax restructuring charges of $18 million, primarily related to restructuring activities that occurred during the year and

the resegmentation of the business that was effective January 1, 2024.

(ii)During 2024, we recorded pre-tax gains of $90 million on the sale of our business in South Korea.

---

| | | |
|:---|:---|:---|
| **A-2** | INGREDION INCORPORATED | 2026 PROXY STATEMENT |

---

**<u>[**Table of Contents**](#ie7e472361805446c8b302de30ed47fbf_19)</u>**

Appendix A<br>

(iii)During 2025, we recorded $10 million of pre-tax impairment charges on our equity investments and equipment due to

restructuring activities. During 2024, we recorded pre-tax impairment charges of $83 million, which primarily related to the

cessation of operations at our Vanscoy, Canada and Alcantara, Brazil manufacturing facilities. Also in 2024, we recorded

pre-tax impairment charges of $18 million to equity method investments and $8 million related to the cessation of

manufacturing operations in the United Kingdom.

(iv)During 2025, we recorded pre-tax benefits of $9 million primarily related to insurance recoveries and a favorable judgment

related to certain indirect taxes. During 2024, we recorded a pre-tax net charge of $7 million for tornado damage incurred

at a U.S. warehouse.

(v)During 2025, we recorded tax provisions of $14 million as a result of the movement of the Mexican peso against the U.S.

dollar and its impact on our Mexico financial statements. During 2024, we recorded tax provisions of $18 million as a result

of the movement of the Mexico peso against the U.S. dollar and its impact on our Mexico financial statements.

(vi)During 2025, we changed our permanent reinvestment status of a foreign affiliate, U.S. state deferred tax remeasurement,

and tax impacts of the foregoing non-GAAP adjustments. The effect of these changes was partially offset by a benefit from

our ability to realize future tax losses in Canada, reversal of prior year tax contingencies, and interest on previously

recognized tax benefits for certain Brazilian local incentives that were previously taxable. During 2024, we recognized

prior-year tax contingencies and net liabilities, recapture of prior-year U.S. tax benefits, and tax impacts of the foregoing

non-GAAP adjustments. The effect of these factors was partially offset by a benefit from our ability to realize tax loss

carryforwards in Canada and interest on previously recognized tax benefits for certain Brazilian local incentives that were

previously taxable.

![2026 Proxy Card_Page_1.jpg](ingr-20260402_g46.jpg)

slide1

![2026 Proxy Card_Page_2.jpg](ingr-20260402_g47.jpg)

Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. V66623-P21068-Z88834 ! ! ! ! !! ! !! ! !! ! !! ! !! ! !! ! !! ! !! ! !! ! !! ! !! For Against Abstain ! !! 1b. Rhonda L. Jordan 1c. Gregory B. Kenny 1d. Charles V. Magro 1e. Victoria J. Reich 1k. James P. Zallie 1j. Dwayne A. Wilson 1i. Patricia Verduin 1h. Jorge A. Uribe 1g. Stephan B. Tanda 2. To approve, by advisory vote, the compensation of the Company's named executive officers. 1f. Catherine A. Suever Note: To transact other business, if any, that is properly brought before the meeting or any adjournment or postponement thereof. INGREDION INCORPORATED THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE "FOR" ALL OF THE NOMINEES LISTED IN PROPOSAL 1, AND "FOR" PROPOSALS 2 AND 3: 1. To elect the 11 nominees nominated by the Company's Board of Directors to serve as directors, each for a term of one year. Nominees: 1a. David B. Fischer 3. To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The shares represented by this proxy/voting

instruction, when properly executed, will be voted in the manner directed herein by the undersigned stockholder(s). If no direction is made, this proxy will be voted FOR each of the nominees for election as a director listed in Proposal 1 and FOR Proposals 2 and 3. If any other matters properly come before the meeting, or any adjournment or adjournments thereof, each person named in this proxy/voting instruction will vote in his or her or its discretion. Please date and sign as name appears hereon. If shares are held jointly by two or more persons, each stockholder should sign. Executors, administrators, trustees, etc., should indicate so when signing. If the signer is a corporation, please sign full corporate name by duly authorized officer. If a partnership or limited liability company, please sign in partnership or limited liability company name by authorized person. For Against Abstain SCAN TO VIEW MATERIALS & VOTE w INGREDION INCORPORATED 5 WESTBROOK CORPORATE CENTER WESTCHESTER, IL 60154 VOTE BY INTERNET Before The Meeting - Go to www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information until 11:59 p.m. Eastern Daylight Time on May 20, 2025 (or until 11:59 p.m. Eastern Daylight Time on May 16, 2025, to instruct the

Retirement Savings Plan Trustee, as applicable). Have your proxy card/voting instruction form in hand when you access the website and follow the instructions to obtain your records and to create an electronic voting instruction form. During The Meeting - Go to www.virtualshareholdermeeting.com/INGR2025 You may attend the meeting via the Internet and vote during the meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions. VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to transmit your voting instructions until 11:59 p.m. Eastern Daylight Time on May 20, 2025 (or until 11:59 p.m. Eastern Daylight Time on May 16, 2025, to instruct the Retirement Savings Plan Trustee, as applicable). Have your proxy card/voting instruction form in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Ingredion Incorporated, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. Your voting instructions must be received by 11:59 p.m. Eastern Daylight Time on May 20, 2025 (or by 11:59 p.m. Eastern Daylight Time on May 16, 2025, to instruct the Retirement Savings Plan Trustee, as applicable). If you vote using the Internet or vote by phone,

please do not mail your proxy. THANK YOU FOR VOTING

slide2

V66624-P21068-Z88834 2025 Annual Meeting of Stockholders Wednesday, May 21, 2025 8:00 a.m. Central Daylight Time www.virtualshareholdermeeting.com/INGR2025 Your vote is important. Please vote by internet, telephone, or mail as soon as possible to ensure that your vote is recorded promptly. Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: Our Notice and Proxy Statement and our Annual Report to Stockholders are available at www.proxyvote.com. Annual Meeting of Stockholders - To Be Held Wednesday, May 21, 2025 THIS PROXY/VOTING INSTRUCTION IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned, a stockholder of Ingredion Incorporated, acknowledges receipt of the Proxy Statement dated April 9, 2025, and except as described in the next paragraphs, appoints James P. Zallie and Tanya Jaeger de Foras, and each of them, as proxies and attorneys-in-fact, with full power of substitution, on behalf of the undersigned and in the undersigned's name, to represent the undersigned at the Annual Meeting of Stockholders to be held on Wednesday, May 21, 2025, at 8:00 a.m., Central Daylight Time, and at any adjournment(s) of the meeting, and to vote all shares of common stock which the undersigned would be entitled to vote if the undersigned were personally

present, on all matters listed on the reverse side. With respect to any shares represented by this Proxy Card/Voting Instruction Form which are votable and held on behalf of the undersigned in the Ingredion Incorporated Retirement Savings Plans (collectively, the "Plan"), the undersigned directs Fidelity Management Trust Company, as Trustee of the Plan, to vote all such shares on the matters shown, and in the manner directed on the reverse hereof, unless to do so would be inconsistent with the Trustee's duties. If you wish to vote the Ingredion Incorporated shares allocated to your Plan account, you must use this Proxy Card/Voting Instruction Form or submit your voting instructions via the Internet or telephone. The cut-off date for submitting voting instructions on the Internet or by telephone to the Trustee is 11:59 p.m. Eastern Daylight Time on May 16, 2025, and such instructions by mail must be received by 11:59 p.m. Eastern Daylight Time on May 16, 2025. If you do not return your signed Proxy Card/Voting Instruction Form or provide Internet or telephonic voting instructions on a timely basis for the shares allocated to your Plan account, those shares will not be voted. If you return a signed Proxy Card/Voting Instruction Form but do not indicate how the shares should be voted on a matter, the shares represented by the

signed Proxy Card/Voting Instruction Form will be voted by the Trustee as the Board of Directors recommends. PLEASE READ THE INSTRUCTIONS ON THE REVERSE SIDE TO VOTE BY THE INTERNET, TELEPHONE OR MAIL. TO VOTE BY MAIL, PLEASE MARK, SIGN AND DATE THIS PROXY AND RETURN IT PROMPTLY IN THE ENCLOSED ENVELOPE. (Continued, and to be signed and dated, on the reverse side.)